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Abstract 
Diagnostic delay is regarded as a major contributor to the continuous rise in tuberculosis (TB) 
cases and the emergence and transmission of multidrug-resistant tuberculosis (MDR-TB) and 
extensively drug resistant tuberculosis (XDR-TB). It is therefore essential that more rapid 
diagnostic methods are developed. Molecular-based assays have the potential for the rapid 
species-specific diagnosis of TB and associated drug-resistances directly from clinical 
specimens. We investigated whether high resolution melting analysis (HRM) could enable 
the rapid diagnosis of TB and associated drug resistance, since the HRM apparatus and 
reagents are relatively inexpensive and the methodology can easily be implemented in high-
incidence, low income regions. 
Application of this methodology allowed for the rapid identification of mycobacterial lymphadenitis 
from fine-needle aspiration biopsy (FNAB) samples in 2 studies. This was done by targeting the 
region of deletion 9 (RD9), present in M. tuberculosis and M. canettii, but absent from all other 
members of the complex. However, the sensitivity of the method was low (51.9% and 46.3%, 
respectively) when compared to the reference standard (positive cytology and/or positive 
culture).  Despite this limitation our method was able to provide a rapid diagnosis in more than 
half of the infected patients with a relatively high specificity (94.0% and 83.3%, respectively). We 
therefore proposed a diagnostic algorithm allowing the early treatment of patients with both HRM 
and cytology results indicative of mycobacterial disease.  
We developed the Fluorometric Assay for Susceptibility Testing of Rifampicin (FAST-Rif) which 
allowed the rapid diagnosis of MDR-TB by detecting rifampicin (RIF) resistance mutations in the 
rpoB gene with a sensitivity and specificity of 98% and 100%, respectively. The FAST-Rif method 
was easily adapted to detect ethambutol (EMB) resistance due to mutations in the embB gene 
with a sensitivity and specificity of 94.4% and 98.4% respectively, as compared to DNA 
sequencing. The FAST-EMB method was a significant improvement over the inaccurate culture-
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based method. We identified a strong association between EMB resistance (and pyrazinamide 
resistance) and MDR-TB and subsequently advised modifications to the current (2008) South 
African National TB Control Programme draft policy guidelines.   
Due to the potential for amplicon release, we adapted the FAST-Rif and FAST-EMB methods to 
a closed-tube one-step method using the detection of inhA promoter mutations conferring 
isoniazid (INH) resistance as a model. The method (FASTest-inhA) was able to identify inhA 
promoter mutations with a sensitivity and specificity of 100% and 83.3%. These mutations are of 
particular interest as they confer low level INH resistance and cross-resistance to ethionamide 
(Eto). Since inhA promoter mutations are strongly associated with XDR-TB in the Western and 
Eastern Cape Provinces of South Africa, data generated by the recently implemented 
GenoType® MDRTBPlus assay may allow individualised treatment regimens to be designed for a 
patient depending on their INH mutation profile. Our proposed treatment algorithm may be 
particularly useful in XDR-TB cases, for which only few active drugs remain available.  
Since current diagnostic methods all carry advantages and disadvantages, a combination of 
phenotypic and genotypic-based methodologies may be the best scenario while awaiting 
superior methods.  
 
 
 
 
 
 
 
 v
Opsomming 
Die onvermoë om tuberkulose (TB), multi-weerstandige tuberkulose (MDR-TB) en uiters 
weerstandige tuberkulose (XDR-TB) vinnig te diagnoseer, is ‘n belangrike oorsaak vir die 
volgehoue toename en verspreiding daarvan. Dit is noodsaaklik dat diagnostiese toetse wat 
vinniger resultate oplewer, ontwikkel word. Molukulêre toetsing het die potensiaal om vinnig 
spesie-spesifieke diagnoses van TB en die weerstandigheid teen TB-medikasie te lewer. Hierdie 
studie wil vasstel of hoë-resolusie smeltingsanalise (HRS) ‘n vinnige diagnose van TB en die 
weerstandigheid teen TB-medikasie kan oplewer aangesien die relatiewe lae koste van reagense 
en apparaat, asook die minimale infrastruktuur en vaardighede wat vir dié toets benodig word, dit 
uiters geskik maak vir pasiënte in gebiede met ‘n hoë TB-insidensie en lae inkomste. 
Die toepassing van die HRS-metode op fynnaald-aspiraatbiopsies in twee afsonderlike studies, 
het gelei tot die vinnige identifisering van mikrobakteriële-limfadenitis. Dit is bemiddel deur die 
gebied van delesie 9 (RD9) teenwoordig in Mycobacterium tuberculosis en M. canettii, maar 
afwesig in al die ander lede van die kompleks, te teiken. Die sensitiwiteit van die metode was 
(51.9% en 46.3%, vir die twee studies onderskeidelik) in vergelyking met die verwysingstandaard 
(positiewe sitologie en/of positiewe kultuur). Ten spyte van dié beperking was ‘n vinnige 
diagnose in meer as die helfte van geïnfekteerde pasiënte met ‘n redelike hoë spesifisiteit 
(94.0% en 83.3%, onderskeidelik) moontlik. ‘n Diagnostiese algoritme wat gebaseer is op die 
resultate van die HRS en sitologie-toetse, is voorgestel om pasiënte vroeër te behandel. 
‘n Fluorometriese toets (FAST-Rif) is ontwikkel vir die vinnige diagnose van MDR-TB deur 
mutasies in die rpoB-geen op te spoor met ‘n hoë sensitiwiteit en spesifisiteit (98% en 100%, 
onderskeidelik). Hierdie mutasies is verantwoordelik vir weerstandigheid teen die antibiotikum 
rifampicin (FAST-Rif) en word beskou as ‘n vinnige diagnose vir MDR-TB. Die FAST-Rif metode 
kon maklik aangepas word om mutasies in die embB-gene, verantwoordelik vir weerstandigheid 
teen die antibiotikum ethambutol (EMB), op te spoor. Die FAST-EMB-metode het ‘n sensitiwiteit 
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en spesifisiteit van 94.4% en 98.4% onderskeidelik getoon in vergelyking met DNS-
volgordebepaling. Die FAST-EMB-metode was ‘n betekenisvolle verbetering op die onakkurate 
kultuurgebaseerde metodes. ‘n Sterk korrelasie tussen EMB-weerstandigheid (en 
weerstandigheid teen pyrazinamide) en MDR-TB is geïdentifiseer.  Vervolgens is veranderinge 
aan die Suid-Afrikaanse Nasionale TB-beheerprogram se Konsepbeleidsgids (2008) voorgestel.   
Om die potensiële vrylating van amplikone te verhoed, is die FAST-Rif en FAST-EMB aangepas 
tot ‘n enkelstap geslote buissisteem deur gebruik te maak van die opsporing van inhA-
promotormutasies wat weerstandigheid teen isoniazid (INH) veroorsaak. Die metode het ‘n 
sensitiwiteit en spesifisiteit van 100% en 83.3% onderskeidelik, getoon. Hierdie mutasies 
veroorsaak laëvlak weerstandigheid teen INH, maar ook kruisweerstandigheid teen ethionamide 
(Eto). Aangesien daar ‘n sterk verbintenis  tussen inhA-promotormutasies en XDR-TB in die Oos- 
en Wes-Kaapprovinsies van Suid-Afrika is, kan data van die GenoType® MDRTBPlus-toets 
moontlik gebruik word om ‘n meer geïndividualiseerde behandeling te ontwerp afhangende van 
die pasiënt se INH-mutasieprofiel. Ons behandelingsalgoritme is veral geskik vir XDR-TB-
pasiënte vir wie daar weinig aktiewe antibiotika beskikbaar is.  
Huidige diagnostiese metodes het almal voor- en nadele, dus bied ‘n kombinasie van fenotipiese 
en genotipiese metodes moontlik die beste oplossing totdat beter metodes ontwikkel word.  
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General Introduction 
 
 
Despite the implementation of Directly Observed Treatment Short-course (DOTS) therapy, 
tuberculosis (TB) remains a high burden disease in many developing countries. It is estimated 
that between 2000 and 2010, 1 billion people will be newly infected with the aetiological agent 
Mycobacterium tuberculosis, resulting in 200 million TB cases and 35 million deaths.1  
This increase in TB cases is spurred on by the current human immunodeficiency virus (HIV) 
epidemic, since 58% of TB cases in South Africa for example are in fact co-infected with HIV.2  
Diagnosis of TB in HIV infected individuals is particularly challenging due to the extra-pulmonary 
nature of the disease in immunocompromised individuals. 
A further concern is that according to the 2008 World Health Organisation (WHO) Global Report 
on Drug Resistance,3,4 an estimated 5.3% of all TB cases were in fact classified as multi-drug 
resistant TB (MDR-TB), which is defined as M. tuberculosis resistant in vitro to both isoniazid 
(INH) and rifampicin (RIF). Of these MDR-TB cases, 7% were classified as extensively drug-
resistant TB (XDR-TB) cases, defined as MDR-TB with additional resistance to any 
fluoroquinolone (FQ) and one of the injectable agents.4 This increase in resistance is largely due 
to the poor management of the DOTS programme and the inability to rapidly diagnose TB and 
associated drug resistance. This may lead to increased morbidity and mortality in sufferers, as 
well as the spread of TB and associated drug resistances to the community.  
Currently, TB diagnosis and drug-susceptibility testing are largely based on phenotypic culture 
methods which result in significant diagnostic delay. Recent advances in phenotypic culture 
methods have reduced the delay to 2 to 10 days,5,6,7 however, the culture of viable bacilli 
requires specialised biosafety facilities and the need for skilled staff. It is therefore essential that 
improved diagnostics are developed which are both affordable and rapid.  
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Recently there has been a movement towards the molecular-based assays8 which have the 
potential for the rapid species-specific diagnosis of TB and associated drug-resistance. Chapter 
1 aims to provide an overview of the current diagnostics (both phenotypic and genotypic-based) 
available.  
Molecular-based assays may drastically reduce turn-around times; however they may be 
hampered by a high financial cost, the need for downstream processing and the potential for 
cross-contamination (among the open-tube based assays). An assay which is rapid, sensitive, 
and specific and does not require downstream processing would be ideal. 
The aim of this dissertation is to investigate the potential of high resolution melting (HRM) 
analysis to improve the diagnosis of TB and associated drug-resistance.  
High resolution melting analysis is a relatively new technique based on the concept that specific 
DNA fragments have specific thermal denaturation profiles which are determined by the 
nucleotide sequence contained therein.9 Thus, any change in the nucleotide sequence would 
alter the thermal denaturation profile, which, in turn, can be detected by measuring the efficiency 
of binding of a fluorescent dye to the DNA fragment at different temperatures.10  
We aim to test whether HRM would be able to rapidly identify M. tuberculosis DNA from fine-
needle aspiration biopsies (FNABs), collected in an inexpensive transport medium, from patients 
with suspected TB lymphadenitis, the most common manifestation of extra-pulmonary TB in 
developing countries.11,12 In Chapter 2 we describe our closed-tube technique targeting the 
Region of Deletion 9 (RD9), present in M. tuberculosis and M. canettii, but absent from all other 
members of the M. tuberculosis complex.13  Although HRM analysis allowed for a rapid and 
species-specific diagnosis of M. tuberculosis lymphadenitis in the majority of patients, we feel 
that there is potential for further optimisation of the methodology. Chapter 3 investigates whether 
the sensitivity and specificity of the assay can be improved by circumventing the need for a 
transport medium bottle and spotting the samples directly onto the simpler FTA® Elute Cards.  
In Chapter 4 we investigate the potential of HRM to rapidly diagnose drug-resistance by 
detecting mutations known to cause rifampicin resistance, an important marker of MDR-TB 
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(mono-resistance to rifampicin is rare and is mostly accompanied by isoniazid resistance). This 
“FAST-Rif” (“Fluorometric Assay for Susceptibility Testing of Rifampicin”) method overcomes the 
difficulties associated with detecting nucleotide transversions, since we analyse the thermal 
denaturation profiles of DNA duplexes formed by annealing DNA fragments (amplified from the 
rifampicin resistance-determining region (RRDR) of the rpoB gene) with (patient sample) and 
without (wild-type laboratory strain (H37Rv)) nucleotide change (heteroduplex and homoduplex, 
respectively). 
In Chapter 5 we demonstrate that the FAST-Rif method can be easily adapted to detecting 
resistance towards other antituberculosis drugs. We chose to look at Ethambutol (EMB) as it 
forms an integral part of first and second-line tuberculosis therapy and current surveillance data 
regarding the incidence of resistance is inaccurate, suggesting that resistance to EMB is rare.  
Both the FAST-Rif and FAST-EMB assays do not address reducing the need for post-
amplification processing. This could lead to potential cross-contamination and subsequent 
misdiagnosis of patients. In Chapter 6 we therefore aim to adapt the FAST method to a single-
tube system (FASTest) using the inhA promoter gene mutations conferring isoniazid (INH) 
resistance as a model.  
Finally, in Chapters 7 and 8, we aim to demonstrate that data derived from this dissertation, as 
well as retrospective data analysis, may be used to formulate suggestions as to how to improve 
treatment policy guidelines, ensuring the appropriate management of patients and preventing the 
acquisition or spread of other drug-resistance phenotypes. 
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Chapter 1 
 
 
Review: Current Technologies for the Diagnosis of 
Tuberculosis and Associated Drug-Resistances 
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1. Introduction 
 
Despite numerous advances in both scientific and medical research, tuberculosis (TB) remains a 
high burden disease in many countries, with an estimated one third of the world’s population 
currently infected with the aetiological agent, Mycobacterium tuberculosis. Failure to rapidly 
identify TB cases can lead to increased morbidity and mortality in sufferers, as well as the spread 
of TB to the community.  
A further concern is that according to the recent Global Report on Drug Resistance, released by 
the World Health Organisation (WHO) in 20081, an estimated 5.3% of all TB cases were in fact 
classified as multi-drug resistant TB (MDR-TB), which is defined as M. tuberculosis resistant in 
vitro to both isoniazid (INH) and rifampicin (RIF), with or without resistance to other anti-TB 
drugs. Of these MDR-TB cases, 7% were in fact classified as extensively drug-resistant TB 
(XDR-TB) cases, which is defined as MDR-TB with additional resistance to any fluoroquinolone 
(FQ) (e.g. ciprofloxacin, ofloxacin (OFL) or moxifloxacin) and one of the three injectables (e.g.  
capreomycin (Cm), kanamycin (Km) or amikacin (Am)).2    
The majority of current diagnostic methodologies are outdated and were implemented several 
decades ago. They perform inadequately in detecting the presence of M. tuberculosis and even 
worse for drug-susceptibility testing (DST). It is essential that new rapid diagnostics are 
developed to complement a well-functioning TB Control Program. There are currently a number 
of diagnostics being developed, however, many of the manufacturers and decision makers 
originate from first-world, low incidence settings. Diagnostics therefore suited to the TB epidemic, 
laboratory infrastructure and funding available in these manufacturing countries may not be of 
use in high burden settings where there are higher proportions of active and latent TB cases. 
This chapter aims to review the current diagnostics available, including immunological, 
bacteriological and genotypic -based methodologies, and to discuss those which show potential 
for further development. 
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2. Diagnostic Methodologies 
 
2.1. Clinical investigations 
According to the Centres for Disease Control and Prevention, a clinical case of TB should have 
a positive Tuberculin Skin Test (TST) reaction, show signs and symptoms that reflect TB, and be 
treated with two or more anti-TB antibiotics.3 
 
 2.1.1 Patient History and Symptom Screening 
Clinicians use various “identifiers” to suspect TB in a patient, going so far as to consider their 
geographical location. Persons from endemic TB areas are subject to high infection pressures 
and are therefore more likely to be infected. A history of previous TB treatment will also raise the 
suspicion for TB, as 16% of TB patients are retreatment cases.1 This could be either due to 
reactivation of dormant M. tuberculosis or due to re-infection.4 Furthermore, a history of previous 
TB treatment and non-compliance is a strong indicator of possible drug-resistance. Infection with 
the human immunodeficiency virus (HIV) also raises suspicion for TB as 58% of TB cases in 
South Africa for example are in fact co-infected with HIV.5   
A cough of more than 2 weeks, is one of the most important indicators of active pulmonary TB 
disease,6,7 however, there may be no pulmonary involvement in many patients. This is especially 
true in HIV co-infected individuals and children.6,7 Using a combination of symptoms (cough, 
weight loss, fever, haemoptysis and night sweats)8 may therefore increase the clinical sensitivity 
of diagnosing active TB in these individuals.  
Diagnosis based on signs and symptoms alone, is not necessarily reliable, since certain TB 
disease symptoms are common to other respiratory ailments (e.g. cough).8 Therefore additional 
diagnostic tools are necessary to confirm active TB disease. 
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 2.1.2 Radiological methods 
Chest X-rays (CXR) are classically the next step in the diagnostic algorithm for a TB suspect in 
first-world countries.9 Typical radiological findings of active TB disease include evidence of 
cavitation, upper-lobe disease and pulmonary fibrosis.  
However, not all TB disease displays radiological changes. Twenty-five to 50% of HIV infected 
individuals may present with apparently normal CXR10,11 due to the higher frequency of extra-
pulmonary disease in these patients. Nevertheless, many sputum smear-negative TB cases may 
present with hilar and mediastinal adenopathies12 or lower-lobe disease13 which is recognisable 
on CXR. A recent study in South Africa amongst mine workers who underwent routine annual 
screening by CXR, showed that the sensitivities and specificities did not differ amongst HIV 
infected and uninfected individuals.14 
Despite being able to aid in diagnosing pulmonary disease, CXR remains a non-specific 
diagnostic for TB. Radiological findings may be difficult to interpret due to alternate 
manifestations of pulmonary disease such as bacteriological pneumonia. Furthermore, inter- and 
intra-observer variation is common and may also affect the interpretation of radiological 
findings.15 The Chest Radiograph Reading System15 or the four-point scoring system16 may 
improve the sensitivity and specificity of the technique by reducing inter-observer variability. 
These scoring/reading systems could therefore enhance the accuracy and improve the value of 
screening TB suspects.  
Disadvantages include the restricted availability of CXR in limited resource settings and the need 
for specialised equipment, high quality film and skilled staff.  
In summary, CXR is a useful and cost effective tool for the identification of TB suspects in low 
incidence settings. Cost may be reduced in high incidence settings if radiography is only used to 
screen sputum smear-negative TB suspects.16 However, as this method is non-specific for TB, 
further diagnostic testing is required to confirm the aetiological agent as M. tuberculosis.17,18 
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2.2. Immunological methods 
Recently, there has been a steady shift towards immunologically-based diagnostics, which are 
particularly useful in identifying M. tuberculosis infections with a relatively high degree of 
accuracy. However, infection is not always indicative of TB disease. This is particularly true in 
high TB disease burden areas, where the majority of persons have been exposed to M. 
tuberculosis at some point in their lifetime. Identifying latent TB infection (LTBI) may however 
hold some advantages, in that persons at high risk for progression to disease 
(immunocompromised and high/low age), may be treated with a prophylactic regimen (e.g. 
isoniazid preventative therapy (IPT)). 
 
2.2.1 Tuberculin Skin Test 
The TST, discovered in 1890, is the oldest diagnostic test for TB and remains a crucial 
surveillance tool in low incidence settings. It involves subcutaneous injection of 0.04 µg 
(equivalent to 2 tuberculin units) of tuberculin purified protein derivative (PPD, a precipitate of 
mixed proteins derived from culture filtrate containing multiple (non-specific) mycobacterial 
antigens), with measurement of the localised immune response (induration) 48 to 72 hours post-
injection. 
The TST is indicative of mycobacterial infection, but does not discriminate between latent and 
active disease. Additionally, since PPD is a mycobacterial antigen, it is not specific for M. 
tuberculosis,19 but for many of the mycobacteria, therefore, it can lead to false positive results in 
persons vaccinated with the live attenuated M. bovis bacilli Calmette-Guérin (BCG) strain and 
those exposed to some of the environmental or non-tuberculosis mycobacteria (NTM).20,21 A 
recent improvement in specificity may be to use the 6-kDa M. tuberculosis early secretory 
antigenic target (ESAT-6).22 However highly homologous proteins are produced by M. kansassi, 
M. szulgai and M. marinum.23-26  
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Anergy can occur and is common in immunocompromised individuals due to reduced cell-
mediated immunity. This leads to an increase in false negative results and a decrease in the 
sensitivity of the TST.20,27 A negative TST result in HIV infected individuals should therefore be 
interpreted with caution.  
The boosting of TST results by BCG vaccination, and anergy in HIV infected individuals, raises 
the question of what the ideal “cut-off” point of the induration should be to indicate LTBI.28 
Whereas general guidelines regard 10 mm induration as a positive result, there is evidence that 
cut-offs which are adapted to age, vaccination and HIV status, may improve the sensitivity of the 
test.29 McGill university now offers an online tool (http://meakin.mcgill.ca/respepi/homeE.htm) 
which takes these and other variables (including country of origin, TST induration size, smoking 
habits and TB contact history) into account to calculate the probability that a TST result is true 
and the relative risk of progressing to active TB.30 
As with CXR, inter- and intra-reader variability in determining the size of the induration may also 
occur. This is further complicated by the need for the patient to return within 48 to 72 hours of 
administration and thus the sensitivity and success of the test are dependent on whether TB 
suspects do return within the specified timeframe, and if so, whether the healthcare worker is 
skilled and available to read the result. 
Although the TST is an old technique which is hampered by numerous disadvantages, it remains 
the method of choice to screen for LTBI. This is particularly useful in developed countries, as 
high risk individuals would be placed on IPT to limit progression to active disease. This has also 
proven successful in HIV infected individuals in whom IPT can reduce the risk of developing 
active TB by 35-76%.31,32 However, this would not be useful in high incidence settings where it is 
necessary to discriminate between active and latent disease. A positive TST result would 
therefore require further investigation, such as microbiological confirmation of active TB disease. 
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2.2.2 Antibody Detection Kits 
M. tuberculosis specific antibody research is a rapidly growing field and many studies have been 
done which focus on identifying these “biomarkers” of TB disease.33-36 It is hoped that these 
biomarkers may provide a much needed point of care diagnostic for active TB disease.37 
Current research has identified numerous M. tuberculosis specific antibodies and host proteins, 
including those against the novel T cell antigen MTB heparin-binding hemeagglutinin38 and the 
CXC chemokine IP-10 (interferon-gamma (IFN-γ)-inducible protein).39 The use of specific 
immunity markers such as T cells and cytokine profiles may improve the diagnosis of infection40 
especially in sputum smear-negative individuals.41,42  
Validation studies of antibody assays in humans have thus far provided inconsistent estimates of 
sensitivity and specificity and therefore there is not enough evidence to substitute sputum smear 
microscopy with these assays.41-44 Further research and development is necessary to improve 
this methodology.  
 
2.2.3 Interferon Gamma Release Assays 
Many studies have been done to determine the validity of Interferon Gamma Release Assays 
(IGRAs) in TB diagnostics. These tests focus on quantifying the human cellular response to M. 
tuberculosis infection.37 More specifically, they measure the amount of IFN-γ released from T 
cells following stimulation with specific M. tuberculosis antigens, including the ESAT-6 and the 
10-kDa culture filtrate protein (CFP-10). However, these antigens may be present in the BCG 
vaccine strain and certain NTMs and are therefore not specific to M. tuberculosis. 23,24,26,45 
Three commercial IGRAs are currently available, the Quantiferon®-TB Gold assay (QFT-G), the 
simplified Quantiferon®-TB Gold In-Tube assay (QFT-GIT) (Cellestis Ltd, Carnegie, VIC, 
Australia) and the T-SPOT®.TB assay (T-SPOT) (Oxford Immunotec, Oxford, UK). The QFT-G 
and QFT-GIT assays analyse whole-blood by enzyme-linked immune-absorbance to detect IFN-
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γ, whereas the T-SPOT uses an immunospot technique applied to purified peripheral blood 
mononuclear cells.46,47 
The QFT-GIT has a lower average sensitivity (70-77%) than the QFT-G (75-80%) and T-SPOT 
assays (90-95%).45,48,49 A recent meta-analysis of IGRAs in various geographical locations 
pooled the specificities and suggested 99% for the QFT-G, 91 -96% for the QFT-GIT and 93% 
for the T-SPOT assay.49,50 Although the specificities of the tests are relatively similar, the T-
SPOT test appears to be the most sensitive for the detection of TB infection.51-53 
As the TST is still regarded as the gold standard in detecting LTBI, studies have been conducted 
to compare TST to IGRAs. The latter carries numerous advantages over TST including that 
suspects need only be seen once for testing, the test provides less discomfort (only blood is 
drawn) and lastly, repeated testing is not affected by “boosting”, as is the case for TST. Results 
of positive IGRAs do however need to be relayed back to the patients, which will necessitate 
arranging follow-up visits (as is the case with TST analysis). In South Africa, a recent comparison 
between TST and IGRAs showed a poor correlation between the tests in a high prevalence TB 
setting amongst HIV infected individuals, with 41%, 28% and 61% of patients positive for TB 
infection by the TST, QFT-GIT and T-SPOT assays, respectively.54 In this study, the T-SPOT test 
proved to once again be the most sensitive assay. However, the TST is the most affordable 
choice in high incidence, low income countries such as South Africa, where the cost (including 
laboratory reagent expenses, excluding labour) is only ~R10 per person, whereas the QFN-GIT 
and T-SPOT cost ~R370 and ~R490 respectively (personal communication, Dr G.F. Black (at a 
current exchange rate of R7.50:US $1)).  
Interferon Gamma Release Assays have a number of drawbacks, including one similar to TST, 
i.e. there is still much debate regarding the most accurate cut-off point for a positive result. This 
is especially true for HIV infected individuals who may have a reduced immune response to the 
antigens. Additionally, IGRAs cannot differentiate between latent and active disease, nor can 
they determine drug-susceptibility profiles.48,55-57 The former is especially problematic in high 
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incidence settings. The reduced sensitivity of the test also implies that cases of active disease 
may be missed and therefore IGRAs should not be relied on to rule out TB disease.58 
Since IGRAs are particularly useful in identifying LTBI in low-incidence settings, the test can be 
used to identify individuals at risk of progression to future disease (children and 
immunocompromised individuals) and therefore influence initiation of prophylactic therapy in 
these persons.48,56,59 Additionally it is thought that IFN-γ circulating levels can be monitored by 
these tests and may be reflective of effective prophylaxis and treatment, however, this has not 
been convincingly shown in high incidence settings.55,60,61 
In summary, IGRAs may provide important data regarding TB infection status in individuals and 
evidence shows an improved sensitivity over TST, however, diagnosis of active disease is still 
dependent on microbiological evidence.62  
 
2.3. Bacteriological methods 
Clinical and immunological diagnostic methods are able to raise the suspicion for TB disease; 
however, further confirmation by bacteriological or molecular methods is needed to verify active 
TB disease and determine the drug-susceptibility profiles of the causative organism.  
A laboratory diagnosis of a TB case is therefore given if M. tuberculosis was isolated by culture 
or amplified by a nucleic acid amplification test (NAAT) from a clinical isolate; or in the case that 
no culture was available, that Acid Fast Bacilli (AFB) were present in the clinical specimen.3 
 
2.3.1 Sputum smear microscopy 
Detection of AFB is the oldest diagnostic test for pulmonary TB and was implemented over a 
century ago. The AFB is usually done by Ziehl-Neelsen (ZN) staining of three sputum samples 
collected on three separate days.63 The sputum smears are then scored as 1+, 2+ or 3+ 
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depending on the bacillary count in each microscopic field. This method remains the most widely 
used and (low) cost-effective diagnostic, which is a key tool in the DOTS strategy, to identify 
infectious patients with a relatively high speed and acceptable specificity.64-67 Additionally, 
sputum conversion (i.e. from positive to less positive or negative) may be a measure of treatment 
improvement or success. 
The estimated current global detection rate of AFB in smear-positive individuals stands at 60%, 
however this rate is much lower (20-40%) in high incidence settings.2,68 This low detection rate is 
due to numerous factors, including that the threshold of detection of the AFB is 104 bacilli per 
millilitre of specimen.67 Therefore patients with low bacterial loads may be missed by AFB 
testing, reducing the sensitivity of the test. This is especially likely in HIV positive patients, as 
they show a lack of Type IV cellular immunity and thus present more often with low bacterial 
loads.2,68 Therefore a negative AFB should not be used to exclude TB diagnosis where the 
clinical suspicion is high and where TB and HIV co-infection is common. Sputum processing 
followed by concentration, either by centrifugation, filtration or prolonged gravity sedimentation, 
has been shown to improve sensitivity by as much as 33% over direct microscopy.65  
The lower sensitivity in high incidence settings may also be due to the elevated number of cases 
which place an intolerable workload on the laboratories. The reading efficiency of the sputum 
smears may therefore decrease over time as the technicians become more fatigued. The WHO 
has acknowledged this and recommends that technicians should be restricted to reading 20 
slides per day to prevent fatigue and possible misdiagnosis.69 The workload may also be 
reduced by collecting and analysing only two samples (instead of the standard three) in high 
burden regions if there is a well functioning external quality assurance (EQA) system in place.70 
A further revision to the case definition for sputum smear positive pulmonary TB proposes that 
only one sample need be positive for AFB, reducing the need to analyse the second sample in 
these cases.71 Developments which may improve throughput and reduce cost include apparatus 
for the bulk staining of AFBs. However, cross-contamination by bacilli may lead to an increase in 
the number of false positive results. Computational reading of slides may also circumvent 
technician fatigue and increase throughput. This may not prove as sensitive as highly skilled 
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staff, but may be an option in settings where the workload is high, where skilled staff is in short 
supply and where rapid diagnosis outweighs sensitivity.  
The specificity of the AFB is also of concern, as it cannot differentiate between M. tuberculosis 
and NTM.72 This is especially important in HIV infected individuals who may have high rates of 
opportunistic NTM infections and in regions where TB is not endemic and NTM infection is 
common.73 
An additional disadvantage is that up to 30% of patients are unable to produce sputum37 (this is 
especially common in children); therefore false-negative results may occur with an associated 
reduction in sensitivity. Alternate methodologies for improving AFB specimen collection include 
sputum induction, fiberoptic bronchoscopies and gastric lavage,37 but implementation of such 
complex, labour intensive and invasive techniques on large scale is not feasible.  
New microbial stains have also been developed to improve the sensitivity and specificity of the 
AFB test, including the fluorescent auramine-rhodamine stain. This fluorescent technique is more 
rapid than ZN-staining74 and increases the sensitivity by almost 10%.75,76 This increased 
sensitivity allows for a reduction in the number of samples analysed, thereby decreasing 
workload and speeding up diagnosis.77 However, fluorescent microscopes and their mercury 
vapour lamps are expensive to buy and to maintain. A recent technological advance includes the 
use of Light-Emitting Diode (LED) Fluorescence Microscopy which reduces the cost of the 
microscope and bulbs; and does not require a specialised dark room.78   
 
 2.3.2 Phenotypic culture 
Culture of M. tuberculosis is regarded as the gold standard for proving a case of TB and it 
remains the most sensitive method for detecting TB infection in any clinical specimen.79 Culture 
is also used (preferentially to sputum smear microscopy) to confirm treatment success37 as the 
method requires only 10-100 M. tuberculosis organisms to be present in the sample, in contrast 
to the 104 necessary for the AFB stain.80 
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The success of culture is dependent on the quality of the specimen collected and the transport 
conditions thereof to the laboratory. The specimens then need to be decontaminated to prevent 
overgrowth of normal flora present in the host prior to incubation in a culture medium.  
The solid phase egg-based Löwenstein-Jensen (LJ) slant method was long considered the gold 
standard culture method in resource limited settings. It requires prolonged incubation of 6 to 8 
weeks before a negative result is confirmed and the average time to a positive result exceeds 4 
weeks. It is a cost-effective technique, but requires infrastructure and skilled staff. The agar 
phase method uses either 7H10 or 7H11 Middlebrook media to improve detection time of positive 
results to less than 4 weeks, but also requires incubation of 6-8 weeks before a result may be 
classified as negative. 
A major drawback of both the solid and agar phase methods is that they are dependent on the 
growth rate of the bacteria and therefore various improvements have been proposed to speed up 
the recovery of M. tuberculosis from culture, including the use of liquid phase and automated 
systems.81-83 
The liquid culture media systems are the most modern and rapid systems and include the use of 
7H12 Middlebrook and other media. They are more rapid than the solid and agar phase culturing 
systems and reduce time to positive results in smear positive samples to less than 2 weeks if 
combined with genotypic techniques for rapid species identification. Longer incubation times are 
necessary for sputum smear negative cases. A disadvantage of the more sensitive liquid culture 
media is that there is a higher rate of bacterial and fungal contamination amongst the samples, 
including a higher rate of NTM recovery. Thus, additional speciation by genotypic methods to 
confirm the presence of M. tuberculosis is recommended.84 Cross-contamination is also more 
common, even in experienced laboratories where 2.5 to 10% of samples may be contaminated 
by another sample.85 
Automation can speed up diagnosis, reduce contamination and improve sensitivity. These 
methods rely on the non-radiometric detection of bacterial growth and include systems such as 
the MB/BacT (Biomerieux), BACTEC 9000 (Becton Dickinson), ESPII (TREK Diagnostic 
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Systems, Inc) and Mycobacterial Growth Indicator Tube (MGIT; Becton Dickinson). The latter is 
rapidly becoming the method of choice in high throughput settings and can be done manually or 
by automation.86 The MGIT method has a sensitivity of up to 10% higher than that of the 
traditional solid or agar medium cultures methods.87-90  
Cultures, in combination with smear microscopy, increase the sensitivity of diagnosing TB and 
also form the basis of further testing, including DST, mycobacterial speciation and 
epidemiological investigations; however, it is essential that more rapid methods are developed to 
prevent the lengthy diagnostic delay. 
 
 2.3.3 Phenotypic Drug Susceptibility testing 
Phenotypic culturing is considered the most significant determinant of drug-susceptibility as it can 
define resistance irrespective of the molecular mechanism responsible for resistance. Various 
methodologies have been reported which vary according to the anti-TB drug being tested and the 
laboratory resources available in the respective settings. Inconsistent results are a common 
occurrence91 and resistance is often underreported, this being especially true for those drugs for 
which the methods have not yet been standardised.79  
The gold standard for DST is the indirect-proportion method on agar medium.92,93 This requires a 
pure culture of a specimen from a clinical source and the subsequent inoculation thereof onto 
solid agar media containing specific concentrations of anti-TB drugs. Resistance is then defined 
by growth on the drug-containing media in comparison to a drug-free control. This indirect 
method therefore implies that results can be obtained only 4-8 weeks following standard culture. 
This has many implications including that the patients may have higher morbidity and mortality 
during the lengthy delay prior to diagnosis and correct therapy, and that there may be 
transmission of drug-resistant strains of M. tuberculosis to close contacts. An additional 
disadvantage to indirect testing and culture is that expensive reagents and biosafety facilities are 
needed.94 
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Liquid based cultures may accelerate the process and most of the automated methods such as 
the BACTEC and MGIT systems have been adapted to do DST. These can reduce time to DST 
results to 2-4 weeks by the indirect method95 and are particularly reliable for the first-line drugs 
INH and RIF.92,93 However, this commercial liquid culture system is not always available.  
Direct susceptibility testing may reduce the diagnostic delay further, in that a pure culture is not 
needed and turnaround time can be reduced to 1-3 weeks.95 However, indirect testing is 
preferred, since the potential for bacterial contamination and the presence of NTMs in direct 
cultures is higher. 
A further limitation of phenotypic DST in high incidence countries is that it is only requested 
following treatment failure. This extends the diagnostic delay even further. Furthermore, standard 
culture-based bacteriological DST is not always an accurate indicator of true drug-resistance. 
This is particularly evident in the case of ethambutol (EMB) resistance as the diagnostic 
breakpoint (5 to 7.5 µg/ml) is close to the Minimal Inhibitory Concentration (MIC) of EMB and true 
resistance may therefore be missed (see Chapter 5 and 7).91 
The ideal improvement to phenotypic DST methods would be to accelerate the growth rate of the 
bacteria, however in the absence of such a possibility, various modifications of the standard 
culturing techniques have been proposed. 
 
 2.3.4 Microscopic detection of early Mycobacterial growth  
  i) Thin-layer agar   
The thin-layer agar (TLA) method was originally developed to rapidly identify M. tuberculosis, 
since the method has been shown to be able to detect a positive culture in an average of 11.5 
days (as compared to the 30.5 days by LJ medium).96 Additionally the method is able to provide 
clues regarding speciation, due to the characteristic cording pattern of M. tuberculosis which is 
visible under the microscope.96 A recent large multi-centre study in South America found that the 
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TLA was more sensitive in detecting M. tuberculosis infection than LJ culture was (92.6% and 
84.7% respectively), however they did observe a slight increase in the contamination rates in the 
TLA method.96 
This method has been adapted towards DST, by the use of quadrant petri-dishes which are then 
filled with thin layers of 7H11 media containing the critical concentrations of the drugs being 
tested. One segment remains drug-free to control for growth. Growth on the drug-containing 
segments would imply drug resistance. This method has been optimised successfully to enable 
the detection of RIF, OFL and Km resistance with sensitivities and specificities of 100% for RIF 
(compared to the BACTEC MGIT 960 method), 100% for OFL and 100% and 98.7% respectively 
for Km (as compared to the proportion method).97 The majority of the results were available in a 
median of 10 days by the indirect method, following a pre-isolation culture step on LJ medium.97 
A recent study investigated direct inoculation of decontaminated sputum samples onto quadrant 
plates with each quarter either containing para-nitrobenzoic acid, INH, RIF or being drug-free. As 
a direct test, the TLA method showed a sensitivity of 91.3% (as compared to 84.7% and 96.7% 
for the LJ and BACTEC MGIT 960 methods, respectively). The contamination rate (4.1%) and 
time to detection (10 days) was similar to that of the BACTEC MGIT 960 (2.2% and 7.1 days, 
respectively), but lower than with direct LJ.98 
The TLA method does not require sophisticated equipment or specialized CO2 incubators, only a 
standard microscope.99 Additionally, the use of solid agar reduces the risk of generating 
aerosols, thereby reducing the risk to the laboratory personnel. However, specialised safety 
conditions are still necessary. 
  ii) The Microscopic-observation drug-susceptibility assay 
The microscopic-observation drug-susceptibility (MODS) assay is similar to the TLA method, 
however the assay uses liquid culturing media in 24-well plates and analysis is done by inverted 
microscope.100 The 7H9 broth contains PANTA (polymyxin B, amphotericin B, Nalidixic acid, 
trimethoprim and azlocillin) which helps limit the growth of contaminating bacteria and fungi. 
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Drug-containing and drug-free control wells can then be inoculated with sputum (direct method) 
or with culture (indirect method). The plates are sealed in Ziplock® bags to prevent aerosol 
release and contamination.101 Growth in both the drug-containing and drug-free wells indicates 
that the isolate is drug-resistant to that specific drug. Speciation is then also done by identifying 
the cording morphology by microscopy.101  
The MODS assay performs well on both smear positive and smear negative sputum samples. A 
recent meta-analysis showed that the sensitivity and specificity for detecting RIF and INH 
resistance was 96% and 96%; and 92% and 96%, respectively.94 The average time to results for 
direct testing was 15-29 days,94 which is longer than for the TLA methodology. However a 
turnaround time of 9 days has been reported in an Ethiopian setting.100  
As with the TLA, the MODS assay does not require specialised equipment, although an inverted 
microscope is not always available in resource limited settings.101 Furthermore, the assay must 
be done in a specialised biosafety laboratory. The test costs an average of US$ 2-3 and does not 
require great technical skill.102,103 However, the method does carry a high workload, as plates 
need to be analysed daily.  
An additional disadvantage for both the TLA and MODS assays is that although the cording 
morphology is unique to the Mycobacteria, the pattern may also be evident in certain NTMs, 
including M. kansassi.102 
 
 2.3.5  Colorimetric assays 
A potential improvement regarding speed and cost of DST in low resource settings is the use of 
colorimetric assays of which various adaptations have been proposed. 
   i) Alamar Blue/Resazurin assay 
The Alamar Blue assay was first proposed in 1995 for the detection of drug-resistant M. 
tuberculosis.104 A subsequent study has found that Alamar Blue and Resazurin are in fact the 
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same compounds, however Resazurin is a non-proprietary agent which is more cost-effective.105 
The blue compound is added to liquid culture medium and is reduced to a pink colour by 
bacterial metabolism. The addition of anti-TB drugs to the media and subsequent colour change 
(from blue to pink) therefore indicates the presence of a resistant isolate. 
This methodology has been used to detect INH, RIF, streptomycin (SM) and EMB resistance and 
the results correlated well with the gold standard agar proportion method. Additionally, results 
were obtainable within 7-14 days by indirect testing.104  
To enable high-throughput, the Alamar Blue and Resazurin assays have been adapted to 
microplate formats.106,107 The Resazurin microtitre assay (REMA) has also been successfully 
adapted to detect resistance to pyrazinamide (PZA) (for which conventional DST is difficult due 
to the low pH required for testing)108 and various second-line anti-TB drugs including OFL, 
ethionamide (Eto), Km, Cm, and para-aminosalicylic acid (PAS).109,110 
  ii) MTT assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay is mostly done as 
an indirect DST during which the yellow compound is reduced to form purple MTT formazan 
crystals by metabolically active M. tuberculosis. The dissolved crystals may then be analysed by 
spectrophotometry. The compound is more expensive than the non-proprietary Resazurin and 
there is the need for an extra solubilisation step.111 
This assay has been used to detect INH and RIF resistance with similar sensitivities and 
specificities to the agar proportion method112 and as with the Alamar Blue and Resazurin assays, 
it has also been adapted to a higher throughput microplate format for the second line drugs Km, 
Cm, Eto, PAS, clarithromycin (Clr), clofazimine (Cfz), levofloxacin (Lfx) and rifabutin (Rfb) which 
correlates well with the 7H11 agar proportion method.113  
The MTT assay also performs well as a direct method using sputum samples for detecting 
rifampicin resistance with an average time to results of 2 weeks.114 
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  iii) Nitrate reductase assay 
M. tuberculosis can reduce nitrate to nitrite by the nitro-reductase enzyme. This inherent ability 
can be exploited to enable more rapid detection of the bacteria and DST during culture.  
The nitrate reductase assay (NRA) involves the addition of potassium or sodium nitrate 
(1000mg/L) to standard culture medium (solid, agar or liquid) which may also contain critical 
concentrations of antibiotics (the concentration that inhibits the growth of 99% of cells in antibiotic 
sensitive strains of M. tuberculosis ).115 If M. tuberculosis is present in the media and is able to 
grow successfully, the nitro-reductase enzyme will convert nitrate to nitrite which can be detected 
by the addition of the Griess reagent (0.2% naphthylenediamine dihydrochloride, 2% 
sulphanilamide and 5% phosphoric acid) which causes a pink-purple colorimetric reaction in the 
reduced samples. A colour reaction in a culture containing antibiotic will therefore indicate 
resistance to that anti-TB drug.116  
The NRA was initially done as an indirect assay on solid LJ media; however, in an attempt to 
shorten detection time, the feasibility of the method has been investigated in liquid cultures and 
by the direct method.116,117 The average time for the detection of M. tuberculosis by the indirect 
method is 23 days94 and high correlation is seen with the standard phenotyping methods, 
especially for the detection of INH and RIF resistance. A recent meta-analysis showed that the 
pooled sensitivity and specificity for detecting RIF resistance with NRA was 99% and 100% and 
for detecting INH resistance, 94% and 100% respectively.94 Sensitivities for SM and EMB 
resistance are however much lower due to the inherent difficulties associated with standard 
phenotypic DST for these drugs,1 therefore they require further analysis to reach the WHO 
proposed minimum efficiencies.118 The method has also been investigated in the detection of 
PZA resistance, which is notoriously difficult to do due to the low pH required by the test.108 By 
using nicotinamide resistance as a marker of PZA resistance, the test could be done in a neutral 
pH and showed a sensitivity and specificity of 91% and 94% respectively.119 
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Although the Colorimetric assays are simple to perform and are particularly useful in resource 
limited settings, the tests still require biosafety laboratories and may be affected by bacterial 
contamination and therefore subsequent speciation is still necessary.79 
 
 2.3.6 Phage Amplification Assays 
To address diagnostic delay, the use of mycobacteriophages (which can replicate rapidly) has 
been investigated. The assay requires infecting mycobacterial cultures with mycobacteriophages 
(most commonly the mycobacteriophage D29).120 These phages are then able to replicate within 
viable mycobacteria, which can be detected either by the phage amplified biological (PhaB) 
assay, or by a luciferase reporter assay.120 The former involves plating the phage onto the rapid 
growing M. smegmatis species which then undergoes lysis and characteristic plaque formation 
as the phage replicates. This will provide a numerical indication as to the number of viable 
bacteria in the original culture. Alternatively, the luciferase reporter phage assay produces light. 
Phage assays can also be used in DST by adding anti-TB agents to the cultures. Non-viable 
bacteria, i.e. those which are drug-susceptible, will not be able to support phage infection and 
replication in the presence of the antibiotics.120  
Numerous validation studies have been done and a recent meta-analysis of 19 studies (including 
8 commercial assays (FASTPlaque-TB kit, Biotec Laboratories Ltd., Ipswich, UK) and 7 
luciferase reporter assays) reported that 11 of the 19 studies showed sensitivities and 
specificities exceeding 95% for detecting RIF resistance. In addition 13 of the 19 studies showed 
more than 95% agreement with the reference standards. A higher sensitivity correlated with 
using culture isolates rather than sputum samples.120 In addition, in a direct comparison with 
smear microscopy, the phage-based assay showed a slightly higher diagnostic accuracy in 
detecting M. tuberculosis disease.121 
In summary, the phage-based diagnosis of M. tuberculosis infection and associated drug-
resistance is a rapid (<2 days turnaround time on culture isolates),79 low cost and highly sensitive 
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method. However, high rates of false positives have been observed120 and contamination may 
affect results. Phages are also able to infect and replicate in multiple mycobacterial species, 
necessitating further speciation by alternative tests.79 
 
2.4. Genotypic methods 
Most phenotypic diagnostic methodologies are hampered by the slow growth rate of the 
mycobacteria and also need further speciation to confirm the aetiological agent as M. 
tuberculosis. Therefore it may be wise to focus on genetic markers within and specific to the M. 
tuberculosis genome to accelerate the diagnosis of both TB and anti-TB drug resistance. 
Genotypic-based diagnoses therefore have a number of potential advantages over phenotypic 
based methods in that (1) there are more data points available to analyse than with phenotypic-
based testing, (2) determination of the phenotype is not dependant on the culturing of the 
bacteria and (3) the method is more specific and can be performed more rapidly. However, 
phenotypic-based methodologies by culture remain the gold standard for the diagnosis of M. 
tuberculosis infection and associated drug-resistance. 
 
 2.4.1 Hybridisation Assays 
Line-probe hybridisation assays are based on the use of the polymerase chain reaction (PCR) to 
amplify regions of interest in the mycobacterial genome followed by reverse hybridisation to 
sequence specific probes. These hybridisation assays are often designed as deoxyribonucleic 
acid (DNA)-strips which can simultaneously detect M. tuberculosis complex infection and anti-TB 
drug resistance.  
In 2008, the WHO released a policy statement in which they suggest that the molecular line-
probe assays that detect RIF resistance (thereby rapidly identifying MDR-TB patients), are the 
most advanced novel diagnostic technology currently available.122 WHO recommended that 
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these assays (more specifically the GenoType® MTBDRplus assay (HAIN Lifescience, GmbH, 
Nehren, Germany)) be implemented directly on all smear-positive sputum samples to enable 
rapid detection of MDR-TB.122,123 However, they acknowledge that mycobacterial culture is still 
necessary for sputum smear-negative samples and for second-line DST.122 
Two commercial line-probe assays are currently available. The INNO-LiPA Rif TB assay 
(Innogenetics, Ghent, Belgium) can detect M. tuberculosis complex and RIF resistance with a 
recent systematic review of the method reporting sensitivities and specificities ranging from 82 to 
100 and 92 to 100% respectively.124 However, this assay is not able to detect additional anti-TB 
drug resistances.123 
An improved assay, the GenoType® MTBDRplus assay is able to detect the most common 
mutations in the rpoB (responsible for RIF resistance) and the katG and inhA promoter genes 
(responsible for resistance to INH).123 A recent meta-analysis reported the sensitivity and 
specificity for detecting RIF resistance to be 98.1% and 98.7%, respectively, and slightly lower 
for detecting INH resistance (84.3% and 99.5%, respectively).123 The average time to analysis 
was only 2 days when done directly on sputum positive samples. The assay also performed well 
in the highly endemic setting of South Africa with the cost being half of that for conventional 
phenotypic testing.125 
A possible application of results obtained from the GenoType® MTBDRplus assay would be in 
treatment guidance. Cases which show inhA promoter mutations may benefit from the use of 
high dose INH therapy125 as these mutations confer low level resistance to INH (as compared to 
the high levels of resistance encoded by katG mutations). 
Recently, Hain LifeSciences released the GenoType® MTBDRsl assay which is capable of 
detecting resistance to FQs, Cm/Am/Km and EMB by targeting the gyrA, rrs and embB genes, 
respectively. A recent study investigated the accuracy of the assay on culture isolates and 
sputum samples compared to conventional second-line DST and reported combined sensitivities 
and specificities of 90.2% and 100% for FQ, 83.3% and 100% for Cm, 86.8% and 100% for 
Am/Km and 59% and 99.1% for EMB resistance, with a turnaround time of only 6 hours.126 
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Hybridisation assays do however have a number of disadvantages, including that these assays 
focus only on the most prominent single nucleotide polymorphisms (SNPs) and not all the known 
SNPs that encode anti-TB drug resistance. As yet unknown SNPs will of course also remain 
undetected. Additionally, these assays require well-trained staff, some dedicated equipment and 
specialised laboratory infrastructure (including dedicated work stations to prevent cross-
contamination). Lastly, but perhaps most importantly, the technique is an open-tube format, with 
the potential for release of amplicons and therefore an increased risk for cross-contamination. 
This may have serious consequences, including an increased rate of false-positive results and 
thus, inappropriate treatment. A possible solution would be to do random repeat assays so as to 
control for contamination. 
 
 2.4.2 DNA chip technology 
DNA Biochip technology is similar to that of the hybridisation assays, in that PCR is done and the 
products are hybridised to a solid phase containing the oligonucleotide probes designed to target 
regions of interest. Binding of the DNA to the probe produces a fluorescent signal which can be 
detected by confocal microscopy. These Biochips are able to simultaneously detect the 
aetiological agent as well as associated drug-resistance.127,128 
Numerous commercial and in-house DNA Chips have been developed including the 
Combichip™ Mycobacterial chip (GeneIn, Busan, Korea) and the DNA microarray (LCD array) 
(Chipron, Berlin, Germany), which can detect resistance to RIF and INH,129,130 the TB-Biochip 
oligonucleotide microarray system (Argonne/Engelhardt biochips, USA/Russia) and the high 
density DNA probe arrays which can detect only RIF resistance;131,132 and the biological 
microchip TB-Biochip-2 (Engelhardt Institute, Moscow, Russia) which can detect for FQ 
resistance.133  
Sensitivities and specificities vary amongst the different systems, but are similar to those of other 
NAATs. Reduced sensitivities for detecting resistance are mainly due to undetected mutations, 
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which occur elsewhere in the genome, or have not yet been identified.131 Biochips have been 
used in high incidence settings and the gel-based biochips able to detect INH, RIF and FQ 
resistance have been certified by the Russian National Regulatory Agency for routine use in 
clinical applications.134 
However, the major drawback of DNA chip technology is the exceptionally high cost of the 
equipment and the difficulty in the interpretation of the data and results.  
 
 2.4.3 Multiplex Ligation-dependent Probe Amplification 
A recent improvement to the solid phase hybridisation assays is the liquid phase multiplex 
ligation-dependent probe amplification (MLPA). This has the potential for overcoming defective 
probes which may be incorporated on the solid-based systems during manufacturing, transport, 
or incorrect handling. Probes in the liquid system can be prepared in bulk and subsequently 
validated on well-characterised strains.135 
The method involves the overnight hybridisation of well-designed probes targeting sequences of 
interest to denatured DNA and subsequent ligation of the probes. Amplification of these ligated 
probe sequences is then done by PCR using one set of primers which are complementary to all 
the pre-designed probes and the resultant amplification products are then visualised by gel 
electrophoresis (if probes were designed to have different lengths) or by capillary 
electrophoresis.135 
A recent study135 investigated the use of MLPA in M. tuberculosis and designed an assay which 
could provide information on drug resistance (probes targeted 5 codons in rpoB, the inhA -15 and 
katG -315 promoter codons; and the embB306 codon; for RIF, INH and EMB resistance 
respectively). The assay also included probes which could identify which principal genotypic 
group the isolate was derived from (gyrA codon 95 and katG codon 463), the putative virulent 
strain Haarlem (ogt codon 15) and the various Beijing lineages (mutT2 codon 58, mutT4 codon 
48, ogt codon 12 and ogt codon 37). Furthermore, speciation was done (16S rRNA gene and 
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IS6110) and in the case of M. tuberculosis isolates, analysis allowed the differentiation of the 
“ancient” and modern forms (TbD1).135 Results were obtainable (in a single tube) within 24 h 
following short term culture (2 weeks) in Middlebrook 7H9 medium and were 100% specific for all 
but 2 probes (mutT4 codon 48 and embB codon 306). The method could detect all the isolates 
harbouring mutations targeted by the probes; however some resistance was not detected, since 
the assay identified only 71% (20/28) of the RIF resistant isolates and 82% (27/34) of the INH 
resistant isolates. Results for EMB were not reported. The reduced sensitivity of the assay may 
be due to the drug-resistance probes chosen. These should be reflective of the most common 
drug-resistance mutations occurring in the regions analysed. However, the assay allows for the 
easy substitution of more region-relevant probes. Furthermore, the authors reported preliminary 
success of the assay applied directly to diluted sputum samples.135 
 
 2.4.4 Single Strand Conformation Polymorphism analysis 
Single Strand Conformation Polymorphism analysis (SSCP) is based on the electrophoretic 
mobility change that a nucleotide substitution causes in single stranded DNA fragments. The 
technique involves PCR amplification of the DNA region of interest, subsequent denaturation to 
form single stranded DNA fragments and then electrophoresis on a polyacrylamide gel. Mobility 
shifts compared to the wild-type reference sample, indicate the presence of a SNP.136  
Screening of the rpoB, katG, inhA and ahpC genes in the genome of M. tuberculosis by PCR-
SSCP showed a sensitivity of 96 and 87% for the detection of RIF and INH resistance 
respectively.137 Specificity in both cases was 100%.137 Nested-PCR followed by SSCP analysis 
for RIF susceptibility has been shown to be similar to conventional DST and DNA sequencing.138 
A recent report investigated the use of nested PCR-SSCP in detecting PZA resistance and 
showed a sensitivity of 86% and specificity of 96% on Chelex purified sputum samples.139 The 
reduced sensitivity was due to a number of PZA resistant samples which did not harbour 
mutations in the target gene, pncA. 
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Since the assay is not able to identify which specific SNP is involved in causing the resistance, 
the method relies on ensuring that the region of interest targeted contains resistance-causing 
mutations only and no silent polymorphisms. An additional disadvantage is that the method is 
labour intensive, requires a high level of technical skill and that results take 24 hours to 
generate.136  
 
 2.4.5 High Resolution Melting Analysis 
The relatively new technology of High Resolution Melting Analysis (HRM) is similar to SSCP 
analysis, since it can also screen for mutations. However, in contrast to assessing the 
electrophoretic mobility of single stranded DNA, it is based on the thermal denaturation profiles of 
specific DNA fragments which are dependent on the nucleotide sequence contained therein.140 
Thus, any change in the nucleotide sequence would alter the thermal denaturation profile, which, 
in turn, can be detected by measuring the efficiency of binding of a fluorescent dye to the DNA 
fragment at different temperatures.141 Numerous HRM platforms are commercially available, 
including the Rotorgene-Q (Qiagen, Venlo, Netherlands), LightCycler LC480 (Roche, Basel, 
Switzerland) and HR-1 (Idaho Technology, Utah, USA) instruments. Several fluorescent dyes 
have also emerged which are ideal for HRM applications as they are fully saturating and DNA 
intercalating. 
Nucleotide transversions (A:T and G:C) can be difficult to detect directly as they have very little 
influence on the overall thermal denaturation profile. This can be overcome by analysing DNA 
heteroduplexes (formed between DNA fragments with and without nucleotide change 
(heteroduplex and homoduplex, respectively)).142  
A recent study applied this technology to detect RIF resistance mutations with simultaneous M. 
tuberculosis complex speciation and reported a sensitivity and specificity of 98% and 100%, 
respectively when applied to purified DNA. No statistical difference was detected in the 
performance of this “FAST-Rif” (“Fluorometric Assay for Susceptibility Testing of Rifampicin”) 
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method when applied to short-term boiled cultures.143 However, the FAST-Rif method was 
hampered by the open-tube format, which could lead to amplicon cross-contamination and the 
reporting of false positive results. A possible solution would be to “seed” the reaction with wild-
type DNA as was done in a similar study in Austria.144 However, this study used purified DNA 
from clinical samples, which adds cost and causes a lengthy diagnostic delay. Additionally, the 
seeding of PCR reactions, could lead to false negative results if the clinical specimens fail to 
amplify.  
HRM for the detection of drug-resistance is further hampered by difficulties associated with 
multiplexing (i.e. for the detection of multiple gene targets) to detect resistance to more than one 
drug in a single run; however, this remains a promising technology due to the rapid assay time 
(~2 hours), high throughput and automation capabilities, and the relatively inexpensive 
equipment required. 
 
 2.4.6 Isothermal amplification methods 
  i) Loop-mediated isothermal amplification 
Loop-mediated isothermal amplification (LAMP) relies on auto-cycling strand displacement DNA 
amplification which is done at a uniform temperature by the enzyme Bst polymerase. This implies 
that no expensive PCR equipment is needed, as the technique requires only a standard 
laboratory water bath or heating block to maintain the uniform temperature. The resulting stem-
looped amplicons can be visually detected by the formation of a white magnesium 
pyrophosphate precipitate.145 However, this precipitate may be difficult to see. A possible 
improvement involves the addition of the fluorescent SYBR Green I dye following amplification, 
however, this would increase the risk of cross-contamination and false-positive results by the 
need to open the tube.146  
Recently the addition of calcein (a fluorescent metal indicator) has enabled improved 
identification of successful amplification while maintaining a closed-tube format. When successful 
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DNA amplification occurs, pyrophosphate ions (P2O74-) are generated which allow the release of 
manganous ion (Mn2+) which quenches the calcein, thereby emitting a more prominent green 
fluorescent signal.146 
The increased specificity of the LAMP technique is due to the incorporation of multiple 
oligonucleotide primers targeting the same region. The enhanced DNA amplification efficiency 
ensures amplification of up to 50 times more than by standard PCR.147  
Numerous LAMP-based assays have been designed to detect M. tuberculosis, target areas 
specific to Mycobacteria include the gyrB,145 rrs148 and rimM146 (encoding 16S rRNA-processing 
protein) genes. A recent study investigated the use of the highly repetitive IS6110 Insertion 
Sequence and reported enhanced sensitivity in both purified and crude samples, detecting 
essentially all smear-positive specimens and half of smear-negative specimens.149 
In summary, LAMP is a rapid (<90 min), highly specific and sensitive technique, which requires 
minimal infrastructure and laboratory skill. However, the technique has only been developed to 
detect M. tuberculosis and currently provide no indication of TB antibiotic susceptibility. 
  ii) Cross-priming Amplification 
An improved methodology for detecting smear negative TB involves adaptation of the LAMP 
technique to include cross-priming amplification (CPA). Ustar Biotech (Hangzhou, China) has 
developed a CPA and detection kit contained in a closed plastic device, which includes 6 to 8 
cross-linked primers targeting the gyrB gene. The CPA occurs with the aid of the Bst enzyme at 
an isothermal temperature (in a waterbath) and the amplified products then hybridise to a lateral 
flow strip housed within the same plastic device.  A recent publication reported sensitivities and 
specificities of 92.8% and 98.8% compared to the BacT/Alert 3D liquid culture method in purified 
sputum samples. Furthermore, they found that CPA was more sensitive at detecting sputum 
smear negative TB than the LAMP assay.150 
In summary, CPA shows many of the same advantages of the LAMP assay, with improved 
smear-negative TB detection, however, as with LAMP, the method has not been adapted to 
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detect drug susceptibility and no internal control system is used. Furthermore, the fairly 
complicated sputum processing in a biological safety cabinet needs to be simplified to improve 
turnaround times.150 
  iii) Rolling Circle amplification  
Rolling Circle Amplification (RCA) is a relatively novel amplification technique which can 
significantly improve the detection of nsSNPs by incorporating padlock probes which are 
complementary to the 5’ and 3’ ends of the target region.151 These are then bridged by a genetic 
linker region, so that when hybridisation to the complementary sequence occurs in the correct 
orientation, DNA ligase will form a closed circular molecule, which is then exponentially amplified 
by RCA.152 Perfect complementarities are necessary for successful amplification, therefore non-
specific binding is restricted. Correct probe design is essential for enhanced specificity, with the 
5’-probe generally designed to have a higher melting temperature (Tm) and the 3’-probe to have 
a lower Tm than that used for ligation of the probe.152 The inclusion of an exonucleolysis step, 
which removes the ligated padlock probes and template PCR product, ensures that amplification 
is ligation-dependant. Rolling Circle Amplification, as with LAMP can be done under isothermal 
conditions using standard laboratory equipment such as a heating block or waterbath.151 
Resultant amplification products may be monitored on real-time PCR instruments following the 
addition of a fluorescent intercalating dye, with the presence of a signal indicating successful 
probe binding.153 
Only one study has been done using RCA for drug-susceptibility testing in M. tuberculosis. This 
study used probes specific to the two most prominent nsSNPs (one in codon 315 of the katG and 
one at position -15 of the inhA gene) conferring INH resistance on purified DNA isolates.153 
Although it is believed that over 80% of INH-resistant isolates harbour one of these two 
mutations,154 the study showed that only 61% of their INH resistant isolates harboured one of 
these mutations and furthermore, that 26% of their INH resistant study population had no 
mutations in the inhA and katG genes. Sensitivities and specificities were not reported.153 
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While RCA is a rapid and cost-effective amplification technique, it is hampered by the number of 
nsSNPs that can be detected in a single analysis run. Furthermore, the absence of probe binding 
and a signal may indicate a false result in the case where amplification failed. Further 
investigation into including amplification controls and the addition of multiple nsSNP targets may 
increase the sensitivity of the assay. Validation on crude isolates is also necessary as culture 
and DNA purification are costly and time-consuming.  
  
 2.4.7. Molecular Beacons 
The real-time based molecular beacon technique is able to detect amplicons as they are 
synthesised and can distinguish single nucleotide substitutions.155,156 The beacons consist of 
hairpin-shaped DNA probes flanked by a fluorescence quencher such as DABCYL (4-(4’-
dimethylaminophenylazo) benzoic acid) and a fluorophore (e.g. fluoroscein).157 When the beacon 
binds to the complementary DNA target sequence, the probe undergoes a conformational 
change which releases the fluorophore from the quencher, resulting in a fluorescent signal which 
can be detected by real-time instrumentation.158 
Advantages of the method include that the assay can be done in a closed tube system and that 
the fluorescent output eliminates the need for post-amplification processing and associated 
amplicon release.157 Additionally, multiple mutations may be targeted in a single reaction due to 
the availability of various fluorophores with different emission spectra.157 Molecular Beacons 
have also been shown to be useful in smear-negative culture positive sputum samples.159 
A recent meta-analysis of Molecular Beacon technology for DST showed a pooled sensitivity and 
specificity of 97 and 100% for RIF resistance and 82 and 100% for INH resistance on clinical 
isolates, respectively.160 The reduced sensitivity in detecting INH resistance detection may be 
due to mutations in other regions of the genome. Most studies focused on mutations in the katG 
and inhA genes, which confer the majority of INH resistance in MDR-TB patients.157 
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The Foundation for Innovative New Diagnostics (FIND) have sponsored the development of an 
automated sputum processing and real-time based molecular beacon assay, the Xpert MTB/RIF 
Assay (Cepheid Inc., Sunnyvale, California, USA), which can detect M. tuberculosis complex and 
associated RIF resistance directly from sputum sample using ultra-sensitive hemi-nested PCR. A 
recent validation study reported a detection limit of 4.5 genomes or 131 colony forming units 
(CFU)/ml (in clinical specimens) per reaction and a turnaround time of less than 2 hours.161 
Additional advantages of the system include the use of independent cartridges, which allow 
individual runs without the need for processing samples in batches. The system is also fully 
automated in that sample decontamination, PCR and real-time analysis occurs within the 
apparatus. An internal amplification control, Bacillus globigii is also included in each cartridge. 
The Xpert MTB/RIF Assay was able to detect M. tuberculosis complex with a 100% sensitivity 
and specificity in smear-positive clinical samples, however, sensitivity was reduced to 71.7% in 
smear-negative cases. The method showed 100% sensitivity and specificity for detecting 19 of 
the most common mutations occurring in the rpoB gene among culture-positive retreatment 
cases from Uganda.161 
Molecular beacons and the automated Xpert MTB/RIF Assay show promise, however, detailed 
cost analysis and further validation studies in high-incidence settings needs to be done. 
 
 2.4.8 Multiplex allele-specific PCR 
The multiplex allele-specific PCR (MAS-PCR) includes several oligonucleotide primers in a single 
PCR reaction which are designed to be allele-specific, implying that they will bind only if the allele 
targeted is present in the sample. Subsequent analysis of the amplicon banding patterns by gel-
electrophoresis will reveal the allele present and the associated drug-susceptibility profile.162 
This technique has shown to be successful in detecting the most common mutations in the katG 
and inhA genes153 encoding INH resistance and the rpoB gene encoding RIF resistance.162 
These studies revealed high specificities; however, sensitivities were low (even less than the 
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GenoType® MTBDRplus hybridisation assay).162 This may be due to the limited number of 
mutations targeted, since only the most prominent nsSNPs causing anti-TB drug resistance are 
targeted.  
An additional disadvantage of MAS-PCR is that it is unable to distinguish heterogeneous 
populations.162 This is especially important in cases of acquired drug-resistance as these 
specimens consist of both drug-susceptible and -resistant bacteria. Furthermore, MAS-PCR does 
not address diagnostic delay as culturing of samples is necessary, including a costly and time-
consuming DNA purification step. No studies have yet investigated the accuracy of the technique 
on crude sputum specimens. Finally, the post-amplification processing by electrophoresis 
requires the opening of tubes, allowing the potential release of amplicons. This is a particular 
concern in high-throughput laboratories where cross-contamination may lead to incorrect DST 
results and patient treatment. 
Validation of MAS-PCR directly on crude sputum specimens and the addition of more targets in 
other genes may improve the assay, however at this point there are more sensitive and specific 
molecular DST methods available.  
 
 2.4.9. Polymerase Chain Reaction Restriction Enzyme Analysis 
Speciation of Mycobacteria is important in identifying the causative agent of disease, since 
treatment may differ for the various species. The gold standard for speciation involves 
sequencing of 16S rRNA, however, this is costly and not possible in many laboratories.163 
Polymerase chain reaction restriction enzyme analysis (PRA) was proposed as a simple and 
rapid amplification method that could speciate Mycobacteria.164 The method involves 
amplification of a 441bp region of the hsp65 gene and subsequent restriction digestion with the 
BstEII and HaeIII enzymes. The digested DNA is then run on standard agarose gels and the 
resulting banding patterns are compared to species-specific patterns described in published 
tables164 or speciated by a web-based algorithm (http://app.chuv.ch/prasite). 
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Numerous studies have been done to validate PRA. Recent data shows that the technique is 
able to amplify mycobacterial DNA from 60% of smear-positive specimens that are not infected 
with M. tuberculosis and is able to speciate NTMs in 94% of those successfully amplified.165 The 
amplification rate improves with increasing smear positivity, with AFB 3+ slides showing an 
identification rate of 100%.166 When compared to bacterial phenotypic identification, PRA shows 
86% concordance and is able to differentiate between many species of mycobacteria, including 
the M. avium complex (MAC) which is common in HIV infected individuals.167 
A recent multicentre analysis of 8 laboratories was done to compare reproducibility of results on 
boiled cultures of 18 different mycobacterial species.163 The PRA showed a success rate from 
44% to 100% across the laboratories, with accuracy being associated with electrophoresis 
running conditions, the use of appropriate DNA size markers and the interpretation of the 
banding patterns.163  
Despite PRA being relatively cost-effective compared to sequencing of 16S rRNA and 
phenotypic classification, standardisation of the methodology and the equipment used is needed 
for accurate speciation. Additionally, training is necessary for correct interpretation of results. The 
PRA method has to our knowledge not been applied to detect drug-resistance, however 
multiplexing would be problematic due to the various restriction sites and enzyme conditions. 
 
 2.4.10. In-house PCR 
To reduce the costs incurred by the purchasing of commercial assays, various in-house PCR 
based assays have been proposed. These vary in technique and post-amplification analysis and 
include many of the techniques described in this section (Section 2.4). 
Recent meta-analyses of in-house PCR for the detection of M. tuberculosis in sputum samples 
found varying results between the reported methods and could therefore not provide pooled 
sensitivities and specificities.168,169 However, the use of nested-PCR methods and IS6110 as a 
target has been associated with higher diagnostic accuracy.168 
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Although in-house PCR methods are generally more sensitive than the commercial assays in 
detecting pulmonary TB, they are less specific and the lack of direct comparisons between the 
various reported “home brew” tests complicate the recommendation of any of these in routine 
diagnosis of M. tuberculosis or associated drug-resistance.170 
  
 2.4.11. Commercial NAATs 
Numerous commercialised NAATs have been developed based on techniques described in this 
section (Section 2.4), including the Gen-Probe Amplified M. tuberculosis Direct test (AMTD) 
(Gen-Probe Inc., San Diego, California, USA), Roche Amplicor Mtb test (Roche Molecular 
Systems, Branchburg, New Jersey), BD-ProbeTec Direct (SDA) (Becton Dickinson Diagnostic 
Systems, Sparks, Maryland, USA) and the GenoType® MTBDRplus assay (HAIN Lifescience, 
GmbH, Nehren, Germany).171 Many of these have been approved by the American Food and 
Drug Administration (FDA) for use in sputum-positive specimens. Recently, a second generation 
AMTD (E-AMTD) was FDA approved for use on smear-negative specimens.171  
Most of these methods rely on M. tuberculosis detection by amplification and analysis of the 16S 
rRNA or IS6110 regions. Fully automated systems such as the COBAS Amplicor MTB (Roche 
Diagnostic Systems, Mannheim, Germany) and the Xpert MTB/RIF Assay (Cepheid Inc., 
Sunnyvale, California, USA) are also available. 
As is the case with in-house PCR assays, a recent meta-analysis of commercial assays for both 
smear-negative and -positive samples, reported significant heterogeneity (p<0.001) between 
commercial NAATs, with sensitivities and specificities ranging from 36 to 100% and 54 to 100%, 
respectively, compared to culture.171 This could be due to the various methodologies employed 
by each commercial test, but the results remained heterogeneous even when stratifying by each 
type of commercial test.171 However, the overall accuracy of commercial assays is higher than 
with in-house assays, due to the high standards of optimisation, numerous validation studies, 
inclusion of amplification controls and the standardisation of reagents.172 
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The commercial assays have significantly reduced turn-around times, however the cost of the 
assays and analysis equipment needed, along with the limited number of resistance-causing 
mutations targeted are their major drawbacks. 
 
 2.4.12. Sequencing 
Sequencing is considered the gold standard in genotypic analysis, since it can reveal the 
complete genetic profile of the region targeted. Any NAAT should be validated against 
sequencing results as well as phenotypic tests to determine diagnostic accuracy. Not only can 
sequencing be used in species identification (by analysis of 16S rRNA)173 and searching for the 
presence of known resistance-causing mutations, but it can also be used to screen for novel 
SNPs which may be associated with drug-resistance.101 
However, the major drawbacks of sequencing are the cost associated with the test, the technical 
skill required to operate the expensive equipment and analyse the resultant electrophereograms 
and the extensive infrastructure needed. This includes the need for separate rooms for DNA 
extraction, sample preparation, PCR, amplification analysis, purification of PCR products and 
DNA sequencing.  
Whole genome sequencing is gaining popularity in research spheres (such as at the Broad 
Institute, MA, USA) as it reveals the genetic sequence of an entire genome. It is hoped that 
future improvements in the technology and drastic reductions in the cost thereof, may make 
whole genome sequencing more accessible in resource limited countries and that genotypic 
testing by this methodology will become routine practice. 
 
In summary, PCR-based genotypic diagnostic tests hold a number of disadvantages in that they 
carry a high financial cost, require technically skilled staff and that there is the potential for cross-
contamination among the open-tube based assays, which is especially serious in high-
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throughput laboratories. Additionally, a negative result should be interpreted with caution since 
PCR inhibitors may be present in the sample analysed. Importantly in the case of DST results, 
not all the relevant resistance-causing mutations have been discovered. Although the specificity 
of the NAATs remains high, the variable sensitivities should be addressed. The most promising 
characteristic of NAATs is the drastic reduction in turn-around times, which are a vast 
improvement over the phenotypic-based assays, however, as NAATs are able to detect non-
viable bacteria as well, these assays should be interpreted with caution and empirical treatment 
undertaken until results can be confirmed by phenotypic and clinical data. 
 
2.5. Others 
 2.5.1. Urine-based tests 
  i) Lipoarabinomannan analysis 
More recently, the detection of lipoarabinomannan (LAM) antigen in urine samples of TB 
suspects has been investigated and has led to the development of a commercial ELISA-based 
assay (Clearview® TB ELISA, Inverness Medical Innovations, Bedford, UK).174 However, 
preliminary validation studies have revealed variable sensitivities, with a recent study reporting 
detection rates as low as 8% in sputum positive patients.174  
  ii) Transrenal DNA 
Short fragments of free DNA arising from the mycobacterial site of infection transverse the renal 
barrier and are excreted from the body in urine.40  These transrenal DNA (Tr-DNA) fragments are 
detectable by nested-PCR from the soluble portion of urine, using modified extraction and 
amplification conditions to isolate the low molecular weight fragments.40  
Previous studies showed promising results amongst HIV infected individuals for detecting M. 
tuberculosis infection,175 however, later studies have shown varying results regarding diagnostic 
accuracy.176,177 These studies however, targeted larger (>500bp) DNA fragments in urine 
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sediments. Recent data suggests that shorter (150 to 200bp) Tr-DNA can be detected (by using 
nested PCR targeting the IS6110 region) from the soluble portion of urine in 79% of culture 
positive TB patients and is undetectable in unaffected control subjects.40 Preliminary data also 
showed that Tr-DNA was no longer detectable in patients who were undergoing effective 
treatment.40 The development of a commercial-based Tr-DNA for the detection of M. tuberculosis 
infection is now underway (Xenomics, NY, USA).  
A particular advantage of the method is that it is non-invasive and may therefore be particularly 
useful in the diagnosis of children and in patients from whom sputum samples are difficult to 
obtain. Further evaluation in HIV-infected individuals is necessary to confirm the increased 
sensitivity in these patients. Multi-centre validation studies are necessary to evaluate the 
diagnostic accuracy amongst HIV-infected individuals and those with extra-pulmonary disease. 
 
 2.5.2 Rapid Analysis of Mycolic acids  
High Performance Liquid Chromatography (HPLC) can be used to do Rapid Analysis of Mycolic 
Acids (RAM),178 which quantitates mycolic acids extracted from an unknown organism. These 
mycolic acids are actively produced during vegetative growth and the resulting HPLC ultraviolet 
or fluorescent patterns can be analysed by software and compared to a database of known 
HPLC profiles to identify the organism. 
High performance liquid chromatography has been shown to be successful in speciation of 
mycobacteria isolated from short-term cultured clinical specimens.179 Additionally the 
chromatograms can also provide a quantitative measure of the total mycolic acids which show an 
almost linear relationship with the numbers of CFU/ml. Drug susceptibility testing can therefore 
be done by analysing peak heights after incubation with anti-TB drugs.180 A recent study showed 
an agreement of the RAM method with phenotypic DST of 99.5% for INH, EMB ad PZA and 
98.7% for RIF after 72 h of incubation, however, sensitivities and specificities were not 
reported.178 As the action of INH is on the mycolic acids of M. tuberculosis, results for INH were 
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more rapid and could be obtained following 30 min of short-term incubation in the Bactec 460 
radiometric growth system and subsequent mycolic acid extraction.178 
Rapid analysis of mycolic acids requires an extensive mycolic acid extraction procedure and is 
sensitive to bacterial contamination which may affect test results and lead to inaccurate 
diagnosis. Despite the possibility of automation, the cost of the HPLC equipment discredits this 
methodology in high incidence, low income areas.79 
 
 2.5.3. Adenosine Deaminase activity (ADA)  
Adenosine deaminase activity is a measurable response (most commonly by the Giusti 
method)181 which is activated by monocytes during the local inflammatory response caused by 
M. tuberculosis infection.182  
A review of the literature indicates that ADA testing is not accurate or useful for the diagnosis of 
pulmonary TB; however it shows promise for the detection of pleural TB and TB 
meningitis.170,183,184 
The determination of the ideal cut-off value for a positive reaction is still under debate and may 
affect diagnostic accuracy. An additional disadvantage is that ADA can be identified in other 
pathologic conditions which negatively influences the specificity of the assay.185,186  
 
 2.5.4. African pouched rats 
A recent study investigated the use of trained giant African pouched rats (Cricetomys 
gambianus) to identify positive sputum specimens by olfactory perception of mycobacterial 
specific volatile compounds).69 They showed a sensitivity in detecting M. tuberculosis infection 
similar to smear microscopy; however the advantage lay in the rats’ resistance to TB infection 
and their high-throughput capabilities. One rat was able to screen 140 samples in 40 min 
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compared to the 40 samples a technician would process in a day (WHO recommends 20 
samples per day).69 The trained rats were therefore up to 30 times faster than technicians.  
This detection system may have application in high TB incidence regions, however, the effect of 
HIV-co-infection on sensitivity and specificity warrants further investigation. Additionally, training 
of rats is a lengthy process and average rat life-span (8 years) and cost of upkeep should be 
taken into account.  
 
Despite the abundance of clinical, immunological, phenotypic and genotypic methodologies for 
detecting both M. tuberculosis and associated drug-resistance, there is no test with a high 
diagnostic accuracy which can be used at the bed-side (point of care). All tests have their 
advantages and disadvantages, with the possible solution to improved accuracy lying rather in 
using a combination of methodologies. For this, attention to cost, the need for infrastructure and 
technical expertise is necessary. Furthermore, the lack of accurate diagnostics for second-line 
drug-resistance warrants further investigation. 
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1. Abstract  
 
Tuberculous lymphadenitis is the most common cause of extra-pulmonary tuberculosis (TB) in 
developing countries. Lymphadenitis caused by non-tuberculous mycobacteria (NTM) requires 
consideration, particularly in immunocompromised patients and children in developed countries. 
Fine-Needle Aspiration Biopsy (FNAB) offers a valuable specimen collection technique, but 
culture confirmation, mycobacterial speciation and drug resistance testing (if indicated) is often 
unavailable in TB endemic areas and result in unacceptable diagnostic delay.  
We evaluated the diagnostic value of high-resolution DNA melting (HRM) analysis in the 
diagnosis of mycobacterial lymphadenopathy using FNAB and an inexpensive transport medium. 
Specimens were collected from patients referred to the FNAB Clinic at Tygerberg Hospital (June 
2007–May 2008) with clinical mycobacterial lymphadenitis. Cytology, culture, and HRM were 
performed on all specimens. The reference standard for disease was defined as positive cytology 
(morphological evidence plus mycobacterial visualisation) and/or a positive culture.  
Specimens were collected from 104 patients and mycobacterial disease was confirmed in 53 
(51.0%); 52 Mycobacterium tuberculosis and 1 NTM. Cytology was positive in 84.9% (45/53) and 
culture in 66.0% (35/53) of patients. HRM identified 52.8% (28/53) of cases. By using the defined 
reference standard, we recorded 52.8% sensitivity and 94.1% specificity (positive predictive 
value 90.3%) with HRM analysis.  
HRM analysis allowed rapid and species specific diagnosis of mycobacterial lymphadenitis in the 
majority of patients, permitting early institution of appropriate therapy. Optimisation of this 
technique requires further study.  
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2. Introduction  
 
Resource limited countries carry the brunt of the global tuberculosis (TB) epidemic, particularly 
those affected by the parallel human immunodeficiency virus (HIV) pandemic.1 According to the 
most recent World Health Organisation (WHO) estimates, in 2007, there were 9.3 million incident 
(newly diagnosed) TB cases of whom 1.4 million (14.8%) were HIV infected. The African region 
accounted for 79% of HIV-infected TB cases.1 Although TB incidence rates seem to plateau 
and/or decline in most regions, absolute numbers continue to rise due to increases in population 
size. The projected scale of the epidemic and ongoing transmission of drug resistant TB remains 
alarming.1 WHO estimated that between 2000 and 2010, 1 billion people will be newly infected 
with M. tuberculosis, resulting in 200 million TB cases and 35 million deaths.2  
Peripheral lymphadenitis is the most common extra-pulmonary manifestation of TB.3,4 TB 
lymphadenitis is also the most common cause of persistent cervical lymphadenopathy in children 
from TB endemic areas.5-7 In developed countries where the incidence of TB is low, NTM are 
frequently responsible for mycobacterial lymphadenitis, particularly in children and HIV-infected 
immunocompromised adults.3,8,9 In patients with a peripheral lymph node mass Fine-Needle 
Aspiration Biopsy (FNAB) is a valuable and underutilised specimen collection technique. This 
simple and safe procedure allows rapid confirmation of mycobacterial disease using 
cytomorphology and direct mycobacterial visualisation with either Ziehl-Neelsen (ZN) staining or 
fluorescence microscopy. 
Mycobacterial culture is required for accurate species determination (speciation) and drug 
susceptibility testing,10-13 because organisms in the M. tuberculosis complex are morphologically 
indistinguishable. The amount of material harvested during FNAB is minimal, and the needle 
needs to be rinsed at the bedside in liquid medium to facilitate culture. Although FNAB can be 
safely performed as an outpatient procedure by well-trained nurses,14 the need for direct 
inoculation and unavailability of liquid culture tubes limited decentralisation. Use of an 
inexpensive transport medium for direct inoculation has been described,15 which should facilitate 
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mycobacterial culture from FNAB’s performed in rural clinics and hospitals. Direct bedside 
inoculation at the time of FNAB collection provides an excellent diagnostic yield, but culture 
results may take up to 6 weeks and requires additional speciation.10,16  
Performing nucleic acid amplification tests (NAATs) on FNAB specimens may provide a rapid 
species specific diagnosis and expedite access to appropriate therapy. A recent systematic 
review demonstrated highly variable results with NAATs to diagnose TB lymphadenitis, reported 
sensitivities ranged between 2 and 100% (specificities 28–100%).17 Most NAATs analyse the 
polymerase chain reaction (PCR) products by gel electrophoresis or other open tube formats, 
which afford the opportunity for laboratory cross-contamination. These technically challenging 
techniques will pose problems in countries with limited laboratory resources. High-resolution 
DNA melting analysis (HRM) is a simple ‘‘closed tube’’ technique that reduces the risk of cross-
contamination. Specific PCR amplicons are identified according to their characteristic DNA 
melting profiles. The amplicons are combined with a saturating dye that fluoresces in the 
presence of double stranded DNA. It is heated through a range of temperatures while 
fluorescence is monitored.18 As the double stranded DNA dissociates (melts) into single strands, 
the fluorescence decreases. The melting peak of the specific infectious agent is identified. M. 
tuberculosis products melt at 90°C and other members of the M. tuberculosis complex at 86°C. 
This simple technique can be used in routine diagnostic laboratories.18,19 
The aim of our study was to evaluate the value of PCR-based HRM analysis,18 to provide a rapid 
and accurate diagnosis of mycobacterial disease using routinely collected FNAB specimens 
directly inoculated into liquid transport medium.  
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3. Materials and Methods 
 
All adults and children referred to the FNAB Clinic at Tygerberg Hospital (June 2007–May 2008) 
with a superficial lymph node mass suggestive of possible mycobacterial lymphadenitis and in 
whom written informed consent to participate in the study was obtained, were included. 
 
3.1. Specimen Collection 
FNAB was done following standard protocol as an outpatient procedure by a pathologist.10 The 
lymph node was stabilised by the aspirator and two needle passes were performed using a 23- 
or 25-g needle attached to a 10 ml syringe while applying a constant suction of no more than 2 
ml. From each aspirate two smears were prepared one fixed with commercial cytology fixative for 
Papanicolaou staining and the other air dried for the Giemsa and subsequent ZN staining. The 
residual material in the syringe and needle was collected by withdrawing an aliquot of liquid 
growth media from the TB transport bottle into the syringe and then expelling the contents back 
into the bottle. No additional needle passes were performed to collect material for microbiology or 
PCR. The TB transport bottles were prepared ‘‘in-house’’ in a laminar flow cabinet: 10 ml 
headspace glass vials containing 1 ml of Middlebrook 7H9 broth (with 0.2% glycerol and 0.05% 
Tween 80 added), sealed with 20 mm TFE/Sil Septa and 20 mm Aluminium open top seals and 
autoclaved at 120°C for 20 min.15  
 
3.2. Cytology 
Stained smears were evaluated for adequacy and to make a morphological diagnosis. If any 
specific lesion such as a lymphoepithelial cyst or neoplasia was present, this was reported. 
Alternatively, we reported ‘‘non-specific reactive lymphadenopathy’’ or ‘‘cytologically consistent 
with mycobacterial infection’’, based on specific morphological criteria.20-22 In immunocompetent 
patients with TB, epithelioid granulomata and epithelioid histiocytes may be identified in a 
background of reactive lymphocytes and plasma cells (Figure 1). A small amount of amorphous 
necrosis may also be identified. In immunocompromised patients, the cytological picture is that of 
abundant necrosis in which neutrophils and cellular debris are prominent (Figure 2). In patients 
with lymphadenitis due to M. bovis BCG or NTM infection, histiocytes with abundant foamy 
cytoplasm may be present.8,23,24  
 
 
Figure 1. Epithelioid granuloma in an immune competent patient. (Papanicolaou, X400).  
Figure 2. Abundant necrosis in which neutrophils and cellular debris are prominent consistent with 
tuberculous lymphadenitis in an immune compromised patient. (Papanicolaou, X400).  
 
Mycobacteria were visualised using a ZN stain performed on a Giemsa stained slide according to 
a slightly modified technique (Figure 3). Smears were differentiated in 3% acid alcohol for 1 
minute and counterstained with 1% methylene blue for 10 seconds only. In addition, one of the 
Papanicolaou stained slides was screened using a Zeiss Axiophot microscope with a fluorescent 
attachment and a wide-band blue excitation filter (450–480 nm); mycobacteria fluoresce as 
brilliant yellow bacilli, thin and slightly curved with polar enhancement and a uniform length of 
2.0–2.7 microns (Figure 4).11 
2 1 
 Figure 3. Modified ZN stain in a lymph node aspirate. (Ziehl-Neelsen, X400).  
Figure 4. Autofluorescence of mycobacteria in a lymph node aspirate. (Papanicolaou, X1000 with a 
wide-band blue excitation filter) 
 
3.3. Microbiology 
In the laboratory, 0.5 ml of the media was aspirated from the TB transport bottle, inoculated into 
a separate MGIT tube containing the PANTA (polymyxin B, amphotericin B, Nalidixic acid, 
trimethoprim and azlocillin) antibiotic mixture and incubated in a BACTEC MGIT 960 machine for 
42 days. All positive MGIT tubes were confirmed to contain acid-fast bacilli in the absence of 
bacterial contamination by ZN staining. Mycobacteria were identified as M. tuberculosis or other 
by standard PCR.25  
 
3.4. Extraction of Mycobacterial DNA 
The TB transport bottles containing the remaining 0.5 ml media were stored at -20°C until further 
analysis. Mycobacteria within a 250 µl aliquot were pelleted by centrifugation at full speed (14 
000 rpm) for 10 minutes. The supernatant was discarded and the bacterial pellet was 
resuspended in 1 ml phosphate buffered saline and re-centrifuged at full speed (14 000 rpm) to 
remove residual blood. Thereafter, the bacterial pellet was resuspended in 30 µl ddH2O and heat 
4 3 
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inactivated at 100°C for 20 minutes. The lysed bacterial extract was stored on filter paper (FTA® 
Classic Card Collection, Storage, and Purification system, Whatman, UK). Genomic DNA was 
eluted from the filter paper cards following manufacturers’ instructions (high pH, low pH protocol) 
and served as the template for subsequent PCR amplification.  
 
3.5. Speciation and HRM analysis 
Primers were designed to amplify the Region of Deletion 9 (RD9), present in M. tuberculosis and 
M. canettii, but absent from all other members of the M. tuberculosis complex. PCR was 
performed as previously described19 using an annealing temperature of 62°C and the following 
primers RD9Fs1 5’-CAA GTT GCC GTT TCG AGC C-3’, RD9FR 5’-GCT ACC CTC GAC CAA 
GTG TT-3’ and RD9INT 5’-CAA TGT TTG TTG CGC TGC-3’.26 Resulting amplification products 
underwent HRM analysis in a RotorgeneTM 6000 real-time rotary analyser (Corbett Life Science, 
Australia). The thermal denaturation profiles were measured as previously described.19 The 
infectious agent was identified by the RotorgeneTM 6000 software according to the presence of 
derivative melt peaks located within defined temperature bins. M. tuberculosis PCR products 
melt at 90°C (M. tuberculosis could not be differentiated from M. canettii, but M. canettii is very 
rarely observed and has not been recorded in the study setting) whereas PCR products of other 
members of the M. tuberculosis complex melted at 86°C (Figure 6). 
 
3.6. Reference Standard for Mycobacterial Disease 
The reference standard for the presence of mycobacterial disease17 was defined as positive 
cytology (morphology consistent with mycobacterial infection plus direct visualisation of the 
organism) and/or positive culture with speciation. 
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3.7. Statistical Analysis 
We assessed the diagnostic accuracy of PCR-based HRM analysis compared to cytology, 
mycobacterial culture and the reference standard as defined using Pearson’s Chi square (χ2) 
and Fisher’s exact tests. All analyses were conducted using Statistica Version 8. Ethics approval 
was obtained from the Institutional Review Board of Stellenbosch University (N05/03/043). 
 
4. Results 
 
FNAB specimens were collected from 104 patients with possible mycobacterial lymphadenitis in 
whom complete cytopathology and mycobacterial culture results were available together with 
PCR-based HRM analysis. The median age was 30 years with a range from 4 months to 62 
years. Children less than 13 years of age compromised 21.2% of the study population. There 
was no significant difference in gender distribution. HIV status was known in 46.1% of patients 
(48/104) and 75% of these were HIV positive (36/48). There were 23 HIV-positive patients and 6 
HIV negative patients with mycobacterial disease as defined by the reference standard above. 
Table I summarises the demographics and diagnostic outcome of the study population. 
Applying the defined reference standard 53 of the 104 patients (51.0 %) were diagnosed with 
mycobacterial lymphadenitis. Mycobacterial culture was positive in 35/53 (66.0 %) patients; 34 
M. tuberculosis and 1 NTM. Cytology was positive in 84.9% (45/53) of the cases. Cytology and 
culture were both positive in 27/53 (50.9%) cases, whereas HRM analysis was positive in 52.8% 
(28/53) of cases identified using the reference standard. The calculated sensitivity of HRM 
analysis was 52.8% and the specificity 94.1% (Table 1) with a negative predictive value of 65.8% 
and a positive predictive value of 90.3%.  
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Table1. Demographics and diagnostic outcome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Numbers Percentage 
Number of cases 104  
Age   
< 2 years 6 5.8 
<13 years 22 21.2 
> 13 years 77 74 
Unknown 5 5 
Gender   
Male 48 46.2. 
Female 51 49.0 
Unknown 5 4.8 
HIV status   
Positive 36 34.6 
Negative 12 11.5 
Unknown 56 53.9 
Cytodiagnoses   
Malignancy 12 11.5 
Reactive node  43 41.4 
Other (e.g. cyst) 4 3.9 
Cytology positive mycobacterial infection 45 43.3 
Cases with mycobacterial disease   
Culture and/or cytology positive (Reference Std) 53 100 
Cytology positive  45 84.9 
Culture positive  35 66.0 
Culture positive and cytology positive 27 50.9 
PCR positive mycobacterial infection 28 52.8 
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Concordance between the different diagnostic modalities and HRM analysis was poor, with 
Kappa values of 0.39 vs. cytology, 0.27 vs. mycobacterial culture, 0.19 vs. both cytology and 
culture, and 0.45 vs. cytology and/or culture (the defined reference standard). Figure 5 shows the 
insensitivity of the HRM method as 59% of isolates confirmed to contain M. tuberculosis by 
cytology and culture were not detected by this method. 
 
 
 
 
 
 
 
Figure 5. A Venn diagram depicting the number of samples positive for the different diagnostic 
methodologies. The reference standard for mycobacterial disease (shaded areas) is a positive Culture 
and/or Cytology/ZN result 
 
To investigate a possible association between mycobacterial load and the result of PCR-based 
HRM analysis, we tested for any correlation between the time to positivity (TTP, often used as a 
surrogate of mycobacterial load) and PCR outcome. Among those with positive mycobacterial 
cultures, no correlation between the time to positivity and PCR-based HRM analysis could be 
demonstrated; mean TTP in PCR positive cases was 18 days compared with 22 days in PCR 
negative cases (p = 0.22) (Figure 6). 
 
16 3 6 
12 5 
3 
11 
HRM 
Cytology/ZN Culture 
Figure 6. Rotorgene software depicting the derivative melt peaks located within defined temperature 
bins. M. tuberculosis products melted at 90°C and 
 
5. Discussion 
 
With global coordination of control efforts TB incidence 
signs of decline in all six world regions. However, the TB disease burden in areas plagued by the 
concurrent HIV pandemic remains at unprecedented levels.
for the development of strong laboratory networks in developing countries, the existing 
infrastructure remains poor in most TB endemic areas. South Africa, despite its relatively 
infrastructure and health care services, in 2007 reported a national TB incidence of 
739.6/100,000 population and an adult TB incidence in the Western Cape Province, a high 
burden region, of 1005.7/100.000.
 
 
M. tuberculosis complex at 86°C.  
rates seem to be stabilising and showing 
1
 Although there is some assistance 
27
  
good 
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In TB endemic areas with ongoing transmission, children constitute a significant percentage of 
the total caseload, estimated at 15–20%.28 Immune immaturity and/or compromise, most often 
due to HIV infection,29,30 influence the risk to develop extra pulmonary and/or disseminated TB as 
well as the likelihood of rapid disease progression and TB-related mortality.31,32 Autopsy studies 
in Africa30,33-36 have shown that up to 54% of deaths in HIV-infected adults and 20% in HIV-
infected children are due to TB. Reducing this mortality and morbidity necessitates early 
detection, efficient diagnosis and timely institution of appropriate therapy. 
FNAB is a simple, non-invasive specimen collection technique in patients with peripheral lymph 
node masses.10 It assists with rapid diagnosis of mycobacterial disease, but also helps to rule out 
alternative diagnoses that may require urgent treatment such as neoplasia. Diagnostic sensitivity 
is dependent on the experience of the pathologist and for mycobacterial disease varies from 32 
to 78%.10,37,38 Identification of the organism is essential particularly in immune compromised 
patients, as other opportunistic infections such as fungal organisms may elicit a similar 
morphological reaction pattern. Mycobacteria may be visualised using ZN staining, which is a 
very simple stain but has suboptimal sensitivity (20– 62%).10,17,39,40 Autofluorescence, using the 
ability of mycobacteria on Papanicolaou stains smears to fluoresce using a blue excitation filter 
requires no additional staining and improves sensitivity (65–67%).10,11 Culture is often regarded 
as the ‘‘gold standard’’, but is limited by poor sensitivity (reported to be as low as 2–34%)38,40 and 
is highly dependent on the culture medium and inoculation technique used. A positive result is 
delayed by 1–6 weeks and requires additional PCR-based testing for speciation. 
Direct NAAT application provides results in 3 to 6 hours and has been evaluated with respiratory 
and non-respiratory specimens such as FNABs.17,39-43 Test sensitivity with respiratory specimens 
is highly dependent on mycobacterial load and use current PCR-based tests are only advised in 
patients with sputum smear-positive TB. Results with extra-pulmonary disease have been 
variable but recent studies have shown excellent results. Use of a nested PCR in cervical TB 
lymphadenitis in Mexican children showed a sensitivity of 96% and a specificity of 93%46 
whereas a study utilising DNA from dried and fixed cytology smears showed a sensitivity of 85% 
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and specificity of 95% using nested PCR, although reference standards are not necessarily 
based on bacteriological confirmation of disease.44 
The majority of these studies use agarose gel electrophoresis to visualise the products, which is 
not practical in a microbiology laboratory. The open tube nature of the procedure also allows the 
release of amplicons, which pose a real risk of cross contamination. A recent systematic review 
evaluating the diagnostic utility of NAATs in TB lymphadenitis identified 36 peer-reviewed 
publications.17 The authors found marked variation in populations, test techniques, reference 
standards, volume of material utilised and quality indicators. Few studies controlled for cross-
contamination and inhibitors in clinical samples, thereby increasing the possibility of both false 
positive and false negative results. The reference standard used most frequently was culture, 
although the authors regard the sensitivity of culture from FNAB to be about 62%. Using an 
imperfect reference standard may lead to an underestimation of test performance, and this is a 
major limitation that is rarely acknowledged.45  
The current study attempted to address some of the shortcomings noted above. The reference 
standard used is a combination of positive cytology, defined as cytomorphological features 
consistent with mycobacterial infection combined with identification of the organism using ZN 
staining or autofluorescence and/or positive culture. The residual material from the fine-needle 
aspirates was collected in TB transport medium in a sealed bottle, minimising the possibility of 
contamination. After washing and concentration of the specimen, the pellets were placed on filter 
paper for storage and to remove inhibitors present in the specimen. After extraction of DNA, the 
products were amplified using primers designed to amplify the Region of Deletion 9 (RD9), 
present in M. tuberculosis and M. canettii, but absent from all other members of the complex.19 
The amplified products were then identified using high resolution melt analysis, which is a closed 
tube format that minimises the possibility of cross-contamination.  
This technique is rapid and simple, and the equipment required for the HRM such as the 
Rotorgene 6000TM real-time rotary analyser (Corbett Life Science, Australia) is relatively 
inexpensive. Up to 72 samples may be processed in a cycle which takes approximately 3 h. The 
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results of PCR using this technique did not differ significantly from that of cytology or culture 
when these were assessed independently against the reference standard. The sensitivity is 
relatively low, but the specificity is high at 94.1% as is the PPV of 90.3%. This enables 
appropriate therapy to be implemented early with a high degree of confidence in the majority of 
patients with disease, while continuing with culture in the PCR negative cases.  
Limited sample volume may have accounted for the low sensitivity observed. No additional 
needle passes or aspirates were performed and the material collected was limited to the residual 
amount left in the needle. Sensitivity may be improved if an additional needle pass is performed 
to obtain material for PCR. No single diagnostic modality was adequately sensitive to enable it to 
be used alone. FNAB provides material for cytology, culture and PCR using the transport 
medium described. This is of particular value in resource limited countries where laboratories 
tend to be centralised.1 Cytology slides once prepared are stable at room temperature, as is the 
transport medium where the mycobacterial organism has been shown to remain viable for up to 7 
days at room temperature, enabling both culture and PCR.14 
 Ideally, the PCR technique could be refined, increasing the sensitivity and thereby eliminating 
the need for culture, which is costly and lengthy. Use of the transport bottle facilitates both 
culture and PCR analysis, but material may be deposited directly onto filter paper for subsequent 
PCR analysis. Refined techniques need to remain simple inexpensive and appropriate for use in 
routine laboratories in countries with limited resources and skills that bear the burden of this 
devastating and persistent disease.  
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1. Abstract  
 
The increased incidence of tuberculosis (TB) lymphadenitis due to the human immunodeficiency 
virus (HIV) epidemic and the significant diagnostic delay by routine culturing methods has led to 
the need for a more rapid diagnostic method. We recently reported a rapid and specific 
molecular-based method which consisted of high-resolution melting (HRM) analysis of fine 
needle aspiration biopsies (FNAB) inoculated into transport medium bottles and subsequently 
spotted onto FTA® Classic Cards (Whatman, UK). In the current study, we aimed to simplify the 
procedure by circumventing the need for a transport medium bottle and spotting the samples 
directly onto the simpler FTA® Elute Cards.  
Fine-Needle Aspiration Biopsy samples were analysed from 65 adults and children with possible 
mycobacterial lymphadenitis and disease was confirmed in 41 patients (63.1%) according to the 
reference standard (positive cytology and/or a positive culture). Cytology was positive in 75.6% 
and culture in 80.5% of patients. HRM identified 46.3% (19/41) TB lymphadenitis samples with a 
sensitivity and specificity of 46.3% and 83.3% respectively as compared to the reference 
standard. This was slightly less than by the previously described method. 
The use of the simpler more cost-effective FTA® Elute Card with the omission of the transport 
medium bottles did not provide an improvement over the previously described indirect method. 
However, both methods were able to provide a rapid and specific diagnosis in ~50% of patients, 
thereby allowing prompt initiation of therapy. The remainder of cases would be diagnosed at a 
later stage through routine phenotypic culturing methods.  
We therefore propose a diagnostic algorithm which takes HRM and cytology results into 
consideration in that if HRM and cytology are indicative of mycobacterial disease, then treatment 
is initiated, if HRM and cytology do not correlate or are both negative for disease, then culture 
results are awaited before treatment initiation.  
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2. Introduction  
 
The number of lymphadenitis cases is steadily rising due to the increased incidence of extra-
pulmonary tuberculosis (TB) spurred on by the human immunodeficiency virus (HIV) 
pandemic.1,2 These lymph node masses are most often analysed by Fine-Needle Aspiration 
Biopsy (FNAB), which is a simple, relatively non-invasive outpatient procedure3 providing 
samples for further investigations including cytomorphology and TB culture.4  
While phenotypic culture of Mycobacterium tuberculosis from a FNAB is regarded as the gold 
standard for diagnosing TB lymphadenitis, the success thereof is dependent on the quality of the 
specimen collected. Transport of the FNAB to the laboratories is also problematic and the 
standard liquid inoculation tubes such as the Mycobacterial Growth Indicator Tubes (MGIT, 
Beckton Dickinson, USA)3 have limited shelf lives and require specific storage requirements. 
Furthermore, due to the slow growth rate of mycobacteria, culture methods may take 2 to 6 
weeks to generate results, therefore leading to a significant diagnostic delay. Cytomorphology 
and direct mycobacterial visualisation with either Ziehl-Neelsen (ZN) staining or fluorescence 
microscopy are more rapid techniques; however they are not considered as a definite diagnosis 
of M. tuberculosis infection and require further speciation.  
To overcome these problems, we recently reported the use of an inexpensive transport medium 
for direct inoculation5 of FNAB. We subsequently evaluated the diagnostic value of a more rapid 
molecular-based methodology, high-resolution melting (HRM) analysis in the diagnosis of M. 
tuberculosis lymphadenopathy. As reported4 initial HRM directly from the transport medium 
bottles had a very low sensitivity, possibly due to the high dilution of the bacteria within the 
samples. We therefore concentrated this DNA and then spotted it onto the FTA® Classic Card 
Collection, Storage, and Purification system (Whatman, UK). Genomic DNA was eluted from the 
cards using a high pH, low pH protocol (according to manufacturer’s instructions). The HRM 
methodology was able to detect 52.8% (28/53) of TB lymphadenitis cases with a sensitivity and 
specificity of 52.8% and 94.1%, respectively. The positive predictive value (PPV) was 90.3% and 
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the negative predictive value (NPV) was 65.8%.4 Although HRM analysis allowed a rapid and 
species-specific diagnosis of M. tuberculosis lymphadenitis in the majority of patients, we felt that 
there was a potential for further optimisation of the methodology.   
The aim of this study was to investigate the sensitivity and specificity of HRM diagnosis of TB 
lymphadenitis by the direct spotting of the FNAB samples onto a simpler, more cost-effective 
FTA® Elute Card Collection, Storage, and Purification system (Whatman, UK), which consists of 
a shortened protocol and circumvents the need for an intermediary transport bottle.  
 
3. Materials and Methods 
 
3.1. Specimen Collection 
Fine-Needle Aspiration Biopsy samples were obtained from 83 adults and children with a 
superficial lymph node mass suggestive of possible mycobacterial lymphadenitis at the FNAB 
Clinic at Tygerberg Hospital between the time periods May 2009 to January 2010. Informed 
consent was obtained from all the study participants and ethical approval granted by the 
University of Stellenbosch, South Africa (N05/03/043). 
Fine-Needle Aspiration Biopsy was done following standard protocol by a pathologist.3 Two 
needle passes were done and from each aspirate two smears were prepared for microscopic 
investigations. The residual material in the syringe and needle (from the first pass) was used to 
inoculate a MGIT tube for routine phenotypic culture by the National Health Laboratory Services 
(NHLS), and the residual material from the second pass was expressed onto the FTA® Elute 
Card Collection, Storage, and Purification system (Whatman, UK). The cards were then 
transported to the laboratory in individual plastic pouches and kept at room temperature for a 
minimum of 24 hours to allow the specimens to dry. 
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 3.2. Phenotypic investigations 
The stained smears were investigated for cytomorphological changes by Papanicolaou stain and 
for the presence of gram negative bacteria by a modified ZN stain as previously described.4 The 
slides were not identifiable as having been prepared from the first or second pass. 
The residual material from the first pass was cultured in a MGIT tube in a BACTEC 960 machine 
for 42 days according to the NLHS standard operating procedure. All positive MGIT tubes were 
confirmed to contain acid-fast bacilli in the absence of bacterial contamination by ZN staining. 
Mycobacteria were identified as M. tuberculosis or other by standard PCR.6  
 
3.3. Extraction of Mycobacterial DNA 
The FTA® Elute Cards were processed according to the manufacturer’s instructions. Briefly, a 
3mm disk from the centre of the spotted sample was transferred to an Eppendorf tube containing 
500µl of ddH2O. The tubes were pulse vortexed three times and the 500µl ddH2O was aspirated 
and substituted with 30µl ddH2O. After a brief centrifugation (10 seconds) to ensure that the disks 
were fully submerged, the tubes were incubated at 95°C for 30 min. The samples were then 
pulse vortexed 60 times and centrifuged so as to separate the matrix from the eluate, which was 
subsequently transferred to a clean Eppendorf tube and stored at -20°C until further analysis.  
 
3.4. Speciation and HRM analysis 
Molecular analysis (PCR and HRM) of the respective FNAB samples was done as previously 
described,4 targeting the Region of Deletion 9 (RD9), present in M. tuberculosis and M. canettii, 
but absent from all other members of the M. tuberculosis complex.7  Samples which failed to 
amplify were reanalysed using PCR primers specific to the human beta-actin gene (hu-â-actin F 
5’-GAG CTA CGA GCT GCC TGA CG-3’ and hu- â-actin R 5’-GTA GTT TAG TGG ATG CCA 
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CAG GAC T-3’). If amplification failed again, these samples were excluded from further analysis 
due to the lack of DNA in these samples. 
 
3.5. Reference Standard for Mycobacterial Disease 
The reference standard for the presence of mycobacterial disease8 was defined as positive 
cytology (morphology consistent with mycobacterial infection plus direct visualisation of the 
organism either by ZN staining or autoflourescence following Papanicolaou staining)4 and/or 
positive culture with speciation.4 
 
3.6. Statistical Analysis 
We assessed the diagnostic accuracy of PCR-based HRM analysis compared to cytology, 
mycobacterial culture and the reference standard as defined using Pearson’s Chi square (χ2) 
and Fisher’s exact tests. All analyses were conducted using Statistica Version 8.  
 
4. Results 
 
FNAB specimens were analysed from 65 of 83 patients with possible mycobacterial 
lymphadenitis for which complete cytopathology and mycobacterial culture results were available 
together with PCR-based HRM analysis. Nine samples did not deliver any DNA by the extraction 
technique (confirmed by reanalysis targeting the human beta-actin gene). Three samples were 
missing culture results and the remaining 6 samples lacked cytology results. These 18 samples 
were excluded from the statistical analysis. Applying the defined reference standard 41 of the 65 
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patients (63.1%) were diagnosed with mycobacterial lymphadenitis. This was slightly more than 
the previously reported 51.0% (Table 1).4 
Cytology/ZN and HRM was positive in slightly fewer patients than in the previous study (75.6% 
vs. 84.9% and 46.3% vs. 58.5%, respectively), whereas culture positivity was  higher (80.5% vs. 
66.0%). Similar results were obtained for samples that were both cytology/ZN and culture 
positive (56.1% vs. 51.0). More importantly the concordance between the various diagnostic 
modalities and HRM analysis remained poor, with Kappa values of 0.19 vs. cytology/ZN, 0.26 vs. 
mycobacterial culture, 0.26 vs. cytology/ZN and culture; and 0.26 vs. cytology/ZN and/or culture 
(the defined reference standard). 
HRM analysis could correctly identify 19 out of 41 TB lymphadenitis samples (defined by the 
reference standard) with a sensitivity and specificity of 46.3% and 83.3% respectively, with a 
PPV of 82.6% and a NPV of 47.6% (Figure 1). This was slightly less than by the indirect 
method.4 High resolution melt analysis incorrectly identified 4/24 samples as containing M. 
tuberculosis DNA. Further investigation revealed that 3 of these patients had been transferred 
from community clinics and therefore limited data was available regarding previous TB history (1 
patient was HIV positive, 1 was a child and 1 had repeated TB investigations).   
 
 
 
 
 
 
 
Figure 1. A Venn diagram depicting the number of samples positive for the different diagnostic 
methodologies. The reference standard for mycobacterial disease (shaded areas) is a positive Culture 
and/or Cytology/ZN result.  
12 5 5 
3 5 
4 
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Table1. Comparison of results obtained from spotting specimens from the transport bottles onto the 
FTA Classic storage system (indirect method)4 to that of direct specimen spotting onto the FTA Elute 
storage system (direct method).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Indirect method4 Direct method 
Numbers of cases 104 65 
Cases with Mycobacterial disease = 
(Reference standard: Culture and/or Cytology or ZN positive)  
 
53 (51.0%) 
 
41 (63.1%) 
Cytology or ZN positive 45 (84.9%) 31 (75.6%) 
Culture positive 35 (66.0%) 33 (80.5%) 
HRM positive 28 (52.8%) 19 (46.3%) 
Culture and Cytology/ZN positive  27 (51.0%) 23 (56.1%) 
Concordance   
HRM vs. Cytology/ZN 0.39 0.19 
HRM vs. Culture  0.27 0.26 
HRM vs. Culture and Cytology/ZN positive 0.19 0.26 
HRM vs. Reference Standard 0.45 0.26 
Performance HRM vs. Reference Standard   
Sensitivity 52.8% 46.3% 
Specificity 94.1% 83.3% 
Positive Predictive Value (PPV) 90.3% 82.6% 
Negative Predictive Value (NPV) 65.8% 47.6% 
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5. Discussion 
 
The use of the simpler more cost-effective FTA® Elute Card with the omission of a transport 
medium did not provide an improvement over the previously described indirect method. 
Furthermore, feedback from the clinicians and nursing staff doing the FNAB revealed that the 
direct spotting of the sample onto the FTA® Elute Card posed a health risk and was difficult to do 
as the target area of the card is small and the FNAB samples are difficult to expel from the 
syringes used. Often residual sample remained in the neck of the syringe. The previous method, 
which involved rinsing the syringe in the transport medium bottles, was able to loosen this 
residual tissue and also prevented unnecessary exposure of the staff to any infectious material. 
A further limitation of the methodology is that it is difficult to know how well DNA dissociates from 
the FTA® Elute Card matrix during the extraction procedure and how well PCR inhibitors remain 
trapped by the same matrix. Furthermore, despite experimenting with various volumes of input 
DNA in the PCR reaction, we did not investigate if larger volumes (>4µl per 25µl reaction) would 
significantly improve the sensitivity of the assay. We propose that in future, the samples will be 
collected in the transport media bottles and that alternative DNA concentration and purification 
methods be investigated to improve the sensitivity of the assay. We will also investigate the 
performance of the Xpert MTB/Rif Assay (Cepheid Inc. Sunnyvale, California, USA) on these 
FNA samples.  
The poor performance of the assay may have been due to the failure to annotate which slides 
were obtained from which pass. Ideally all the diagnostic modalities should be compared to 
samples obtained from the same pass (i.e. either all from the first or second pass) so as to 
overcome possible sampling errors/bias. However, despite the low sensitivity (46.3%) of the 
HRM analysis, 19 of 41 patients were able to have a rapid and specific (83.3%) diagnosis within 
one day of undergoing a FNAB. This implies that these patients could be started on early anti-
tuberculosis treatment, thereby reducing transmission of disease, morbidity and mortality. 
Although 22 patients were missed by HRM analysis, these patients could be confirmed at a later 
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stage by phenotypic culture. We therefore propose the following diagnostic algorithm while 
awaiting improved diagnostic methods: if HRM analysis is positive for the presence of M. 
tuberculosis DNA and cytology is suggestive of Mycobacterial disease, then anti-tuberculosis 
treatment is started. If HRM analysis is positive, but cytology does not indicate Mycobacterial 
disease, or if HRM analysis is negative, then await phenotypic culture results before initiating 
treatment.  
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1. Abstract  
 
The emergence and transmission of multidrug-resistant tuberculosis (MDR-TB) and extensively 
drug resistant tuberculosis (XDR-TB) have raised concern about diagnostic delay associated with 
culture-based drug susceptibility testing methods. The association between rifampicin resistance 
and MDR-TB or XDR-TB makes it an important genetic marker for genotypic drug susceptibility 
testing. In this chapter, we describe the analysis of the physical properties of the rifampicin 
resistance-determining region (RRDR) in the rpoB gene by high-resolution thermal melt analysis 
as a method for detecting rifampicin resistance in Mycobacterium tuberculosis complex. The 
RRDR from the M. tuberculosis complex was amplified by PCR from DNA templates extracted 
from sputum cultures of M. tuberculosis or the laboratory strain (H37Rv) in the presence of a 
fluorescent DNA binding dye. Subsequent mixing of the amplification products from the 
respective sputum cultures and the laboratory strain and thermocycling allowed the formation of 
DNA duplexes. The thermal denaturation properties of these DNA duplexes were determined by 
measuring the derivative of the intensity of fluorescence at different temperatures. Analysis of 
DNA extracted from 153 sputum cultures showed a sensitivity of 98% and a specificity of 100% 
for the detection of rifampicin resistance compared to the “gold standard” culture-based 
phenotyping method. No statistical difference was detected in the performance of the method 
when applied to crude DNA from 134 boiled cultures. This method, named “FAST-Rif” 
(“Fluorometric Assay for Susceptibility Testing of Rifampicin”), allowed the rapid, reliable, and 
easy detection of genotypic rifampicin resistance as a marker for MDR-TB and XDR-TB. 
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2. Introduction  
 
Drug resistance remains a serious threat to tuberculosis (TB) control worldwide.1 This is 
especially true for multidrug-resistant TB (MDR-TB), which is defined as disease caused by 
Mycobacterium tuberculosis that is resistant in vitro to both isoniazid and rifampicin, with or 
without resistance to other anti-TB drugs. A recent survey estimated that 424,203 MDR-TB cases 
were diagnosed worldwide among new and retreatment cases in 2004.2 In 2004, a study of 
samples submitted to selected national reference laboratories worldwide estimated that in the 4 
years between 2000 and 2004, 20% of the samples tested represented MDR-TB cases and that 
10% of these were extensively drug-resistant TB (XDR-TB) cases (defined at that time as 
resistant to three of six classes of second-line drugs).3 In October 2006, the World Health 
Organization redefined XDR-TB as being MDR-TB with additional resistance to any 
fluoroquinolone (e.g., ciprofloxacin, ofloxacin, or moxifloxacin) and to at least one of three 
injectable second-line anti-TB drugs used in treatment (capreomycin, kanamycin, or amikacin).4 
In order to combat the threat of drug resistance, it is essential that new rapid diagnostics are 
developed to complement a well-functioning TB control program. Recent advances in phenotypic 
drug susceptibility testing include the use of mycobacterial growth indicators5,6 and phage-based 
assays.7 Although these methods are able to report phenotypic resistance in 2 to 10 days, the 
culture of viable bacilli poses a health risk to laboratory personnel and thereby requires high 
levels of biosafety.  
To overcome these limitations and to improve the speed of detection of drug resistance, 
numerous PCR-based methods have been described.8 However, the number of different non-
synonymous single nucleotide polymorphisms (nsSNPs) conferring resistance remains a major 
challenge to the successful development of genotypic drug susceptibility testing methods. 
Pragmatically, this has been partially circumvented by developing assays which analyse the most 
prominent nsSNPs, with some reduction in sensitivity and specificity due to this. However, many 
of these methods are hampered by the need for downstream processing to enable the detection 
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of nsSNPs within the PCR-amplified domain (e.g., hybridisation to immobilised oligonucleotides,9 
microarray,10 dot blot hybridisation,11 denaturing high-performance liquid chromatography,12 and 
DNA sequencing13,14). The complexity of these methods and the need for multiple steps to 
perform them greatly increase the risk of cross-contamination and thereby misdiagnosis. An 
assay which is rapid, sensitive, and specific and does not require downstream processing, 
thereby minimising cross-contamination, would be ideal. 
A study by Williams et.al.,15 showed that heteroduplexes could be used to determine rifampicin 
susceptibility by analysing conformational changes created by nsSNPs in the DNA fragments. 
We proposed that the analysis of thermal denaturation profiles of heteroduplexes could be used 
to enhance the detection of nsSNPs conferring resistance in M. tuberculosis. In theory, the 
thermal denaturation profile of a specific DNA fragment is dependent on the nucleotide sequence 
of that fragment.16 Thus, any change in the nucleotide sequence would alter the thermal 
denaturation profile, which in turn could be detected by measuring the efficiency of binding of a 
fluorescent dye to the DNA fragment at different temperatures.17  
However, nucleotide transversions (A:T and G:C) remain difficult to detect, since they have very 
little influence on the overall thermal denaturation profile. To circumvent this limitation, we 
proposed that the efficiency of detecting transversions and transitions could be enhanced by 
analysing the thermal denaturation profiles of DNA duplexes formed by annealing DNA 
fragments with and without nucleotide change (heteroduplex and homoduplex, respectively).  
In this study, we tested these concepts by analysing the unique thermal denaturation properties 
of the rifampicin resistance- determining region (RRDR) of the rpoB gene to develop a method 
for the detection of rifampicin resistance. Mono-resistance to rifampicin is rare and is mostly 
accompanied by isoniazid resistance. Therefore, the rifampicin resistance profile could be used 
as a marker for suspected MDR-TB and XDR-TB cases. 
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3. Materials and Methods 
 
3.1. Preparation of pure DNA templates 
M. tuberculosis was cultured from sputa (obtained from TB patients) on Löwenstein-Jensen 
medium, and genomic DNA was extracted as previously described.18  
 
3.2. Preparation of crude DNA templates 
Decontaminated sputum specimens were cultured at 37°C in BACTEC 12B medium (Becton 
Dickinson) for 7 days in the BACTEC 460 system, and the bacteria were pelleted by 
centrifugation, resuspended in 100 µl BACTEC 12B medium, and boiled to generate a crude-
DNA template.19 
 
3.3. Drug susceptibility testing 
Drug susceptibility testing was done by the National Health Laboratory Service, using the indirect 
proportion method on Middlebrook medium containing critical concentrations of 0.2 µg/ml 
isoniazid and 30 µg/ml rifampicin. Following DNA sequencing and high-resolution thermal melt 
analysis, specimens with discrepant phenotypic results were subjected to rifampicin drug 
susceptibility testing in mycobacterial growth indicator tubes (Becton Dickinson) according to the 
manufacturer’s instructions. 
 
 
3.4. DNA sequencing of the RRDR of the rpoB gene 
The DNA sequence of the RRDR of the rpoB gene of each sputum culture (pure and crude DNA) 
was determined as previously described.20 The genotypes and phenotypes of the respective 
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isolates were determined prior to high-resolution thermal melt analysis, and these results were 
blinded to the high-resolution thermal melt operator. 
 
3.5. PCR amplification of the RRDR 
DNA templates (pure or crude) extracted from different sputum cultures, the laboratory strain 
(H37Rv, having a rifampicin-susceptible genotype), different members of the M. tuberculosis 
complex (M. canettii, M. tuberculosis, M. africanum, M. microti, M. pinnipedii, M. caprae, and M. 
bovis [Mycobacterial Reference Laboratory, Institut Pasteur, France]), or different species of non-
tuberculous mycobacteria (M. alvei, M. arupense, M. avium, M. chelonae, M. elephantis, M. 
fortuitium, M. goodii, M. intracellulare, M. interjectum, M. kansasii, M. kumamotonense, M. 
marinum, M. montefiorense, M. monacense, M. moriokaense, M. paraffinicum, M. peregrinum, 
M. porcinum, M. rhodesiae, and M. terrae [speciated by 16S rRNA DNA sequencing]21) were 
subjected to PCR amplification (Figure 1, step 1) in a reaction mixture containing 25 ng DNA 
template, 5 µl Q-Buffer, 2.5 µl 10X buffer, 2 µl 25 mM MgCl2, 4 µl 10 mM deoxynucleotide 
triphosphates, 1 µl of each primer (50 pmol/ µl) (rpoB Forward, 5’-CGC CGC GAT CAA GGA 
GTT C-3’; rpoB Reverse short, 5’-GCC CGG CAC GCT CAT GT-3’), 1 µl (1/100 dilution) Syto 9 
fluorescent dye (Molecular Probes), and 0.125 µl HotStarTaq DNA polymerase (Qiagen, 
Germany) and made up to 25 µl with distilled water. Amplification was initiated by incubation at 
95°C for 15 min, followed by 35 to 45 cycles at 94°C for 45 s, 64°C for 45 s, and 72°C for 45 s. 
After the last cycle, the samples were incubated at 72°C for 10 min. Amplification was confirmed 
by high-resolution melt analysis (see below). To minimise laboratory cross-contamination, the 
preparation of the PCR mixes, the addition of the DNA, and the PCR amplification were 
conducted in physically separated rooms. Negative controls (water) were included to detect 
reagent contamination.  
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3.6. DNA duplex formation 
After amplification, a 12.5 µl aliquot of the PCR product containing the amplified RRDR from 
each sputum culture was mixed with a 12.5 µl aliquot of the amplified RRDR from the laboratory 
strain H37Rv (Figure 1, step 2). Each mixture was subjected to a second round of cycling without 
adding additional PCR components (95°C for 1 min, followed by 10 cycles at 94°C for 30 s, 62°C 
for 30 s, and 72°C for 30 s, followed by incubation at 72°C for 5 min). This procedure generated 
DNA duplexes between the respective RRDR amplification products from the sputum culture and 
the standard laboratory strain. 
 
3.7. High-resolution thermal melt analysis 
The DNA duplexes were subjected to high-resolution thermal melt analysis in a Rotorgene 6000 
real-time analyser (Corbett, Australia) (Figure 1, step 3). The thermal denaturation profile was 
measured over the temperature range from 80°C to 95°C, and fluorometric readings were taken 
every 0.1°C. Rotorgene software was used to calculate the derivative of the intensity of 
fluorescence at different temperatures (dF/dT), thereby generating a plot where the derivative 
peak(s) represents the Tm value of the DNA duplexes. Rifampicin drug susceptibility was 
assigned by the software according to the presence of a derivative peak(s) located within a 
defined temperature bin(s) (width, 1.5°C). A derivative plot with a single derivative peak 
(homoduplex) was classified as drug susceptible, while a derivative plot with two derivative peaks 
(homo- and heteroduplexes) was classified as drug resistant.  
 
3.8. Statistical analysis 
The statistical software program Statistica 7.1 was used to calculate the sensitivity and specificity 
of PCR amplification or genotypic drug susceptibility testing at a confidence interval (CI) of 95%. 
Figure. 1. Flow diagram of the high
methodology. In step 1, DNA extracted from the laboratory strain (H37Rv) or the respective sputum 
cultures was subjected to PCR amplification of the RRDR of the 
In step 2, RRDR DNA duplexes were formed between the amplified RRDR of the laboratory strain 
and the amplified RRDR of the respective sputum cultures by mixing of the PCR products and 
subsequent thermocycling. In step 3
analysis (HRM). Genotypic drug susceptibility was scored according to the shape of the dF/dT plot 
and the presence of derivative peaks in defined temperature bins.
-resolution thermal melt genotypic drug susceptibility testing 
M. tuberculosis complex 
, DNA duplexes were subjected to high-resolution thermal melt 
 
 
rpoB gene. 
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4. Results 
 
To determine the specificity of the primers used for the PCR amplification of the M. tuberculosis 
complex RRDR, DNA templates from 7 different members of the M. tuberculosis complex and 20 
different species of non-tuberculous mycobacteria were amplified. The specificity of M. 
tuberculosis complex RRDR amplification was 100% compared to the 16S rRNA DNA sequence 
data.  
To test whether the thermal denaturation properties of the RRDR could be used to detect 
nsSNPs conferring rifampicin resistance, DNA duplexes (formed between the RRDRs amplified 
from DNA extracted from phenotypically and genotypically well-characterised sputum cultures [n 
= 34] and the laboratory strain [H37Rv], respectively) were subjected to high-resolution thermal 
melt analysis in the presence of a saturating concentration of the fluorescent dye. Figure 2 shows 
the dF/dT values of DNA duplexes. Rifampicin-susceptible isolates were characterised by the 
presence of a single derivative peak, representing homoduplexes (Figure 2A), while rifampicin 
resistant isolates were characterised by the presence of two distinct derivative peaks at defined 
temperatures, representing homo- and heteroduplexes, respectively (Figure 2B). This 
demonstrated that the high-resolution thermal melt method could be used to identify nsSNPs 
conferring rifampicin resistance.  
To determine the performance of this method, purified DNA from 80 phenotypically rifampicin-
susceptible and 73 phenotypically rifampicin-resistant sputum cultures was analysed (the 
operator was blinded to the genotypic and phenotypic rifampicin resistance data). The method 
showed a sensitivity of 98% (95% CI, 94% to 101%) and a specificity of 100% (95% CI, 100% to 
100%) for scoring the presence of nsSNPs encoding rifampicin resistance in relation to the “gold 
standard” phenotypic drug susceptibility testing method (see Appendix 1). The positive predictive 
value was 100%, and the negative predictive value was 97%.  
 
Figure. 2. dF/dT values of the DNA duplexes. (A) Isolates were scored as susceptible to rifampicin 
based on the presence of a single derivative peak within a defined temperature bin (homoduplex). (B) 
Isolates were scored as resistant to rifampicin based on the presence of two derivative peaks in 
defined temperature bins (homo- and heteroduplex).
 
To determine whether the high-resolution thermal denaturation genotyping technique could be 
used to analyse crude DNA templates, 44 phenotypically rifampicin
phenotypically rifampicin-resistant boiled sputum cultures were analysed. Performance analysis 
showed the technique had a sensitivity of 94% (95% CI, 90% to 99%) and a specificity of 96% 
(95% CI, 90% to 101%) (see Appendix 2). The positive predictive value was 98%, and the 
negative predictive value was 88%.
 
-susceptible and 90 
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Using the thermal denaturation genotyping technique, a total of 14 different nsSNPs were 
detected at six codons in the RRDR and an insertion between codons 514 and 515 (data not 
shown). 
 
Discussion 
 
In this chapter, we report the development of a novel PCR-based fluorometric assay for testing of 
susceptibility to rifampicin, called FAST-Rif. This method allowed for the rapid detection of 15 
different mutational events in the RRDR of the rpoB gene conferring rifampicin resistance in M. 
tuberculosis complex. The advantage of this method over previously described methods9-14 was 
the simplicity of the method, the broad spectrum of nsSNPs detected by each analysis, and the 
high sensitivity and specificity achieved.  
However, the method did not provide information about which nsSNP conferred resistance. This 
should not be seen as a limitation, since the primary objective for routine diagnostics would only 
be to determine the presence or absence of an nsSNP conferring resistance, thereby enabling 
the correct treatment to be administered to the patient. The sensitivity of this technique was not 
confounded by the presence of synonymous single nucleotide polymorphisms, since these have 
not been identified in the RRDR.22 We acknowledge that our method was not able to identify 
nsSNPs conferring rifampicin resistance which fell outside of the RRDR. This implies that 
approximately 5% of cases with rifampicin resistance will be not be detected by the described 
method. Similarly, most of the previously described genotypic drug susceptibility testing 
methods9-14 would not be able to detect nsSNPs outside of the RRDR. 
In this study, the FAST-Rif method was based on two independent PCRs, which ensured the 
optimal non-competitive amplification of both the clinical and reference templates. Attempts to 
convert the method to a single-tube format were hampered by the competitive nature of the PCR. 
We envisage that this method could be adapted to a single-tube format if the two PCRs were 
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separated by a septum. After PCR amplification, the two PCRs could be mixed by inverting the 
tube, thereby avoiding the need to open the reaction tube. This would have further advantages, 
since it would simplify the method while avoiding the risk of cross-contamination following 
aerosolisation of amplicons. Furthermore, the single-tube (South African provisional patent 
2007/06915, see Appendix 3) format would allow for high throughput and automation.  
We acknowledge that the quality and amount of the input DNA remain a bottleneck for the 
applicability of all PCR based genotypic drug susceptibility testing methods. However, in this 
study we showed that the FAST-Rif method could efficiently amplify “crude DNA”, thereby 
enabling a diagnosis to be made within a matter of 3 to 4 h following short-term culture. This 
diagnostic interval could be shortened further if the RRDR could be efficiently and routinely 
amplified from M. tuberculosis DNA purified from sputum.  
Application of this methodology in the routine screening of clinical isolates would enable the rapid 
diagnosis of rifampicin resistance23, thereby increasing the suspicion index for both MDR-TB and 
XDR-TB. This information would permit the attending clinician to request drug susceptibility 
testing for additional anti-TB drugs, thereby ensuring the appropriate management of the TB 
case and preventing the acquisition of other drug resistance phenotypes. Furthermore, the rapid 
diagnosis of rifampicin resistance would assist in limiting the transmission of drug-resistant TB to 
close contacts.  
Given the affordability of the described method (cost not exceeding that of a standard PCR), as 
well as the ease of use, it should be possible to implement this methodology to improve case 
detection in most settings, thereby enhancing the overall control of the drug-resistant-TB 
epidemic. The versatility of this method implies that it could be adapted to detect nsSNPs 
conferring resistance to other anti-TB drugs.  
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Adaptation of the Fluorometric Assay for Susceptibility Testing 
to detect Ethambutol Resistance 
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1. Abstract  
 
Ethambutol (EMB) forms an integral part of first and second-line tuberculosis therapy due to the 
inaccuracy/lack of surveillance data, suggesting that resistance to EMB is regarded rare. Drug-
susceptibility testing (DST) for EMB is inaccurate and may lead to underestimation of true 
resistance frequencies, which may have a negative effect on the TB control program. Improved 
methodologies involve molecular-based testing, focusing on the embB gene conferring EMB 
resistance. We describe a fluorometric assay based on the formation of DNA duplexes and the 
use of High Resolution Melting analysis to rapidly detect EMB resistance in cohorts of isoniazid 
mono-resistant, rifampicin mono-resistant and multi-drug resistant (MDR-TB) tuberculosis 
isolates.  
The method was optimised on a subset of 98 well-characterised (DNA sequencing) EMB 
susceptible and resistant samples. The region flanking codon 306 of the embB gene from the 
Mycobacterium tuberculosis complex was amplified by PCR from crude cultures of M. 
tuberculosis or the laboratory strain (H37Rv) in the presence of a fluorescent DNA binding dye. 
Subsequent mixing of the amplification products from the respective sputum cultures and the 
laboratory strain and thermocycling allowed the formation of DNA duplexes. The thermal 
denaturation properties of these DNA duplexes were determined by measuring the derivative of 
the intensity of fluorescence at different temperatures. Analysis of the 97 amplifiable well-
characterised isolates showed a sensitivity and specificity of 94.4% and 98.4% respectively, 
compared to DNA sequencing, with a positive predictive value (PPV) of 97.1% and a negative 
predictive value (NPV) of 96.8% respectively.  
We applied the method to a cohort of crude samples and found that EMB resistance was not 
associated with rifampicin mono-resistance, since only 4.3% of 47 isolates harboured mutations 
in the embB306 region. Initial screening of 86 isoniazid mono-resistant isolates revealed that 
8.1% were resistant to ethambutol, however, subsequent sequencing of these ethambutol 
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resistant isolates showed the presence of mutations in the rpoB gene, implying additional 
resistance to rifampicin (i.e. MDR-TB). 
Analysis of 228 MDR-TB isolates showed a strong association of EMB resistance with MDR-TB, 
since 57.5% of the isolates harboured mutations in the embB306 region, conferring EMB 
resistance. In contrast, only 9.2% were phenotypically resistant by routine culture on solid media.  
The method proved rapid and reliable for the detection of EMB resistance and data could be 
used to help reformulate the South African Tuberculosis Program guidelines, thereby ensuring 
the appropriate management of patients and preventing the acquisition or spread of other drug-
resistance phenotypes. 
 
2. Introduction  
 
Ethambutol (EMB) is a first-line anti-tuberculosis drug which targets arabinosyltransferase 
(encoded by the embB gene) involved in cell wall biosynthesis.1 Inhibition of this enzyme by the 
drug results in the failure to synthesise the cell wall, an accumulation of mycolic acids in the 
bacteria and subsequent cell death.2 Ethambutol forms an integral part of the Directly Observed 
Treatment Short-Course (DOTS) strategy and its use is continued in second-line therapy (the 
DOTS Plus strategy) due to the shortage of alternative second-line drugs and surveillance data 
(or lack thereof), which suggests that resistance to EMB is rare.3 However, DST for EMB is 
inaccurate,4 as the diagnostic breakpoint (5 to 7.5 µg/ml) is close to the Minimal Inhibitory 
Concentration (MIC) of EMB and true resistance may therefore be missed.5  
Despite numerous publications arguing for6-10 and against2,11,12 mutations in codon 306 of the 
embB gene causing EMB resistance, a recent allelic exchange experiment in EMB susceptible 
and resistant strains showed that embB codon 306 mutations do increase the EMB MIC to cause 
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low level EMB resistance (MIC < 16 µg/ml).5 These embB codon 306 mutations may interact with 
mutations in other genes to generate high-level EMB resistance (MIC = 16 to 40 µg/ml).5 
A recent study done in Cape Town, South Africa, showed that routine phenotypic analysis by the 
National Health Laboratory Services (NHLS) failed to identify 91% of EMB resistant isolates 
using the indirect proportion method on Middlebrook solid medium compared to the liquid culture 
medium-based method, confirming the inaccuracy of EMB phenotypic testing.4 This inaccuracy 
was further confirmed by genotypic sequencing of codon 306 of the embB gene which harbours 
70-90% of the EMB resistance-causing mutations.13  
The difficulties associated with phenotypic EMB susceptibility testing may have inadvertently had 
a negative effect on the TB control program. This hypothesis is further strengthened by evidence 
showing a strong association of EMB resistance with that of isoniazid and rifampicin resistance 
(multi-drug resistant (MDR-TB)).4 Therefore failure to recognise EMB resistance may be 
implicated in the development of MDR-TB and extensively drug-resistant (XDR-TB) 
tuberculosis.14 New draft policy guidelines (2008) on the treatment of MDR-TB (formulated by the 
South African National TB Control Programme) suggest that drug-susceptibility testing (DST) for 
EMB determines the treatment regimen for MDR/XDR-TB. Therefore it is essential that improved 
DST methods are implemented for the accurate detection of EMB resistance. 
We describe an adaptation of the Fluorometric Assay for Susceptibility Testing of Rifampicin 
resistance (FAST-RIF)15 to detect EMB resistance (FAST-EMB), based on the analysis of the 
thermal denaturation profiles of DNA  duplexes spanning codon 306 of the embB gene of 
Mycobacterium tuberculosis.  
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3. Materials and Methods 
 
3.1. Preparation of DNA templates 
M. tuberculosis cultured from 98 sputum cultures was used to optimise the FAST-EMB method. 
The embB gene for each specimen had been previously sequenced,4  demonstrating mutations 
at codon 306 in 37 specimens (EMB resistant) and wild type sequences in 61 specimens (EMB 
sensitive).  
Crude DNA extracted from 47 rifampicin mono-resistant samples, 86 isoniazid mono-resistant 
samples and 228 MDR-TB patients was used to determine the incidence of EMB resistance 
amongst these sub-groups.  
Briefly, each sputum specimen was cultured at 37°C in BACTEC 12B medium (Becton 
Dickinson) for 7 days in the BACTEC 460 system, and the bacteria were pelleted by 
centrifugation, resuspended in 100 µl BACTEC 12B medium, and boiled to generate a crude-
DNA template.16 
 
3.2. Drug susceptibility testing 
Drug susceptibility testing was done by the National Health Laboratory Service, using the indirect 
proportion method on Middlebrook medium containing critical concentrations of 5µg/ml EMB.  
The phenotypes and genotypes of the respective isolates were determined prior to High 
Resolution Melting (HRM) analysis, and these results were blinded to the HRM analysis operator 
(K.H).  
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3.3. PCR amplification and HRM analysis of the embB gene 
Crude DNA templates obtained from different sputum cultures and the laboratory strain (H37Rv, 
pan susceptible) were subjected to PCR amplification as previously described.15 Briefly, each 
reaction mixture consisted of 2µl crude DNA template, 5 µl Q-Buffer, 2.5 µl 10X buffer, 2 µl 25 
mM MgCl2, 4 µl 10 mM deoxynucleotide triphosphates, 1 µl of each primer (50 pmol/ µl) (embB 
2F 5’- CAT GTC ATC GGC GCG AAT-3’, embB R new 5’-GCG CCA GCA GGT TGT AAT ACC-
3’), 1 µl (1/100 dilution) Syto 9 fluorescent dye (Molecular Probes), and 0.125 µl HotStarTaq DNA 
polymerase (Qiagen, Germany) and was made up to 25 µl with distilled water. Amplification was 
initiated by incubation at 95°C for 15 min, followed by 45 cycles at 94°C for 45 s, 62°C for 45 s, 
and 72°C for 45 s. After the last cycle, the samples were incubated at 72°C for 2 min.  
Amplification products of the sputum cultures and the laboratory wild-type strain were mixed (1:1) 
and allowed to form DNA duplexes as previously described.15 Resultant homo- and 
heteroduplexes were subjected to HRM analysis in the Rotorgene 6000 real-time analyser 
(Corbett, Australia). The thermal denaturation profiles were measured over the temperature 
range from 80°C to 95°C, and fluorometric readings were taken every 0.1°C. The presence of 
absence of mutations within the amplified domain was assigned by the software according to the 
presence of a derivative peak(s) located within a defined temperature bin(s). A derivative plot 
with a single derivative peak (homoduplex) was classified as EMB susceptible, while a derivative 
plot with two derivative peaks (homo- and heteroduplexes) was classified as resistant to EMB.  
 
3.4. Statistical analysis 
The statistical software program Statistica 7.1 was used to calculate the sensitivity and specificity 
of the FAST-EMB method as compared to DNA sequencing of the embB gene region of interest 
at a confidence interval (CI) of 95%.  
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4. Results 
 
The methodology was optimised on a cohort of 98 genetically well-characterised crude DNA 
samples. HRM analysis showed the presence of DNA homo- and/or heteroduplexes. EMB-
susceptible isolates were identified by the presence of a single derivative peak (Tm = 86.2°C), 
representing homoduplexes (Figure 1A), while EMB resistant isolates were identified by the 
presence of two distinct derivative peaks at defined temperatures (Tm = 86.2°C and 84.4°C), 
representing homo- and heteroduplexes, respectively (Figure 1B).  The FAST-EMB method 
could correctly identify all 34 of 36 (94.4%) amplifiable isolates harbouring one of the three most 
common embB codon 306 mutations (GTG, ATC or ATA) and 60 of 61 (98.4%) wildtype (ATG) 
isolates. The discrepant results were re-submitted for DNA sequencing to confirm their embB306 
sequences. The two samples which were incorrectly scored by HRM analysis as EMB 
susceptible did in fact harbour embB codon 306 (GTG) mutations. The sample incorrectly scored 
as resistant could not be confirmed by re-sequencing as the working sample was depleted and 
subsequent efforts at re-culturing were unsuccessful due to a loss of viability. One isolate also 
repeatedly failed to amplify (using various primer sets) following re-culture; this could be due to 
the presence of inhibitors. The method showed a sensitivity and specificity of 94.4% and 98.4% 
respectively as compared to DNA sequencing, with a positive predictive value (PPV) of 97.1% 
and a negative predictive value (NPV) of 96.8% respectively (excluding  the amplification failure).  
High resolution melting analysis of 47 rifampicin mono-resistant and 86 isoniazid mono-resistant 
isolates (DST according to the NHLS) showed an incidence of concurrent EMB resistance of 
4.3% and 8.14%, respectively. The 7 isoniazid mono-resistant isolates which showed mutations 
in the embB gene underwent sequencing of the rpoB gene and were found to harbour mutations 
conferring resistance to rifampicin, confirming the association with MDR-TB. 
High resolution melting analysis of 228 crude DNA extracts from MDR-TB cultures from the 
Western Cape showed that 131 (57.5%) harboured mutations in the embB gene region analysed, 
suggesting resistance to EMB. In contrast, only 9.2% (13/141 tested by routine DST) were 
phenotypically resistant by routine culture on solid media. Sequencing of a random selection of 
20 of these isolates showed correlation in 19/20 samples. The single discrepant result was due 
to a rare mutation in codon 328 of the 
assay. These results confirm that EMB resistance is strongly associated with MDR
 
Figure 1. dF/dT values of the DNA duplexes. (A) Isolates were scored as susceptible to EMB based on the 
presence of a single derivative peak within a defined temperature bin (homoduplex). (B) Isolates were scored as 
resistant to EMB based on the presence of two derivative
heteroduplex). 
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Discussion 
 
Despite evidence for the association of embB mutations and ethambutol resistance,5 the  clinical 
significance of these mutations remains controversial.2,11,12 A recent publication documenting the 
evolution of drug resistance showed positive selection for EMB resistance.17 These isolates 
harboured a mutation in the embB gene at codon 306. Together this suggests that the 
concentration of EMB used in the current treatment regimen is sufficient to select for low level 
EMB resistant strains and that this treatment with the standard dose would be of little benefit in 
patients with strains harbouring the embB306 mutations. Thus it is essential that genetic based 
DST tools are developed to rapidly classify isolates of M. tuberculosis as resistant or susceptible 
to EMB.  
We describe the successful adaptation of the FAST-Rif method15 to allow for the reliable 
detection of EMB resistance by changing only the primers used to amplify the target region in the 
embB gene. The method was highly sensitive and specific (94.4% and 98.4%, respectively), 
compared to DNA sequencing and also detected resistance missed by routine DST.  
Analysis of 47 rifampicin mono-resistant isolates revealed a weak association with EMB 
resistance. However, 8.1% of the 86 isoniazid mono-resistant isolates harboured mutations in the 
embB gene. This was of particular concern as these patients would not be considered as MDR-
TB cases and would therefore receive an incorrect (first-line) treatment regimen in which only 2 
effective drugs are prescribed (rifampicin and pyrazinamide). However, subsequent sequencing 
of the rpoB gene in these samples revealed mutations in this gene which confer resistance to 
rifampicin. These isolates were therefore incorrectly classified as isoniazid mono-resistant by 
phenotypic drug-susceptibility testing, implying that these MDR-TB patients are unintentionally 
being treated during first-line therapy with only one effective drug (pyrazinamide) which is not 
used in the continuation phase of treatment. This may therefore lead to the more rapid evolution 
of pre-XDR and XDR-TB in these patients.  
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Analysis of 228 MDR-TB isolates collected in early 2008 indicated that 57% of the isolates were 
in fact resistant to EMB, thereby confirming the strong association of EMB resistance in MDR-
TB.4 Most importantly, routine phenotypic DST failed to identify EMB resistance in 85.4% of 
these MDR-TB isolates. This finding is similar to the previously reported 90% resistance missed 
in the same setting.4  
The strong association of EMB resistance with MDR-TB and the inaccuracy of routine phenotypic 
DST have potentially serious implications for the South African Tuberculosis Program’s treatment 
guidelines. We believe that our data should be used to help reformulate current draft guidelines 
and ensure the appropriate management of patients. This is especially important as the current 
draft policy guidelines (South African National TB Control Programme) suggest that DST for EMB 
determines the treatment regimen for MDR/XDR-TB. If phenotypically susceptible, the guidelines 
suggest that EMB should be included in the regimen as the 5th drug. If resistant, EMB should be 
replaced with terizidone or cycloserine as the 5th drug. We propose that in the absence of 
genotypic-based DST for EMB, it should be assumed that all MDR-TB cases are resistant to 
EMB and that these patients should be treated with terizidone or cycloserine as well as receive 4 
other effective anti-tuberculosis drugs. This is in line with the WHO guidelines18 which state that 
EMB may be included in the regimen, but not counted. 
The FAST-EMB shares similar advantages to that of the FAST-Rif method, as it is a simple, cost 
effective method that allows for the rapid identification of EMB resistance (3 to 4 h following 
short-term culture). The method was not able to provide information on which nsSNP conferred 
resistance and failed to detect resistance due to mutations occurring in regions outside of the 
embB codons analysed. However, the method was a considerable improvement over 
phenotypic-based DST. Unfortunately the methodology is based on two independent PCRs and 
required the opening of tubes to generate DNA duplexes, thus there is a potential for cross-
contamination. It would therefore be useful to convert the method to a single-tube format.  
Given the affordability and superior accuracy of the described FAST-EMB method, it would be 
useful in the routine diagnosis of EMB drug-resistance and should be considered for 
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implementation into the TB control program so as to ensure the appropriate management of the 
TB case and to preventing the acquisition or spread of further drug-resistance phenotypes. 
Furthermore, we recommend that the FAST-EMB be used on all isolates with rifampicin resistant 
results (a marker of MDR-TB) by the GenoType® MTBDRplus assay (HAIN Lifescience, GmbH, 
Nehren, Germany) due to the high rates of undetected EMB resistance amongst MDR-TB 
isolates. 
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Chapter 6 
 
 
Single-tube Detection of Drug-resistance in Mycobacterium 
tuberculosis – Detection of inhA Promoter Mutations conferring 
Isoniazid Resistance 
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1. Abstract 
 
Diagnostic delay is an important contributing factor to the increase in multi-drug resistant 
tuberculosis (MDR-TB) cases. Genotypic-based assays may drastically reduce turn-around 
times; however they are hampered by a high financial cost and the potential for cross-
contamination (among the open-tube based assays). We describe a single, closed-tube 
fluorometric method for the detection of inhA promoter mutations and associated isoniazid and 
ethionamide resistance.  
Thermal denaturation profiles of homo- and heteroduplexes formed between DNA from a 
reference sequence (wild type) and a clinical sample were analysed by high-resolution melting 
analysis.  Briefly, the clinical isolates were PCR amplified and the resultant amplicons then 
annealed to a modified complementary single stranded DNA oligonucleotide allowing extension 
of the amplicon and the incorporation of the adaptor sequence. Primers specific to the adaptor 
sequence and the original 3’ sequence ensured a final PCR product that reflected amplification of 
both the wild type sequence and the sequence present in the clinical isolate.  
The method was able to identify inhA promoter mutations from crude DNA obtained from the 
sputum cultures of 77 patients with INH resistant TB. The sensitivity and specificity was 100% 
and 83.3%, respectively compared to DNA sequencing analysis. The positive predictive value 
(PPV) was 87.2% and the negative predictive value (NPV), 100%. The specificity of the assay 
was improved to 93.5% by visual analysis of the derivative plots by experienced and 
inexperienced operators. Sensitivity remained high (98.4%) and the pooled PPV and NPV was 
94.7% and 98.0%, respectively. Visual scoring was more specific than automatic scoring due to 
limitations with the Rotorgene software.  
Rapid identification of inhA promoter mutations would help to guide treatment regarding the 
inclusion of ethionamide and the use of high dose isoniazid therapy. 
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2. Introduction 
 
The global incidence of multi-drug resistant tuberculosis (MDR-TB) cases is steadily increasing1,2 
despite the implementation of Directly Observed Treatment Short-course (DOTS) therapy in most 
countries. This increase is largely attributed to poor management of the DOTS programme and 
the inability to rapidly diagnose drug resistance. Currently, drug-susceptibility testing is largely 
based on culture which is hampered by lengthy turn-around times, expensive equipment, high 
reagent costs and the need for skilled staff and extensive biosafety facilities. It is therefore 
essential that improved diagnostics are developed which are both affordable and rapid. 
Recent advances in molecular line-probe assays has led the World Health Organisation (WHO) 
to release a policy statement3 in which they recommend that these assays (more specifically the 
GenoType® MTBDRplus assay (HAIN Lifescience, Germany)) be  implemented directly on all 
smear-positive sputum samples to enable rapid (<2 days) detection of  MDR-TB.3,4 This assay 
targets the most common mutations in the rpoB gene (responsible for rifampicin (RIF) resistance) 
and the katG and inhA promoter genes (responsible for resistance to isoniazid (INH)).4 A recent 
meta-analysis demonstrated that the application of this test reduces diagnostic delay to less than 
48 hours,4 with high sensitivity and specificity to identify RIF resistance which is an important 
marker of MDR- and extensively drug-resistant (XDR)-TB.  Specificity was excellent for INH as 
well, although sensitivity estimates were modest and variable, since several genes are involved 
in conferring INH resistance and probes for these genes are not included in the current test. This 
may lead to false-negative results in cases where resistance is due to mutations elsewhere in the 
genome, or where they are situated outside the probe area of the assay. More importantly, the 
GenoType® MTBDRplus assay is an open-tube assay which allows for the potential release of 
amplicons, thereby leading to a possible increased rate of false-positive results and subsequent 
inappropriate treatment. This is a particular concern in high-throughput laboratories and this 
requires specialised infrastructure with highly skilled staff. 
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Current efforts in the development of a closed-tube assay include the automated real-time based 
molecular beacon Xpert MTB/RIF Assay5 (Cepheid Inc., Sunnyvale, California, USA). This 
method is capable of detecting multiple targets in the genome in less than 24 hours; however, it 
is hampered by the high cost of the analysis equipment. 
We recently reported a fluorescence-based assay, the Fluorometric Assay for Susceptibility 
Testing to detect RIF (FAST-Rif)6 and ethambutol (FAST-EMB) resistance which rely on the 
analysis of the thermal denaturation profiles of amplification products of specific DNA 
fragments/targets.6 In this assay the thermal denaturation profile was dependent on the 
nucleotide sequence of the DNA fragment,7 therefore any changes in the nucleotide sequence 
would alter this profile, which, in turn, could be detected by measuring the efficiency of binding of 
a fluorescent dye to the DNA fragment at different temperatures.8 To enable the efficient 
detection of A:T and G:C nucleotide transversions, the FAST-Rif and FAST-EMB techniques 
relied on the generation of DNA homo- and heteroduplexes (formed between amplification 
products generated from a wild type reference strain and the clinical sample). However, this step 
required 2 independent PCR reactions with post-amplification mixing of the PCR products. This 
open-tube system, as is the case with the GenoType® MTBDRplus assay, could lead to potential 
cross-contamination. Furthermore, the amplification of the reference strain in the absence of 
amplification of the clinical isolate may lead to the overrepresentation of false-susceptible results. 
A possible solution to these limitations would be to seed the PCR reaction with the wild type 
reference strain prior to amplification.9 Homo- and heteroduplexes would then be generated as 
amplification proceeds. This approach has recently been followed using purified DNA from 
clinical samples,9 however, this purification step adds cost to the assay and increases diagnostic 
delay. Furthermore, the seeding of PCR reactions does not overcome the possibility of false-
susceptible results in cases where a clinical sample may fail to amplify due to insufficient DNA. 
In this study we developed a single, closed-tube fluorometric method which aimed to overcome 
the need for post-amplification processing, thereby preventing the release of amplicons. Figure 1 
illustrates the method of simultaneous amplification of both the wild type and clinical DNA target 
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templates. We present a proof of concept for this FAST easy single-tube method using the inhA 
gene promoter target as a model and have termed the method FASTest-inhA. The inhA gene 
encodes the enoyl-acyl carrier protein reductase which is responsible for low-level resistance to 
INH, however the resistance-causing mutations are more frequently located in the upstream 
promoter region.10 Although INH resistance may be due to mutations in a number of genes, over 
80% of these are present in either the katG gene or the inhA gene promoter region.11  
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Figure 1. Proposed FASTest-inhA method. (A) During the initial amplification step, primers complementary to a 
specific target sequence in the genome of the clinical isolate are used for amplification (primers inhA F3 and inhA 
R2, see Table 1). (B) The 3’ to 5’ amplification product can now anneal to the complementary single stranded 
wild type DNA oligonucleotide (with a unique 5’-adaptor sequence) allowing (C) extension of the amplicon and 
the incorporation of the adaptor sequence. (D) The extended amplicons are amplified with primers 
complementary to the adaptor sequence (primer external F, see Table 1) as well as primers complementary to 
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the original 3’ sequence (primer inhA R2, see Table 1). The resulting PCR products will reflect amplification of 
both the wild type sequence and the sequence present in the clinical isolate. These products have the potential to 
form either homo- or heteroduplexes depending on the sequence of the DNA in the clinical isolate. (E) The 5’ to 
3’ amplification product cannot anneal to the single stranded wild type DNA oligonucleotide and will only undergo 
linear amplification which should be undetectable by high resolution melt (HRM) analysis. 
 
3. Materials and Methods 
 
3.1. Preparation of pure DNA templates 
Mycobacterium tuberculosis from 11 sputum samples (obtained from patients with MDR-TB and 
XDR-TB) was cultured on Löwenstein-Jensen medium and genomic DNA was extracted as 
previously described.12 This purified DNA was used to optimise the FASTest-inhA method.  
 
3.2. Preparation of crude DNA templates 
Decontaminated sputum specimens from 77 randomly selected patients with INH-mono resistant, 
MDR-TB and XDR-TB were cultured at 37°C in BACTEC 12B medium (Becton Dickinson) for 7 
days in the BACTEC 460 system, and the bacteria were pelleted by centrifugation, resuspended 
in 100 µl BACTEC 12B medium, and boiled to generate a crude-DNA template as previously 
described.13 The growth index of the cultures was not measured. 
 
3.3. Drug-susceptibility testing 
Drug-susceptibility testing was done by the National Health Laboratory Service (NHLS) as 
previously described using the indirect proportion method on Middlebrook medium containing 
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critical concentrations of 0.2 µg/ml isoniazid (INH). All isolates analysed were resistant to INH 
(mutations either in the inhA gene promoter or the katG gene (used as negative controls)). 
 
3.4. DNA sequencing of the inhA gene promoter region 
The DNA sequence of the inhA gene promoter region of each sputum culture was determined by 
PCR amplification in a reaction mixture containing 2 µl crude DNA template, 5 µl Q-Buffer, 2.5 µl 
10X buffer, 2 µl 25 mM MgCl2, 4 µl 10 mM deoxynucleotide triphosphates, 1 µl of each primer 
(50 pmol/µl) (inhA P5 and inhA P3, Table 1) and 0.125 µl HotStarTaq DNA polymerase (Qiagen, 
Germany) and made up to 25 µl with distilled water. Amplification was initiated by incubation at 
95°C for 15 min, followed by 45 cycles each at 94°C for 45 s, 60°C for 45 s, and 72°C for 45 s. 
Samples were then incubated at 72°C for 10 min to ensure complete product extension and were 
sent for subsequent sequencing analysis. The genotypes remained blinded to the high resolution 
melt (HRM) operator. The 11 pure DNA templates consisted of 8 samples with mutations at 
positions either -15 or -17 of the inhA promoter region and 3 wild type specimens (INH resistance 
due to mutations in the katG gene). The crude dataset consisted of 41 samples harbouring 
mutations at positions -8, -15 and -17 of the inhA gene promoter region and 36 specimens 
having a wild type sequence (INH resistance due to mutations in the katG gene).  
 
3.5. Asymmetric PCR amplification of the inhA gene promoter region  
DNA templates (pure or crude) extracted from different sputum cultures were subjected to PCR 
amplification in a reaction mixture containing 50 ng purified or 2 µl crude DNA template, 5 µl Q-
Buffer, 2.5 µl 10X buffer, 3 µl 25 mM MgCl2, 4 µl 10 mM deoxynucleotide triphosphates, 1 µl of 
each primer (external F, inhA F3 and inhA R2), 1 µl of the synthesised wild type sequence, 1 µl 
(1/100 dilution) Syto 9 fluorescent dye (Molecular Probes), and 0.125 µl HotStarTaq DNA 
polymerase (Qiagen, Germany) and made up to 25 µl with distilled water. The working 
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concentrations used and the sequences of the oligonucleotide primers and the synthesised wild 
type oligonucleotide are shown in Table 1.  
Amplification was initiated by incubation at 95°C for 15 min, followed by 2 cycles each at 94°C for 
45 s, 67°C - 64°C (decreasing by 1°C every 2 cycles) for 45 s, and 72°C for 45 s. After the 8 
touchdown cycles, the samples underwent a further 35 cycles at 94°C for 45 s, 62°C for 45 s, 
and 72°C for 45 s. Samples were then incubated at 72°C for 10 min to ensure complete product 
extension. Homo- and heteroduplexes were formed during amplification, which was subsequently 
confirmed by HRM analysis (see below).  
To minimise laboratory cross-contamination, the preparation of the PCR mixes, the addition of 
the DNA, and the PCR amplification were conducted in physically separated rooms. Negative 
controls (water) were included to detect reagent contamination.  
 
Table 1. Oligonucleotide sequences and concentrations used  
Primer Name  pmol/µl 5’ to 3’ Sequence 
wild type 0.5 
5’-ACATCCTACACACGCTCTCATGTCTCGTGGACATACC 
       GATTTCGGCCCGGCCGCGGCGAGACGATAGGTTGTC-3’ 
inhA F3 7.5  5’-CTCGTGGACATACCGATTTCG-3’ 
inhA R2     50 5’-CTGAACGGGATACGAATGGG-3’ 
external F     50 5’-ACATCCTACACACGCTCTCATGTC-3’ 
inhA P5 *     50 5’-CGCAGCCAGGGCCTCGCTG-3’ 
inhA P3 *     50 5’-CTCCGGTAACCAGGACTGA-3’ 
*primers used for DNA sequencing 
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3.6. High-resolution melting analysis 
The DNA duplexes were subjected to HRM analysis in a Rotorgene 6000 real-time analyser 
(Qiagen, Germany). The thermal denaturation profiles were measured over the temperature 
range of 80°C to 90°C, and fluorometric readings were taken every 0.1°C (ramp time was 2 
seconds per 0.1°C). The Rotorgene software was used to calculate the derivative of the intensity 
of fluorescence at different temperatures (dF/dT), thereby generating a plot where the derivative 
peak(s) represents the Tm value of the DNA duplexes. Clinical samples were classified as either 
wild type or mutant inhA gene promoter sequences by the software according to the presence of 
a derivative peak(s) located within a defined temperature bin(s). A derivative plot with a single 
derivative peak at a Tm of 86.64°C (homoduplex, bin width 1°C) was classified as wild type for 
the inhA gene promoter region, while a derivative plot with two derivative peaks at Tm’s of 
86.64°C and 85.5°C (homo- and heteroduplexes, bin width 1°C and 0.5°C respectively) was 
classified as harbouring a mutation in this region.  
The HRM derivative plots of the 77 consecutive samples of the dataset were also scored visually 
by 3 blinded operators (one experienced and two inexperienced).  
 
3.7. Statistical analysis 
The statistical software program Statistica 7.1 was used to calculate the sensitivity and specificity 
of PCR amplification for detecting the presence of inhA gene promoter mutations at a confidence 
interval (CI) of 95% compared to DNA sequencing analysis. 
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4. Results 
 
The methodology was optimised on a cohort of 11 genetically well-characterised purified DNA 
samples obtained from sputum cultures from patients with MDR-TB and XDR-TB. In all instances 
the HRM analysis was able to differentiate between homo- and heteroduplexes (Figure 2). 
Mutations at position -15 and -17 of the inhA gene promoter region were correctly identified in 
100% (n=8) of the isolates which harboured an inhA promoter mutation. All the wild type 
specimens were correctly identified by HRM analysis.  
To determine whether the single-tube HRM method could be used to analyse crude DNA 
templates, decontaminated sputum specimens from 77 patients with INH-mono resistant TB, 
MDR-TB or XDR-TB were analysed. Rotorgene software correctly identified 100% (n=41) of the 
isolates containing an inhA promoter mutation. However, this software incorrectly scored 6 of the 
36 wild type samples as harbouring a mutation leading to an overall specificity of 83.3% (95% CI, 
70% to 96.7%) compared to DNA sequencing analysis. The sensitivity of the assay was 100% 
(95% CI, 100% to 100%), with a positive predictive value (PPV) of 87.2% and a negative 
predictive value (NPV) of 100%. The performance of the automatic scoring could not be 
improved further due to software limitations. Figure 3 shows the typical derivative plots 
generated, including correctly scored mutation harbouring isolates; and correctly and incorrectly 
scored wild type isolates. Isolates harbouring a mutation in the inhA gene promoter showed a 
homoduplex peak with a lower Tm than wild type isolates which had a slightly higher Tm. 
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peaks in defined temperature bins (homo- and heteroduplex, width 1°C and 0.5°C respectively). (B) 
Derivative peaks shifted to the right, but were correctly scored as wild type using the same defined 
temperature bins (homoduplex). (C) Isolates were incorrectly scored as harbouring a mutation due to 
the presence of a small peak in the defined heteroduplex temperature bin (arrows). 
 
To determine whether the scoring performance could be improved, 77 HRM derivative plots 
(including the 6 scored incorrectly by the software) were visually scored by one experienced and 
two inexperienced operators (following a short 5 min training session). The experienced and 
inexperienced operators showed a pooled sensitivity and specificity of 98.4 % (range: 97.6% to 
100%) and 93.5% (range: 86.1% to 100%) for detecting mutations in the inhA promoter gene 
compared to DNA sequencing. The average PPV was 94.7% and the NPV was 98.0%, 
respectively. The inter-reader agreement was high, with a Fleisch Kappa score of 0.88 (95% CI: 
0.79 to 0.95). Visual scoring was thus more specific than automatic scoring by the Rotorgene 
software.  
 
5. Discussion 
 
We report the successful development of a single closed-tube fluorometric assay for the 
detection of mutations (and associated drug-resistance) using purified or crude M. tuberculosis 
DNA templates. This FASTest-inhA method was able to identify mutations occurring at positions 
-8, -15 and -17 of the inhA gene promoter. However, the current Rotorgene software was unable 
to distinguish between background noise and signal in a small proportion (7.8%) of the wild type 
sequence samples.  
This could be directly ascribed to the presence of impurities in the crude DNA templates (a 
known limitation of HRM methodologies)14 which resulted in derivative curves which showed 
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inter-sample variation according to peak height and peak Tm. Adding a DNA purification step 
would largely resolve the above limitations, however, this additional step would increase the cost 
of the assay and contribute to diagnostic delay. A possible solution would be to introduce 
synthesised oligonucleotide sequences in each PCR reaction to act as calibrators allowing the 
normalisation of derivative curves.15 Custom software can then be developed to align the 
calibrators of each sample in an analysis run, thereby aligning the peaks and minimising Tm 
variation.15 The resultant homo- and heteroduplex bins can then be narrowed so as to avoid the 
scoring of aberrant peaks or overlapping samples. Introducing additional oligonucleotides into a 
PCR reaction may however reduce amplification efficiency;15 therefore it would be more 
advantageous to find an alternative solution. We propose that the manufacturers design an 
additional software application which will normalise all the derivative plots of a run according the 
homoduplex peak, to a pre-defined Tm. Aligning this homoduplex peak would allow the 
heteroduplex peak to align in samples harbouring a mutation, while keeping wild type samples 
with the smaller false peak aligned at a lower peak height and different Tm. Once again, 
narrowing analysis bins should be able to differentiate the samples more accurately (see Figure 
4). 
The FASTest-inhA assay was a significant improvement over the FAST-Rif6 and FAST-EMB 
methods in that we included an amplification control, which ensured that amplification failures 
could be identified (only clinical samples containing M. tuberculosis DNA will be amplified). 
Furthermore, the closed tube system reduced the time to results (<2hours following short term 
culture) and the risk of amplicon release.  However, in its present format, the assay may not be 
as advantageous as the GenoType® MTBDRplus assay which provides a more powerful readout, 
including speciation and multiple drug-resistance targets. However, the FASTest-inhA method 
does overcome inter-reader variation and lays the foundation for a considerably more affordable 
and safer closed-tube assay, which could be adapted to multiple targets. The assay also has the 
potential for large scale automation, which should be particularly attractive in low-income, high 
TB incidence settings.  
 
  
 
 
Figure 4. Illustration of proposed normalisation of thermal denaturation peaks. (A) Typical output of 3 
isolates (1 with a mutation and 2 without). The peaks are not aligned. (B) Expected output following 
normalisation to a pre-defined Tm for the homoduplex peak (in this case 86.7°C). The wild-type isolate 
with the small first peak will now be scored correctly as the bins can be narrowed to exclude 
background noise. 
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In addition, we acknowledge that our method was not able to identify INH resistance which was 
due to mutations in genes other than the inhA promoter region, however, inhA promoter 
mutations are of particular interest as these confer low level INH resistance, therefore cases 
which harbour these mutations may benefit from the use of high/standard dose INH therapy.16 
Recent data from the Western Cape Province of South Africa showed that 53.6% of INH mono-
resistant clinical samples and 38.2% of MDR-TB samples harboured mutations in the inhA gene 
or promoter region.17 These mutations were also strongly associated (70%) with XDR-TB in a 
cohort of 85 XDR-TB patients.16 This implies that these patients have low level INH resistance 
and may benefit from high dose INH therapy.16 This is of particular clinical importance in patients 
resistant to most or all of the available antibiotics. Additionally, inhA promoter mutations have 
been implicated in cross-resistance to the second-line anti-tuberculosis drug ethionamide, which 
forms part of the treatment regimen for MDR-TB.16 Thus genotypic drug-susceptibility testing 
(including the GenoType® MTBDRplus assay) for INH resistance through mutations in the inhA 
gene may be extremely beneficial in tailoring MDR-TB and XDR-TB treatment regimens.16 
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1. Abstract  
 
The increase in multidrug-resistant tuberculosis (MDR-TB), defined as Mycobacterium 
tuberculosis resistant in vitro to at least isoniazid (INH) and rifampicin (RIF), is a global concern. 
It is estimated that 511 000 MDR-TB cases occur globally each year. The World Health 
Organisation (WHO) consequently released an emergency update on their management 
guidelines, recommending that treatment of MDR-TB should include at least 4 effective drugs, 
and that standardised treatment regimens should be based on resistance patterns for each 
country/region. Most importantly, treatment regimens should not depend on the results of drug 
susceptibility testing (DST) for ethambutol (EMB) or pyrazinamide (PZA). In response, the South 
African Department of Health prepared a draft drug-resistant TB treatment policy in which PZA 
remains one of the 4 effective drugs, while EMB should be replaced with terizidone or 
cycloserine, if there is resistance to EMB (disregarding inaccurate DST). In South Africa, there is 
a high frequency of undetected EMB and PZA resistance and their association with MDR-TB. 
Therefore, we recommend that the WHO guidelines in which 4 other effective drugs are used to 
treat MDR-TB, be followed more closely. EMB and PZA can be included if they are not counted 
as one of the 4 effective drugs. However, this does not address the root cause of the 
amplification of resistance in undiagnosed MDR-TB patients in South Africa, which can only be 
achieved by the implementation of rapid DST methods in all TB cases before initiating therapy. 
This protocol would curb the amplification of resistance and the evolution of XDR-TB. 
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2. Forum  
 
The number of MDR-TB cases has steadily increased despite the widespread implementation of 
the directly observed treatment short-course (DOTS) and DOTS-plus strategies.1,2 A survey in 
South Africa estimates that 1.8% of new TB cases and 6.7% of retreatment TB cases are MDR-
TB,1 equating to approximately 14 000 MDR-TB cases each year.1 The manner in which the 
WHO DOTS strategy has been implemented in South Africa to control TB might have 
inadvertently lead to the amplification of resistance in MDR-TB cases.3-5 Consequently, it is 
important to review the epidemiology of drug resistance in the country and make informed 
evidence-based suggestions on improving the current treatment strategy.  
The WHO DOTS-plus treatment guidelines for treating MDR-TB focus on the use of various 
bactericidal or bacteriostatic anti-tuberculosis drugs with a proven efficacy against M. 
tuberculosis. They are classed as either first-line (normally used to treat new and drug-
susceptible TB cases) or second-line (normally used to treat MDR-TB or extensively drug-
resistant TB (XDR-TB)). EMB and PZA, two first-line drugs, are often used in combination with 
various second-line drugs to treat MDR/XDR-TB. Their inclusion in the latter treatment regimen 
was based on the absence of alternative second-line drugs and surveillance data (or lack 
thereof), which suggests that resistance to EMB and PZA is rare.6 However, DST for both EMB 
and PZA is inaccurate.7,8 The National Health Laboratory Service (NHLS) in Cape Town missed 
90% of EMB resistance using the indirect proportion method on Middlebrook solid medium 
compared with a liquid culture medium.7 Of the EMB-resistant isolates, 87% were also resistant 
to INH and RIF. These results were confirmed by DNA sequencing which identified mutations in 
the embB gene which conferred resistance to EMB in all the above isolates.7,9 In 2008, we 
showed in a cohort of 228 MDR-TB isolates from the Western Cape that 131 (57.5%) harboured 
mutations in the embB gene, suggesting that they were resistant to EMB (see Chapter 5). Only 
9.4% were phenotypically resistant by routine culture on solid media. In a drug resistance 
surveillance study in children in the Western Cape from March 2007 through February 2009, 12 
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out of 24 (50%) with confirmed MDR-TB were phenotypically resistant to EMB, confirming the 
high rate of EMB resistance in adult MDR-TB cases (HSS, personal communication). 
DST for PZA is not routinely performed in South Africa owing to the complexity of the culture 
conditions (low pH medium is required, which negatively affects the growth and viability of M. 
tuberculosis).10 To address the largely unknown frequency of resistance to PZA, a recent study 
(using the non-radiometric BACTEC mycobacterial growth indicator tube (MGIT) 960 method) 
showed that 53.5% of drug-resistant isolates (various resistance patterns) from the Western 
Cape were resistant to PZA. This finding was confirmed by DNA sequencing of the pncA gene, 
which encodes for the mechanism of resistance.8,11 This study importantly showed a highly 
significant association between MDR-TB and PZA resistance (p<0.001)8 that was confirmed in 
isolates collected as part of a national drug-resistance survey where 52.1% of MDR-TB isolates 
showed additional resistance to PZA.12  
The association between EMB and PZA resistance and MDR-TB in South Africa (a setting where 
MDR-TB is primarily transmitted)13 stems from the manner in which the DOTS strategy has been 
implemented since 1996. New TB cases are routinely diagnosed by sputum smear microscopy or 
culture without DST. In the absence of routine DST, it is assumed that all new TB cases are 
drug-susceptible until treatment failure or relapse occurs. Therefore, according to the current 
2004 South African treatment guidelines (South African National Tuberculosis Control 
Programme Practical Guidelines 2004), a new TB patient with undiagnosed MDR-TB will be 
treated with 4 first-line drugs (INH, RIF, PZA and EMB) during the intensive phase of therapy (the 
first 2 months), which implies that the treatment regimen will contain only 2 effective drugs: EMB 
and PZA. Since PZA is a poor companion drug to prevent the acquisition of resistance, it is 
highly probable that resistance to EMB and/or PZA will follow, as is evident by the above data. If 
patients fail to show sputum conversion after 5 months of treatment, they would be regarded as a 
treatment failure and be shifted to the category II regimen (i.e. South African current retreatment 
guidelines) with the addition of streptomycin (SM) in the first 2 months of retreatment. DST will 
then be requested (which may take months),14 during which time resistance to any remaining 
effective drugs may develop (i.e. EMB, PZA and/or SM). Consequently, the MDR-TB epidemic 
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will become largely associated with EMB, PZA and SM resistance. In addition, during the 
diagnostic delay period, transmission to close contacts may occur, thereby perpetuating the 
MDR-TB epidemic. 
According to the South African National Tuberculosis Control Programme Practical Guidelines 
2004, a patient will only be placed on the standardised treatment for MDR-TB after DST results 
become available. This could be at least 6 to 7 months after initial therapy started. The patient 
will be placed on the current standardised MDR-TB treatment regimen which includes a 
fluoroquinolone (usually ofloxacin or ciprofloxacin), amikacin (Am) or kanamycin (Km), 
ethionamide (for which the strain may be resistant if inhA promoter region mutation is the cause 
of INH resistance), PZA and EMB (replaced with cycloserine or terizidone if resistant to EMB). 
Resistance to PZA,8 EMB7 and ethionamide15 is commonly associated with MDR-TB and, if not 
detected, patients with MDR-TB may only receive 2 effective drugs (a fluoroquinolone and Am or 
Km) of which Am or Km is not used during the 12 to18-month continuation phase of therapy. This 
situation could lead to unintentional monotherapy during the continuation phase, with possible 
acquisition of resistance to the fluoroquinolones, leading to pre-XDR-TB (one resistance mutation 
away from XDR-TB).13 Therefore, many MDR/XDR-TB cases are presently being inadvertently 
under-treated, which may strongly influence treatment outcome. This scenario may be repeated 
as treatment regimens are adjusted, leading to the eventual evolution of XDR-TB.4 
To address the difficulties associated with DST for EMB and PZA, the WHO in 2008 released an 
emergency update on guidelines for treating drug-resistant TB in which they acknowledged that 
MDR-TB treatment regimens should not be dependent on the results of DST for EMB or PZA.16 
They recommended that treatment of MDR/XDR-TB should include at least 4 drugs with certain 
or almost certain effectiveness. Treatment regimens can be individualised or standardised if 
resistance patterns for the country/region are known. EMB could be included in a regimen 
provided that it is not counted as one of the effective 4 drugs, and that PZA may be used for the 
entire treatment if deemed effective (based on DST) but must also not be counted as one of the 
4 effective drugs. Ciprofloxacin is no longer recommended for treatment of TB.16  
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New draft policy guidelines (2008) are being formulated by the South African National TB Control 
Programme based on the WHO recommendations. These guidelines aim to address diagnostic 
delay as well as treatment of MDR/XDR-TB. They suggest that DST should be done on patients 
failing to show clinical or bacteriological improvement at 2 months of treatment or at 3 months in 
cases where the intensive phase was extended (as opposed to 5 months in the old guidelines). 
In contrast to the WHO, these guidelines recommend that DST for EMB determines the 
treatment regimen for MDR/XDR-TB. If susceptible, EMB should be included in the regimen as 
the 5th drug (this disregards the inaccuracy of EMB DST). If resistant, EMB should be replaced 
with terizidone or cycloserine as the 5th drug. These guidelines also recommend the inclusion of 
PZA as one of the 4 effective drugs but acknowledge that, in the absence of DST, it should be 
assumed that all isolates are resistant. Given the strong evidence of high levels of resistance to 
PZA in South Africa associated with MDR-TB, we suggest that, in the absence of DST for PZA, 
this drug should not be counted as one of the 4 effective drugs, but may be included in the 
regimen.  
In light of the WHO recommendations and the high levels of undetected resistance to EMB and 
PZA in South Africa, it is essential that the revised guidelines for MDR-TB treatment are 
implemented in South Africa together with improved routine DST. In the interim, it should be 
assumed that all MDR-TB cases are resistant to EMB and PZA and, although treatment with 
these drugs can be continued, they should not be counted as one of the 4 effective drugs, to 
prevent the emergence of additional resistance and the possible evolution of XDR-TB. 
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1. Abstract  
 
SETTING: Western Cape and Eastern Cape Provinces of South Africa. 
OBJECTIVE: To assess a potential association between the evolution of extensively drug-
resistant (XDR) strains of Mycobacterium tuberculosis and mutations in katG or the inhA 
promoter. 
DESIGN: Analysis of the frequency distribution of isoniazid resistance conferring mutations in a 
population sample of drug-resistant strains of M. tuberculosis. 
RESULTS: In the Western Cape and Eastern Cape Provinces, respectively, the percentage of 
strains exhibiting inhA promoter mutations increased significantly from 47.8% and 70.7% in 
multidrug-resistant (MDR) strains to 85.5% and 91.9% in XDR strains. Data from the Western 
Cape revealed that significantly more XDR strains showed mutations in the inhA promoter than in 
katG (85.5% vs. 60.9%; p<0.001), whilst the respective proportions were equal for INH resistant 
non-MDR strains (~30%). 
CONCLUSIONS: InhA promoter mutations are strongly associated with XDR tuberculosis in 
South Africa. We suggest that this is due to the dual resistance to ethionamide and (low-dose) 
isoniazid conferred by inhA promoter mutations. The use of molecular probe assays such as the 
GenoType® MTBDRplus assay, which allow for the detection of inhA promoter mutations, could 
enable adjustment of the treatment regimens depending on the pharmacogenetic properties of 
the mutations detected. 
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2. Introduction  
 
Multidrug-resistant tuberculosis (MDR-TB), defined by resistance to at least isoniazid (INH) and 
rifampicin (RIF), threatens TB control programs in many parts of the world.1 Amplification of drug 
resistance in MDR-TB can lead to virtually untreatable extensively drug-resistant tuberculosis 
(XDR-TB), defined as MDR-TB plus additional resistance to a fluoroquinolone and one of the 
injectable second-line drugs kanamycin (Km), amikacin (Am) or capreomycin (Cm).2-5 
In South Africa, all new cases of TB are treated with a combination of four anti-TB drugs [INH, 
RIF, pyrazinamide (PZA) and ethambutol (EMB)] in the absence of drug susceptibility testing 
(DST).6,7 Streptomycin is added to this regimen for retreatment cases while DST is being 
performed. If resistance to INH and RIF is detected, the treatment regimen is adjusted to include 
second-line anti-TB drugs. Since 2002 the treatment of MDR-TB has been largely standardised 
and includes a fluoroquinolone [mostly ofloxacin (OFL)], an aminoglycoside (Am or Km), PZA, 
EMB or cycloserine, and ethionamide (Eto).6,8 This regimen assumes that resistance to EMB and 
PZA is rare. However, there is mounting microbiological evidence to suggest a strong association 
between MDR-TB and EMB and PZA resistance.6,9,10 Furthermore, several molecular 
epidemiological studies have suggested that MDR-TB is largely transmitted.11-15 This questions 
the validity of the current treatment guidelines6 and calls for the development of rapid diagnostics 
for DST.16 
Cases of drug-resistant TB emerge due to ineffective treatment, patient non-adherence to 
therapy, or the transmission of drug-resistant strains of M. tuberculosis.2-4 On a molecular level, 
drug resistance in M. tuberculosis develops through spontaneous mutations in target genes 
followed by the natural selection of these resistant bacteria upon exposure to anti-TB drugs.3,4 
Various drug resistance causing mutations in M. tuberculosis have been characterised to 
date.3,17,18 It is well documented that mutations in the inhA promoter confer low-level resistance 
to INH and cross-resistance to Eto, while mutations in katG at codon 315 exclusively confer high-
level resistance to INH.18-21 Similarly, mutations in the rpoB gene account for >95% of RIF 
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resistance.22 Thus, molecular assays identifying specific drug resistance causing mutations may 
be used to accelerate DST, which is considered critical to prevent amplification and transmission 
of drug resistance.16 In this respect, the WHO endorsed GenoType® MTBDRplus assay has been 
implemented in several settings to assist culture based DST; it detects most of the mutations 
conferring RIF resistance as well as the principal mutations in the katG gene and inhA promoter 
which confer INH resistance.16 
Considering the dual resistance to INH and ETH conferred by the inhA promoter mutation and 
the use of these drugs for first and second-line treatment, respectively, this study aimed to 
determine whether M. tuberculosis strains harbouring mutations in the inhA promoter are 
associated with XDR-TB, in South Africa. Moreover, we assessed the usefulness of the 
MTBDRplus assay for the detection of mutations conferring INH resistance in order to guide 
treatment regimens for MDR-TB. 
 
3. Materials and Methods  
 
3.1 Data from the Western Cape Province 
Strains of M. tuberculosis used for this study were selected from a large collection of drug-
resistant strains, isolated from altogether 4524 TB patients mostly between 2001 and 2009. 
Between 2001 and 2007, drug-resistant isolates from patients visiting health facilities in two of 
the four health districts in the Western Cape Province were collected. From 2008, drug-resistant 
isolates from patients visiting health facilities in all of the health districts were collected. Routine 
DST was done by the National Health Laboratory Service (NHLS) and included testing for INH, 
RIF and EMB resistance. In 2007, routine DST was revised to include testing for OFL, Am and 
Eto resistance. Mutations in the inhA promoter and katG were identified by dot-blot techniques or 
partial gene sequencing as explained elsewhere.23 For the analysis of the frequency of mutations 
in the inhA promoter and katG in INH resistant strains (Table 1), only sequencing data was 
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considered. Isolates from our collection of strains that were included in this analysis were INH 
resistant and were tested for mutations in either the inhA promoter or the katG gene or both. 
Multiple isolates from the same patient were included only if they showed different mutations. 
The convenience sample for this analysis included isolates obtained from 527 patients. For the 
analysis of the mutation patterns in different drug resistance classes (Table 2, Figure 1), all 
available data including results from dot-blot analyses was considered. Isolates that were 
included in this analysis were tested for mutations in both the inhA promoter and katG. A 
convenience sample was selected for INH resistant non-MDR (INH mono-resistant and poly-
resistant) and MDR strains. However, the majority of XDR-TB strains were analysed. Only one 
M. tuberculosis isolate per patient was considered and the analysed sample contained isolates 
from 459 patients.  
This study was approved by the Stellenbosch University Ethics Committee. 
 
3.2 Data from the Eastern Cape Province 
During the period from July 2008 to January 2009 a convenience sample of isolates from 263 
patients corresponding to approximately one third of all MDR-TB isolates cultured from patients 
visiting heath facilities in the Eastern Cape Province was collected. Routine DST was done by 
the NHLS, Eastern Cape. Mutations in the inhA promoter were identified by DNA sequencing.23 
 
3.3 Statistical analyses 
Statistical analyses were performed in Stata/IC v10.1. Associations between distinct drug 
resistance groups and the occurrence of mutations in katG or the inhA promoter were 
determined by the Pearson’s chi-squared test. The difference in the proportions of XDR strains 
with mutations in katG or the inhA promoter was determined by the two-sample z-test of 
proportions. A level of α<0.05 was considered statistically significant. 
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4. Results  
 
4.1 Western Cape Province 
Mutations identified by partial sequencing of the katG gene and the inhA promoter are listed in 
Table 1. KatG mutations at codon 315 and inhA promoter mutations at nucleotide position -15 
constituted the majority (32.2% and 58.2%, respectively) of the observed nucleotide changes 
(Table 1). Of all mutations identified, the MTBDRplus assay could potentially detect alterations in 
katG codon 315 and in the inhA promoter at nucleotide positions -8, -15 and -17, either 
specifically through a mutation probe or through the absence of a hybridization signal for one of 
the wild-type probes. Consequently, in theory, the MTBDRplus assay might detect up to 96.4% of 
the mutation events herein identified by sequencing (Table 1). 
To investigate any potential associations between sequence changes in katG or the inhA 
promoter and XDR-TB, we calculated the proportion of strains with mutations in these genetic 
regions for different drug resistance classes (INH resistant non-MDR strains, MDR strains and 
XDR strains; Table 2, Figure 1). The percentage of strains with an inhA promoter mutation 
increased significantly from 30.1% in INH resistant non-MDR strains to 58.5% in MDR strains 
and 85.5% in XDR strains (overall 2.8-fold increase, Χ2=74.6, p<0.001; Table 2, Figure 1). 
Although the percentage of strains with a katG mutation also increased, the rate of increase was 
lower (2.1-fold, Χ2=28.7, p<0.001) and attributable to a strain cluster, which also harboured an 
inhA promoter mutation (data not shown). Significantly more XDR strains showed mutations in 
the inhA promoter than in katG (85.5% vs. 60.9%, p<0.001), whilst the respective proportions 
were equal for INH resistant non-MDR strains (~30%; Table 2, Figure 1). 
Importantly, 41.7% of all INH resistant non-MDR strains did not exhibit any mutations in katG or 
the inhA promoter (Table 2, Figure 1). However, this was significantly less frequently observed in 
MDR- and was not seen in XDR-TB cases. Also of note, a proportion of almost 40% of the MDR 
and XDR strains showed a mutation in the inhA promoter only and without any detected mutation 
in katG (Table 2, Figure 1). 
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Figure 1. Patterns of point mutations in the inhA promoter and katG by drug resistance class in 
strains of M. tuberculosis in the Western Cape Province.  
 
Key: The MDR group includes XDR group 
 only others: Strains with no mutations detected in katG or the inhA promoter 
 katG\inhA promoter: Strains with mutations detected in katG but not in the inhA promoter 
 inhA promoter∩katG: Strains with mutations detected in the inhA promoter and in katG 
 inhA promoter\katG: Strains with mutations detected in the inhA promoter but not in katG 
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Table 1 Frequency of mutations identified by sequencing of the katG gene and the inhA promoter of INH resistant strains of M. tuberculosis in the 
Western Cape Province 
 
Gene Position Mutation Present  Absent Sum % Present % Mutations % Cum. Mutations 
inhA promoter -15 point mutation 224 157 381 58.8% 55.9% 55.9% 
inhA promoter -17 point mutation 21 360 381 5.5% 5.2% 61.1% 
inhA promoter -8 point mutation 2 379 381 0.5% 0.5% 61.6% 
katG 315 point mutation 139 277 416 33.4% 34.7% 96.3% 
katG 387 point mutation 2 414 416 0.5% 0.5% 96.8% 
katG 77 point mutation 1 415 416 0.2% 0.2% 97.0% 
katG 299 point mutation 1 415 416 0.2% 0.2% 97.3% 
katG 302 point mutation 1 415 416 0.2% 0.2% 97.5% 
katG 314 insertion 1 415 416 0.2% 0.2% 97.8% 
katG 320 point mutation 1 415 416 0.2% 0.2% 98.0% 
katG 408 point mutation 1 415 416 0.2% 0.2% 98.3% 
katG 483 point mutation 1 415 416 0.2% 0.2% 98.5% 
katG 119 deletion 3 130 133 2.3% 0.7% 99.3% 
katG 76 point mutation 1 132 133 0.8% 0.2% 99.5% 
katG 137 point mutation 1 132 133 0.8% 0.2% 99.8% 
katG 198 point mutation 1 132 133 0.8% 0.2% 100.0% 
Total     401           
                  
Position: Amino-acid positions are indicated for transcribed regions (katG) and base-pair positions are indicated for untranscribed regions (inhA 
promoter)  
Present: Among the INH resistant strains tested, number of strains showing a point mutation for the indicated gene at the indicated position 
Absent: Among the INH resistant strains tested, number of strains not showing a mutation for the indicated gene at the indicated position 
Sum: Number of INH resistant strains tested for a specific mutation for the indicated gene at the indicated position 
% Present: Among the INH resistant strains tested, percentage of strains showing a mutation for the indicated gene at the indicated position 
% Mutations: Number of times a specific mutation has been detected divided by the total number of detected mutation events 
% Cum. Mutations: Cumulative percentage of % Mutations 
      
Total: Total number of detected mutation events 
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Table 2 Patterns of point mutations in the inhA promoter and katG by drug resistance class in strains of M. tuberculosis in the 
Western Cape Province 
 
Mutation   non-MDR INH
R
   MDR   XDR 
  N % CI   N % CI   N % CI 
inhA promoter\katG   61 29.6% 23.5%-36.4%   100 39.5% 33.5%-45.8%   27 39.1% 27.6%-51.6% 
inhA promoter∩katG   1 0.5% 0.0%-2.7%   48 19.0% 14.3%-24.4%   32 46.4% 34.3%-58.8% 
katG\inhA promoter   58 28.2% 22.1%-34.8%   73 28.9% 23.4%-34.9%   10 14.5% 7.2%-25.0% 
only others   86 41.7% 34.9%-48.8%   32 12.6% 8.8%-17.4%   0 0.0% 0.0%-5.2%* 
inhA promoter   62 30.1% 23.9%-36.9%   148 58.5% 52.2%-64.6%   59 85.5% 75.0%-92.8% 
katG   59 28.6% 22.6%-35.3%   121 47.8% 41.5%-54.2%   42 60.9% 48.4%-72.4% 
Total   206 100.0% N/A   253 100.0% N/A   69 100.0% N/A 
                          
MDR group includes XDR group                   
inhA promoter\katG: Strains with mutations detected in the inhA promoter but not in katG     
inhA promoter∩katG: Strains with mutations detected in the inhA promoter and in katG         
katG\inhA promoter: Strains with mutations detected in katG but not in the inhA promoter     
only others: Strains with no mutations detected in katG or the inhA promoter         
inhA promoter: Strains with mutations detected in the inhA promoter           
katG: Strains with mutations detected in katG                 
Total: Total number of strains tested                   
N: Number of strains of the same drug resistance group with the respective drug mutation pattern   
%: Percentage of strains of the same drug resistance group with the respective drug mutation pattern   
CI: 95% confidence intervals                   
* One-sided, 97.5% confidence interval                 
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4.2 Eastern Cape Province 
An extensive set of MDR-TB and XDR-TB strains isolated from TB patients in the Eastern Cape 
Province was analysed in order to determine whether the association between the inhA and 
XDR-TB is restricted to the Western Cape Province. Table 3 and Figure 2 show all mutations 
identified in the inhA promoter and their mutation frequencies in MDR and XDR strains. 
In this setting, the proportion of isolates with an inhA promoter mutation also increased 
significantly during amplification of resistance from MDR-TB (70.7%) to XDR-TB (91.9%; 1.3-fold 
increase; Χ2=13.9, p<0.001; Table 3, Figure 2). In contrast to the Western Cape Province, the 
inhA promoter mutation at nucleotide position -17 was the predominant mutation found in this 
region. 
 
  
Figure 2. Frequency of point mutations in MDR and XDR strains of M. tuberculosis in the Eastern Cape Province 
 
Key: MDR group includes XDR group 
 only others: Strains with no mutations detected in katG or the inhA promoter 
 katG\inhA promoter: Strains with mutations detected in katG but not in the inhA promoter 
 inhA promoter∩katG: Strains with mutations detected in the inhA promoter and in katG  
inhA promoter\katG: Strains with mutations detected in the inhA promoter but not in katG
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Table 3 Frequency of point mutations in MDR and XDR strains of M. tuberculosis in the Eastern Cape Province 
 
Gene   Position   MDR   XDR 
    Present  Absent Sum % Present % Mutation N % CI   N % CI 
inhA   -17   134 129 263 51.0% 72.0% 134 51.0% 44.7%-57.1%   62 83.8% 73.4%-91.3% 
inhA   -15   30 233 263 11.4% 16.1% 30 11.4% 7.8%-15.9%   4 5.4% 1.5%-13.3% 
inhA   -8   22 241 263 8.4% 11.8% 22 8.4% 5.3%-12.4%   2 2.7% 0.3%-9.4% 
only others       N/A N/A N/A N/A N/A 77 29.3% 23.8%-35.2%   6 8.1% 3.0%-16.8% 
inhA   all   N/A N/A N/A N/A N/A 186 70.7% 64.8%-76.2%   68 91.9% 83.2%-97.0% 
Total       186         263 100.0%     74 100.0%   
                                
MDR group includes XDR group             
          
Position: Nucleotide positions are indicated         
          
Present: Among the MDR strains tested, number of strains showing a point mutation for the indicated gene at the indicated position 
Absent: Among the MDR strains tested, number of strains not showing a mutation for the indicated gene at the indicated position 
Sum: Number of MDR strains tested for a specific point mutation for the indicated gene at the indicated position 
  
% Present: Among the MDR strains tested, percentage of strains with a point mutation detected for the indicated gene at the indicated position 
% Mutations: Number of times a specific mutation has been detected divided by the total number of detected mutation events 
N: Number of strains of the same drug resistance group with the respective drug mutation pattern 
        
%: Percentage of strains of the same drug resistance group with the respective drug mutation pattern 
        
CI: 95% confidence intervals             
          
Total: Total number of detected mutation events or total number of MDR/XDR cases 
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5. Discussion  
 
Our results show a significant association between inhA promoter mutations and XDR-TB in two 
South African Provinces (Tables 2 and 3, Figures 1 and 2). This may suggest a selective 
advantage of strains harbouring an inhA promoter mutation to become XDR strains, within the 
current treatment regimen. At least two distinct processes may explain the observed 
accumulation of XDR-TB strains with an inhA promoter mutation. First, inhA promoter mutations 
may have evolved during exposure to INH during first-line treatment. MDR strains evolving from 
such strains also would have demonstrated cross resistance to Eto. If Eto resistance remained 
undetected there was an increased probability for these strains to acquire resistance to second-
line drugs due to the treatment regimen having one less effective drug. Second, a significant 
proportion of XDR-TB strains initially might have been susceptible to Eto; however, continuous 
exposure to this drug could have lead to the acquisition of inhA promoter mutations and Eto 
resistance.3,4,17-21 
The strong association between the presence of inhA promoter mutations and XDR-TB may also 
apply to other regions in South Africa and other parts of the world. In a recent study in Portugal, 
98.0% of 50 MDR strains tested showed resistance to Eto and 91.4% of 58 MDR strains tested 
showed an inhA promoter mutation.24 A retrospective study on XDR-TB isolates from four 
provinces of South Africa showed that 30 of the 41 strains tested (73.2%), were resistant to 
Eto.25 These findings may again be explained by the scenario described above. Future studies 
should investigate to what extend the observed association between inhA promoter mutations 
and XDR-TB also applies to other settings. 
Our population study has some limitations. Mutation analyses of katG and the inhA promoter of 
isolates from the Western Cape Province was done on a convenience sample of INH resistant 
non-MDR and MDR strains. However, the majority of the XDR strains from this setting have been 
analysed and no bias is evident for this group of strains. We know that the Beijing lineage of 
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strains was overrepresented in our sample of the INH resistant non-MDR and MDR strains. In 
the Western Cape Province, drug-resistant Beijing strains are strongly associated with inhA 
promoter mutations [11,14, unpublished results]. Therefore, our analyses overestimated the 
proportion of strains with an inhA promoter mutation in INH resistant non-MDR and in MDR 
strains. Moreover, XDR strains were overrepresented in our sample of MDR strains of the 
Western Cape Province. Therefore, the increase in the proportion of strains with an inhA 
promoter mutation from non-MDR INH resistant strains to XDR strains is likely to be even more 
pronounced and our analyses have been conservative with regards to this observation.  
Our results may have been influenced by the considerable contribution of transmission of drug-
resistant strains to MDR-TB, in South Africa.11-15 Therefore, the percentage composition of 
distinct drug resistance mutations in different drug resistance groups may fluctuate if significant 
changes in the transmission rates of strains occur that are associated with specific mutations. It 
is also conceivable that the observed association between inhA promoter mutations and XDR-TB 
is not due to a selective advantage of these mutations, but is caused by their coincidental 
presence in a few highly transmitted drug-resistant strains that are particularly successful for 
other reasons. An alternative hypothesis for a potential selective advantage of inhA promoter 
mutations in the evolution of XDR-TB may be decreased fitness cost of these mutations 
compared to mutations in katG. Our analyses could have been distorted due to the partial 
sequencing only of katG in this study. However, other mutations in katG than those described 
here are infrequently detected in INH resistant clinical isolates3,18 (Table 1) and their influence on 
our analyses is therefore likely to be minor or absent. 
Our study suggests that in principle, the MTBDRplus assay could detect 96.4% of all mutation 
events identified by partial sequencing of the katG gene and the inhA promoter of an extensive 
sample of INH resistant strains of M. tuberculosis from the Western Cape Province (Table 1). 
However, for this setting, our results clearly showed that mutations in genes other than katG or 
the inhA promoter accounted for more than 40% and 12% of all cases of INH resistant non-MDR 
and MDR cases, respectively. This illustrates that culture based phenotypic DST should not be 
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replaced but rather assisted by molecular drug resistance typing techniques in order to achieve 
the highest possible sensitivity for the detection of drug-resistant isolates. Otherwise, this will 
inevitably lead to the selection and spread of INH resistant strains with properties that remain 
undetected by the molecular identification methods currently in use. 
The MTBDRplus assay has been implemented for routine DST in several countries including 
some provinces in South Africa. With the introduction of the assay to assist culture based DST, 
information on the presence of the most important drug resistance mutations in isolates of M. 
tuberculosis from TB patients becomes readily available to clinicians. This may allow adjustment 
of the treatment regimens depending on the pharmacogenetic properties of the mutations 
detected.26 
For TB patients infected with strains harbouring an inhA promoter mutation, Eto must not be 
considered an effective drug of the treatment regimen. However, because the inhA promoter 
mutation only confers low-level resistance to INH, high-dose or standard dose INH may be 
included in the treatment regimen of such cases if the infecting strains do not also exhibit any 
additional high-level INH resistance mutations.26 In many settings, the most frequently observed 
high-level INH resistance mutations are found in codon 315 of katG,3 which are detectable by the 
MTBDRplus assay.16 The information that high-dose INH may be included in treatment regimens 
is particularly valuable in XDR-TB cases, for which only few active drugs remain available. In this 
respect, our observation that approximately 40% of the MDR and XDR strains from the Western 
Cape Province exhibit a mutation in the inhA promoter but not in katG, is of special importance. 
In Figure 3, we propose guidelines for the individualised treatment of TB patients based on the 
drug resistance mutation patterns detected by the MTBDRplus assay. These recommendations 
also consider our previous observations of a high percentage of EMB and PZA resistance in 
MDR strains in South Africa.6 
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Figure 3. Proposed guidelines for the individualised treatment of TB patients in South Africa contingent on MTBDRplus DST results 
Use standard first line drugs.
Do not consider INH and ETH as effective drugs for treatment. 
Use second line drugs other than ETH to replace INH in the 
drug regimen. High-dose INH may be considered for 
treatment.
Do not consider INH or high-dose INH as an effective drug for 
treatment. Replace INH by an effective second line drug for 
treatment.
Do not consider INH or high-dose INH and ETH as effective 
drugs for treatment. Use second line drugs other than ETH to 
replace INH in the treatment regimen.
Do not consider RIF as an effective drug for treatment.
Replace RIF by an effective second line drug for treatment.
Use second line drugs for treatment. Do not consider ETH, 
EMB and PZA as effective drugs for treatment. High-dose INH 
may be considered for treatment.
Use second line drugs for treatment. Do not consider high-
dose INH, EMB and PZA as effective drugs for treatment.
Use second line drugs for treatment. Do not consider high-
dose INH, ETH, EMB and PZA as effective drugs for treatment.
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General Conclusion 
 
 
Despite the abundance of clinical, immunological and genotypic-based methodologies for 
detecting both Mycobacterium tuberculosis and associated drug-resistance, phenotypic culture 
still remains the gold standard. However, this method is dependent on the growth rate of M. 
tuberculosis, which is notoriously slow (doubling rate of 16 hours in optimal laboratory 
conditions).1 Diagnostic delay is regarded as a major contributor to the continuous rise in 
tuberculosis cases and the associated emergence and transmission of multidrug-resistant 
tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB). It is therefore 
essential that new and more rapid diagnostic methods are developed. 
Genotypic-based assays show the most promise as they circumvent the need for culture and 
have the potential to provide a species-specific result within hours of obtaining a sample. 
Numerous methodologies have been described including hybridisation-based assays,2,3 DNA 
Chip technologies,4,5 multiplex ligation-dependent probe amplification,6 single strand 
conformation polymorphism analysis,7,8 isothermal amplification methods,9-11 molecular 
beacons,12,13 multiplex allele-specific PCR,11,14 PCR restriction enzyme analysis,15,16 and various 
other in-house17 and commercial-based methodologies. Although DNA sequencing is considered 
the gold standard in genotypic-based assays, the cost of the equipment and reagents is too high 
for routine implementation in low-income countries. This is also the case with many of the other 
methodologies listed above, some of which are further hampered by the need for post-
amplification processing. An open-tube format allows for the potential release of amplicons and 
the possibility of cross-contamination and reporting of false positives.  
We therefore investigated the potential of high resolution melting analysis (HRM) to improve the 
rapid diagnosis of TB and associated drug resistance. The HRM apparatus and reagents are 
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relatively inexpensive and the methodology can easily be implemented in high-incidence, low 
income regions. 
We firstly demonstrated that HRM was capable of rapidly identifying mycobacterial lymphadenitis 
from fine-needle aspiration biopsy (FNAB) samples. These FNABs were rinsed in an inexpensive 
transport medium and subsequently spotted onto FTA® Classic Cards (Whatman, UK) for later 
purification. The HRM method delivered a species-specific result by targeting the region of 
deletion 9 (RD9), present in M. tuberculosis and M. canettii, but absent from all other members of 
the complex18 (human infection with M. canettii is rare). The method showed a sensitivity of 
51.9% and a specificity of 94.0% as compared to the reference standard (positive cytology 
and/or positive culture with speciation). To simplify the method, we circumvented the need for the 
transport medium and spotted the samples directly onto the simpler FTA® Elute Cards. However, 
the procedure posed an increased risk to the health practitioners doing the FNAB, due to the 
potential for aerosolisation of any infectious material. Furthermore the samples often remained in 
the luer of the syringe and were not capable of being fully expelled onto the cards (using the 
previous method it was possible to remove this trapped sample by rinsing in the transport 
medium). The method delivered a slightly lower sensitivity and specificity (46.3% and 83.3%, 
respectively) than by rinsing in the transport medium. Unfortunately, none of the diagnostic 
modalities (HRM, cytology or culture) were sufficiently sensitive which may be due to the 
paucibacillary nature of mycobacterial lymphadenitis. 
Despite the low sensitivities of both methods, HRM was able to rapidly identify more than half 
(study 1 = 57.4%, study 2 = 56.1%) of the patients with mycobacterial lymphadenitis with a 
relatively high specificity. Early treatment could therefore be initiated in these patients with a high 
degree of confidence. We have suggested a diagnostic algorithm which takes HRM and cytology 
results into consideration. 1) If the HRM analysis is positive for the presence of M. tuberculosis 
DNA and cytology is suggestive of mycobacterial disease, anti-TB treatment is initiated. 2) If 
HRM analysis is positive, but cytology does not indicate mycobacterial disease, or if HRM 
analysis is negative, then await phenotypic culture results before initiating treatment. Future 
studies are planned to improve this algorithm as well as to test alternate genotypic methods 
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including the GenoType® MDRTBPlus (Hain Lifesciences, Germany) and the GeneXpert 
MTB/RIF Assays (Cepheid Inc., California, USA) which are capable of rapidly identifying MDR-
TB. We will reinvestigate storing the sample in a transport medium as it allows for dislodging any 
trapped sample as well as subsequent analysis by culture. 
High resolution melting was also used to identify mutations within target regions. We developed 
the Fluorometric Assay for Susceptibility Testing of Rifampicin (FAST-Rif) which was capable of 
rapidly identifying MDR-TB by detecting M. tuberculosis complex-specific rifampicin (RIF) 
resistance mutations. The method involved PCR amplification of the rifampicin resistance-
determining region (RRDR) of the rpoB gene from short-term cultures (clinical isolates) and from 
a wild type laboratory strain (H37Rv) in the presence of a fluorescent DNA binding dye. These 
amplification products were then mixed to form DNA duplexes which were then analysed by 
HRM. The method had a sensitivity of 98% and a specificity of 100% for the detection of RIF 
resistance compared to the gold standard culture-based phenotyping method. The advantage of 
this method over previously described methods19-24 was its simplicity, the broad spectrum of non-
synonymous single nucleotide polymorphisms (nsSNPs) detected by each analysis (15 different 
mutational events in the RRDR of the rpoB gene), and the high sensitivity and specificity 
achieved.  
The HRM method proved versatile in that we were able to adapt it to rapidly identify ethambutol 
(EMB) resistance by detecting mutations in the embB gene. Ethambutol is an integral part of first-
line therapy and its use is continued in second-line therapy due to surveillance data suggesting 
that EMB resistance is rare.25 However, drug-susceptibility testing (DST) for EMB is inaccurate26 
and the recent evidence demonstrating the clinical significance of mutations in the embB gene27 
suggests that genotypic-based diagnosis of EMB resistance may be more accurate. Our FAST-
EMB method showed a sensitivity and specificity of 94.4% and 98.4% respectively for detecting 
mutations in the embB gene as compared to DNA sequencing. We found that although EMB 
resistance was not associated with RIF mono-resistance or isoniazid (INH) mono-resistance, 
there was a strong association with MDR-TB, since 57.5% of the isolates (n=228) harboured 
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mutations in the embB 306 region, conferring EMB resistance. In contrast, only 9.2% were 
phenotypically resistant by routine culture.  
Based on the strong association of EMB resistance and MDR-TB identified by this study and 
other studies,26,27 as well as the strong association of pyrazinamide (PZA) resistance and MDR-
TB,25,28 we believe that the continued use of EMB and PZA based on the results of phenotypic 
DST will/has lead to the rapid evolution of MDR and XDR-TB in these patients. The World Health 
Organisation (WHO) has acknowledged that MDR-TB treatment regimens should not be 
dependent on the results of DST for EMB or PZA and that at least 4 drugs with certain or almost 
certain effectiveness are used (EMB and PZA are not counted).29 In contrast to the WHO, the 
new South African National TB Control Programme draft policy guidelines (2008) advise that 
DST for EMB determines the treatment regimen for MDR/XDR-TB. If susceptible, EMB should be 
included in the regimen as the 5th drug. If resistant, EMB should be replaced with terizidone or 
cycloserine as the 5th drug (this disregards the inaccuracy of DST). These guidelines also 
recommend the inclusion of PZA as one of the 4 effective drugs but acknowledge that, in the 
absence of DST, it should be assumed that all isolates are resistant.  
In light of the WHO recommendations and the high levels of undetected resistance to EMB and 
PZA in South Africa we propose that in the absence of an accurate DST method for both EMB 
and PZA, that it should be assumed that all MDR-TB cases are resistant to both anti-TB drugs 
and that although treatment with these drugs can be continued, they should not be counted as 
one of the 4 effective drugs.  Adopting this notion may prevent the emergence of additional 
resistance and the possible evolution of XDR-TB. Furthermore, given the affordability and 
superior accuracy of the described FAST-EMB method over routine DST, it would be useful in 
the routine diagnosis of EMB drug-resistance and should be considered for implementation into 
the TB control program so as to ensure the appropriate management of the TB case and to 
prevent the acquisition or spread of further drug-resistance phenotypes.  
The FAST-Rif and FAST-EMB methods were rapid, cost effective, highly sensitive and specific 
and, in the case of EMB, a considerable improvement over phenotypic-based DST.  We 
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acknowledge that these methods require post-amplification processing (to mix amplification 
products) with the potential for cross-contamination and the possible reporting of false positive 
results. This is especially worrying in high throughput laboratories. Efforts to convert the method 
to a single-tube format were hampered by the competitive nature of the PCR. We therefore 
designed a tube with a septum (South African provisional patent 2007/06915, see Appendix 3) 
which would allow simultaneous and non-competitive amplification of the two PCRs. After PCR 
amplification, the two PCRs could be mixed by inverting the tube, thereby avoiding the need to 
open the reaction tube. We are in the process of approaching manufacturers to develop a 
prototype so as to provide a proof of concept. An alternative solution would be to seed the PCR 
reaction with the wild type reference strain prior to amplification.30 However, the seeding of the 
PCR reaction, as well as the use of a tube with a septum, will not overcome the possibility of 
false-susceptible results in cases where a clinical sample may fail to amplify due to insufficient 
DNA.  
We were however able to convert the FAST method to a closed-tube one-step method (FASTest-
inhA) using the detection of inhA promoter mutations conferring INH and associated ethionamide 
(Eto) resistance as a model. Briefly, in a single closed tube, clinical isolates were PCR amplified 
and as amplicons were generated, one of the strands (3’ to 5’) annealed to a modified 
complementary single stranded DNA oligonucleotide (5’ to 3’) allowing extension of this amplicon 
and the incorporation of an adaptor sequence. Primers specific to the adaptor sequence and the 
original 3’ sequence ensured a final PCR product that reflected amplification of both the wild type 
sequence and the sequence present in the clinical isolate. The method was able to identify inhA 
promoter mutations with a sensitivity and specificity of 100% and 83.3%, respectively compared 
to DNA sequencing analysis. The specificity of the assay was improved to 93.5% by visual 
analysis of the derivative plots by experienced and inexperienced operators. Visual scoring was 
more specific than automatic scoring due to limitations with the Rotorgene software, which was 
unable to distinguish between background noise and signal in a small proportion (7.8%) of the 
wild type sequence samples. This could potentially be improved by adding a DNA purification 
step; however, this would increase the cost of the assay and contribute further to diagnostic 
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delay. Alternatively, synthesised oligonucleotide sequences could be introduced in each PCR 
reaction to act as calibrators, thereby allowing the normalisation of derivative curves to these 
calibrators.31 However, the addition of these oligonucleotides into the PCR reaction may reduce 
amplification efficiency.31 We therefore proposed the design of an add-on software application 
which would normalise all the derivative plots of a run according the homoduplex peak, to a pre-
defined Tm. Aligning this homoduplex peak would allow the heteroduplex peak to align in 
samples harbouring a mutation, while keeping wild type samples with the smaller false peak 
aligned at a lower peak height and different Tm. This would then allow the samples to be scored 
more accurately. 
The FASTest-inhA assay was a significant improvement over the FAST-Rif18 and FAST-EMB 
methods in that it included an amplification control, which ensured that amplification failures 
could be identified (only clinical samples containing M. tuberculosis DNA will be amplified). 
Furthermore, the closed-tube system reduced the time to results (<2hours following short term 
culture) and the risk of amplicon release. This diagnostic interval could be shortened further if our 
targets could be efficiently and routinely amplified directly from sputum. The method may lay the 
foundation for a more affordable and safer closed-tube assay, which could be adapted to multiple 
targets. The assay also has the potential for large scale automation, which should be particularly 
attractive in low-income, high TB incidence settings.  
Although our methods were not able to identify the particular mutations involved in resistance, 
this should not be seen as a limitation, since the primary objective for routine diagnostics would 
only be to determine the presence or absence of an nsSNP conferring resistance, thereby 
enabling the correct treatment to be administered to the patient. We specifically targeted regions 
within the rpoB, embB and inhA promoter genes in which no known synonymous SNPs have 
been identified. We also acknowledge that our method was not able to detect nsSNPs conferring 
RIF, EMB and INH resistance which fell outside of the areas we targeted; however, in the case of 
RIF and EMB we would miss only 5%32 and 10-30%33 of resistance, respectively. Similarly, the 
majority of the genotypic-based drug susceptibility testing methods listed above would also not 
be able to detect nsSNPs outside of these regions.  
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Furthermore, although over 80% of the mutations conferring INH resistance occur in either the 
katG or inhA promoter gene,33 inhA promoter mutations are of particular interest as these confer 
low level INH resistance, therefore cases which harbour these mutations may benefit from the 
use of high dose INH therapy.34 These mutations have also been implicated in cross-resistance 
to the second-line anti-tuberculosis drug Eto, which forms part of the second-line treatment 
regimen for MDR-TB.34  
We provided data showing that in the Western and Eastern Cape Provinces of South Africa, inhA 
promoter mutations are strongly associated with XDR-TB, which we believe may be due to the 
dual resistance to Eto and (low-dose) INH conferred by these mutations. We also suggest that 
since 40% of INH resistant (non-MDR-TB) and 12 % of MDR-TB cases do not harbour a 
mutation in either the katG or inhA promoter genes in our setting, that culture-based DST is still 
necessary, but could be complemented by genotypic-based studies in order to achieve the 
highest possible sensitivity for the detection of drug-resistant isolates. The GenoType® 
MTBDRplus assay has been implemented for routine DST in several countries including some 
provinces in South Africa. The data generated by this assay may provide clinicians the 
opportunity to adjust treatment regimens for a patient depending on the pharmacogenetic 
properties of the mutations detected.34 We subsequently proposed guidelines for the 
individualised treatment of TB patients based on the drug resistance mutation patterns detected 
by the MTBDRplus assay. Ethionamide should not be considered an effective drug in TB patients 
infected with strains harbouring an inhA promoter mutation, however high-dose INH may be 
included in the treatment regimen of such cases if the infecting strains do not also exhibit any 
additional high-level INH resistance mutations (most commonly occurring in the katG gene).34 
This treatment algorithm may be particularly useful in XDR-TB cases, for which only few active 
drugs remain available.  
In conclusion, we have shown that our methods are simple and affordable and they can easily be 
adapted to provide species-specific diagnosis of M. tuberculosis infection and various associated 
drug-resistances. Furthermore, such technology can be applied to advise individualised 
treatment regimens. However, the lack of diagnostics for second-line drug resistance is worrying 
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and our method proved difficult to adapt towards these drugs. We believe this may be due to a 
number of reasons, including that the genes and mutations conferring second-line drug 
resistance are less well defined (and in some cases still unknown) and that in our setting, XDR-
TB is more often acquired, implying that patients often have a mixed population of both wild-type 
and mutation carrying strains in their clinical specimens.35 Finally a universal problem of all the 
genotypic-based assays which target DNA is that they are able to detect non-viable bacteria. We 
therefore advise that while awaiting the ideal diagnostic, improved accuracy may lie in using a 
combination of both phenotypic and genotypic-based methodologies.  
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Appendix 1 
 
Table 1: Comparison of the results of the rifampicin drug-susceptibility testing methods followed, 
including the gold standard phenotyping method, DNA sequencing and the FAST-RIF analysis, on 
purified DNA specimens. 
  
Sample 
Rif Phenotype 
(Corrected)1 
rpoB codon 
mutated FAST-RIF 
1 Sensitive  Sensitive 
2 Resistant 531 Resistant 
3 Resistant 531 Resistant 
4 Sensitive  Sensitive 
5 Sensitive  Sensitive 
6 Sensitive  Sensitive 
7 Sensitive  Sensitive 
8 Sensitive  Sensitive 
9 Sensitive  Sensitive 
10 Sensitive  Sensitive 
11 Sensitive  Sensitive 
12 Sensitive  Sensitive 
13 Resistant 531 Resistant 
14 Sensitive  Sensitive 
15 Resistant 531 Resistant 
16 Sensitive  Sensitive 
17 Sensitive  Sensitive 
18 Sensitive  Sensitive 
19 Resistant 531 Resistant 
20 Resistant 526 Resistant 
21 Resistant 531 Resistant 
22 Sensitive  Sensitive 
23 Sensitive  Sensitive 
24 Sensitive  Sensitive 
25 Sensitive  Sensitive 
26 Sensitive  Sensitive 
27 Resistant 531 Resistant 
28 Resistant 531 Resistant 
29 Resistant 531 Resistant 
30 Resistant 531 Resistant 
31 Resistant 531 Resistant 
32 Sensitive  Sensitive 
33 Sensitive  Sensitive 
34 Sensitive  Sensitive 
35 Sensitive  Sensitive 
36 Sensitive  Sensitive 
37 Resistant 531 Resistant 
38 Resistant 531 Resistant 
39 Resistant  wt 2 Sensitive 
40 Sensitive  Sensitive 
41 Sensitive  Sensitive 
42 Resistant 531 Resistant 
43 Sensitive  Sensitive 
44 Sensitive wt Sensitive 
45 Resistant 531 Resistant 
46 Sensitive  Sensitive 
47 Resistant 526 Resistant 
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48 Sensitive  Sensitive 
49 Resistant 526 Resistant 
50 Resistant 531 Resistant 
51 Sensitive  Sensitive 
52 Resistant 526 Resistant 
53 Resistant 531 Resistant 
54 Sensitive  Sensitive 
55 Resistant 531 Resistant 
56 Resistant 531 Resistant 
57 Resistant 531 Resistant 
58 Sensitive  Sensitive 
59 Sensitive  Sensitive 
60 Resistant 531 Resistant 
61 Resistant 531 Resistant 
62 Resistant 531 Resistant 
63 Sensitive  Sensitive 
64 Resistant 531 Resistant 
65 Resistant 533 Resistant 
66 Resistant ins Resistant 
67 Resistant 531 Resistant 
68 Resistant 531 Resistant 
69 Sensitive  Sensitive 
70 Sensitive  Sensitive 
71 Resistant 531 Resistant 
72 Resistant wt 2 Sensitive 
73 Resistant 531 Resistant 
74 Sensitive  Sensitive 
75 Resistant 531 Resistant 
76 Resistant 531 Resistant 
77 Resistant 531 Resistant 
78 Resistant 531 Resistant 
79 Resistant 531 Resistant 
80 Sensitive  Sensitive 
81 Sensitive  Sensitive 
82 Resistant 516 Resistant 
83 Sensitive  Sensitive 
84 Sensitive  Sensitive 
85 Resistant 516 Resistant 
86 Resistant 531 Resistant 
87 Sensitive  Sensitive 
88 Resistant 531 Resistant 
89 Resistant 531 Resistant 
90 Sensitive  Sensitive 
91 Resistant 531 Resistant 
92 Resistant 531 Resistant 
93 Resistant 516 & 526 Resistant 
94 Sensitive  Sensitive 
95 Resistant 531 Resistant 
96 Sensitive  Sensitive 
97 Sensitive  Sensitive 
98 Resistant 531 Resistant 
99 Sensitive  Sensitive 
100 Resistant 526 Resistant 
101 Sensitive  Sensitive 
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102 Sensitive  Sensitive 
103 Sensitive  Sensitive 
104 Sensitive  Sensitive 
105 Resistant 531 Resistant 
106 Resistant 531 Resistant 
107 Resistant 531 Resistant 
108 Resistant 531 Resistant 
109 Resistant 533 & 511 Resistant 
110 Sensitive  Sensitive 
111 Resistant 531 Resistant 
112 Sensitive  Sensitive 
113 Sensitive  Sensitive 
114 Resistant 531 Resistant 
115 Sensitive  Sensitive 
116 Resistant 531 Resistant 
117 Resistant 531 Resistant 
118 Resistant 531 Resistant 
119 Sensitive  Sensitive 
120 Resistant 531 Resistant 
121 Resistant 531 Resistant 
122 Resistant 531 Resistant 
123 Resistant 531 Resistant 
124 Sensitive  Sensitive 
125 Sensitive  Sensitive 
126 Resistant 531 Resistant 
127 Sensitive  Sensitive 
128 Sensitive  Sensitive 
129 Sensitive  Sensitive 
130 Resistant 531 Resistant 
131 Resistant 531 Resistant 
132 Sensitive  Sensitive 
133 Sensitive  Sensitive 
134 Sensitive  Sensitive 
135 Resistant 531 Resistant 
136 Resistant 531 Resistant 
137 Resistant 526 Resistant 
138 Sensitive  Sensitive 
139 Resistant 531 Resistant 
140 Resistant 531 Resistant 
141 Resistant wt 3 Resistant 
142 Resistant 531 Resistant 
143 Sensitive  Sensitive 
144 Resistant 531 Resistant 
145 Sensitive  Sensitive 
146 Sensitive  Sensitive 
147 Resistant 531 Resistant 
148 Sensitive  Sensitive 
149 Sensitive wt Sensitive 
150 Resistant 531 Resistant 
151 Sensitive  Sensitive 
152 Sensitive  Sensitive 
153 Resistant 531 Resistant 
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Appendix 2 
 
Table 1: Comparison of the results of the rifampicin drug-susceptibility testing methods followed 
including the gold standard phenotyping method, DNA sequencing and the FAST-RIF analysis, on 
crude DNA specimens. 
 
Sample 
Rif Phenotype 
(Corrected)1 
rpoB codon 
mutated FAST-RIF 
1 Resistant 531 Resistant 
2 Resistant 531 Resistant 
3 Sensitive  Sensitive 
4 Resistant 526 Resistant 
5 Sensitive  Sensitive 
6 Sensitive  Sensitive 
7 Sensitive  Sensitive 
8 Sensitive  Sensitive 
9 Resistant 533 Resistant 
10 Sensitive 511 4 Resistant 
11 Resistant 531 Resistant 
12 Resistant 516 Resistant 
13 Resistant 516 Resistant 
14 Resistant wt 2 Sensitive 
15 Resistant 533 Resistant 
16 Sensitive  Sensitive 
17 Sensitive  Sensitive 
18 Resistant 526 5 Sensitive 
19 Resistant 513 Resistant 
20 Sensitive  Sensitive 
21 Resistant 533 Resistant 
22 Resistant 531 Resistant 
23 Sensitive  Sensitive 
24 Sensitive  Sensitive 
25 Resistant 516 Resistant 
26 Resistant 531 Resistant 
27 Resistant 531 Resistant 
28 Resistant 513 Resistant 
29 Resistant 516 Resistant 
30 Resistant 516 Resistant 
31 Resistant 531 Resistant 
32 Resistant 531 Resistant 
33 Resistant 531 Resistant 
34 Sensitive  Sensitive 
35 Resistant 531 Resistant 
36 Resistant 531 Resistant 
37 Resistant 531 Resistant 
38 Resistant 531 Resistant 
39 Resistant 531 5 Sensitive 
40 Sensitive  Sensitive 
41 Sensitive  Sensitive 
42 Resistant 531 Resistant 
43 Resistant 531 Resistant 
44 Resistant 516 Resistant 
45 Resistant 516 Resistant 
46 Resistant 531 Resistant 
47 Resistant wt 2 Sensitive 
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48 Resistant 516 Resistant 
49 Resistant 531 Resistant 
50 Resistant 526 Resistant 
51 Resistant 526 Resistant 
52 Resistant 516 & 511 Resistant 
53 Resistant 526 Resistant 
54 Resistant 531 Resistant 
55 Sensitive  Sensitive 
56 Sensitive  Sensitive 
57 Resistant 526 Resistant 
58 Resistant  Resistant 
59 Sensitive  Sensitive 
60 Resistant 531 Resistant 
61 Resistant 531 Resistant 
62 Resistant 531 Resistant 
63 Sensitive  Sensitive 
64 Sensitive  Sensitive 
65 Resistant 531 Resistant 
66 Sensitive  Sensitive 
67 Resistant 531 Resistant 
68 Resistant 531 Resistant 
69 Sensitive 
 
Sensitive 
70 Resistant 531 Resistant 
71 Sensitive 
 
Sensitive 
72 Resistant 531 Resistant 
73 Resistant 531 Resistant 
74 Sensitive 
 
Sensitive 
75 Resistant 531 Resistant 
76 Sensitive 
 
Sensitive 
77 Sensitive 
 
Sensitive 
78 Resistant 531 Resistant 
79 Sensitive wt Sensitive 
80 Resistant 531 Resistant 
81 Resistant 531 Resistant 
82 Resistant 531 Resistant 
83 Sensitive 
 
Sensitive 
84 Sensitive wt Sensitive 
85 Sensitive 
 
Sensitive 
86 Sensitive 
 
Sensitive 
87 Sensitive 
 
Sensitive 
88 Resistant 531 Resistant 
89 Resistant 516 Resistant 
90 Resistant 531 Resistant 
91 Resistant 531 Resistant 
92 Resistant 526 Resistant 
93 Resistant 531 Resistant 
94 Resistant 531 Resistant 
95 Sensitive 
 
Sensitive 
96 Resistant 531 Resistant 
97 Sensitive 
 
Sensitive 
98 Resistant 531 Resistant 
99 Resistant 531 Resistant 
100 Resistant 526 Resistant 
101 Sensitive wt Sensitive 
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102 Resistant 526 Resistant 
103 Resistant 531 Resistant 
104 Resistant 531 Resistant 
105 Resistant 531 Resistant 
106 Resistant 531 Resistant 
107 Sensitive 
 
Sensitive 
108 Resistant 531 Resistant 
109 Sensitive 
 
Sensitive 
110 Sensitive 
 
Sensitive 
111 Sensitive 511 4 Sensitive 
112 Sensitive 531 3 Resistant 
113 Resistant 531 Resistant 
114 Sensitive 
 
Sensitive 
115 Resistant 516 Resistant 
116 Resistant 531 Resistant 
117 Resistant 531 Resistant 
118 Sensitive 
 
Sensitive 
119 Resistant 531 Resistant 
120 Resistant 531 Resistant 
121 Resistant 533 Resistant 
122 Resistant 531 Resistant 
123 Resistant 531 Resistant 
124 Resistant wt 2 Sensitive 
125 Sensitive 
 
Sensitive 
126 Resistant wt 2 Sensitive 
127 Sensitive 
 
Sensitive 
128 Resistant 531 Resistant 
129 Resistant 531 Resistant 
130 Resistant 531 Resistant 
131 Resistant 531 Resistant 
132 Sensitive 
 
Sensitive 
133 Resistant 531 Resistant 
134 Resistant 531 Resistant 
 
1 Corrected phenotype result following reanalysis of any discrepant results 
2 The mutation conferring rifampicin resistance lies outside of the RRDR 
3 The culture became contaminated and no further tests could be performed 
4 Correct result – may implicate that mutations in the codon 511 do not confer Rifampicin resistance 
5 DNA quality may have affected results 
 
 
 
 
 
 
 
 
 
 170
Appendix 3 
 
 
 
 171
 
 
 
 
 172
 
 
 
 
 
 
 173
 
 
 
 174
 
 
 
 
